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Abstract 
 
Adenoviruses are the most commonly used vectors for clinical gene therapy applications, 
accounting for 24% of all clinical trials to date, the majority of which are based on Ad 
serotype 5 (Ad5). However, the high prevalence of neutralising antibodies and a range of 
“off target” interactions result in liver sequestration, hepatic transduction and decreased 
circulation times. Such interactions include Kupffer cell uptake and binding to blood 
components such as erythrocytes, platelets, complement and coagulation factors. Recent 
studies have shown that hepatocyte transduction by Ad5 is mediated by a high-affinity 
interaction between coagulation factor X (FX) and the Ad5 major capsid protein hexon, 
with FX bridging the virus to heparan sulphate proteoglycans (HSPGs) on the cell surface. 
This thesis has focused on gaining a greater understanding of the Ad5:FX pathway and 
potential strategies for its manipulation. 
FX, a key component of the blood coagulation system, is a zymogen of a vitamin K-
dependent serine protease that is primarily synthesised in the liver and circulates in the 
bloodstream at 8-10 µg/ml. It is composed of a light chain consisting of a domain rich in γ-
carboxylated glutamic acid (Gla) residues, two epidermal growth factor-like domains and a 
serine protease (SP) heavy chain. The Gla domain of FX binds to the virion by docking in 
the cup formed by each hexon trimer, whilst the SP domain tethers the Ad5:FX complex to 
the hepatocyte surface through binding HSPGs. Previously, it was demonstrated that 
pharmacological blockade of the heparin-binding proexosite (HBPE) in the SP domain 
prevents FX-mediated cell binding. Here, the specific residues of FX which mediate Ad5 
attachment to HSPGs were identified. Employing mutagenesis techniques each of the 
seven basic residues R93, K96, R125, R165, K169, K236 and R240 that were previously 
shown to bind heparin, were converted to alanine. This mutated FX was termed “SP 
mutant”. Stable cell lines were generated to constitutively produce the wild-type and SP 
mutant rFX protein in the presence of vitamin K. The conditioned media was affinity 
purified using a FX specific mouse monoclonal antibody 4G3 coupled to sepharose. The 
rFX proteins were quantified by ELISA, had the predicted molecular weight of 59 kDa and 
were biologically active, as shown by conversion to FXa in the presence of tissue factor 
and FVIIa. Surface plasmon resonance (SPR) analysis demonstrated the SP mutations had 
no effect on FX-specific binding to the Ad5 hexon. However the proexosite mutations 
ablated FX-mediated Ad5 cell surface binding, internalisation, cytosolic transport and gene 
transfer as shown by confocal microscopy, qPCR and quantification of transgene 
expression. Assessing the involvement of rFX with single (R125A) and double 
 xxv 
(R93A_K96A, R165A_K169A and K236A_R240A) point mutations in the SP domain, 
indicated the residues exhibit different levels of contribution to Ad5:FX complex binding 
to HSPGs. The seven SP mutations also inhibited FX-mediated Ad5 binding to mouse liver 
sections ex vivo. Taken together, this study uncovered that basic residues within the HBPE 
of FX have a fundamental role in Ad5:FX complex engagement with HSPGs at the surface 
of target cells. This study contributes to the existing knowledge of the FX-mediated Ad5 
transduction pathway. 
Whilst the classical in vitro CAR-mediated Ad5 infection mechanism has been extensively 
studied, the post-binding events governing FX-mediated Ad5 intracellular transport and 
gene expression have not been fully characterised. This study employed a panel of small 
molecule inhibitors of cellular kinases in vitro to investigate cellular and signalling events 
occurring during FX-mediated Ad5 infection. Blockade of protein kinase A, p38 mitogen-
activated protein kinase and phosphatidylinositol 3-kinase significantly hindered efficient 
Ad5 intracellular trafficking and colocalisation with the microtubule organising centres 
(MTOC), as shown by confocal microscopy, indicating their fundamental involvement in 
the pathway. Screening a library of 80 diverse kinase inhibitors for effects on FX-mediated 
gene transfer, highlighted the compound ER-27319 had the ability to prevent Ad5 
transduction in vitro. Previous work reported that ER-27319 acts by binding to the 
immunoreceptor tyrosine based activation motif (ITAM) of the FcεRI receptor gamma 
subunit in mast cells to prevent spleen tyrosine kinase (Syk) activation. Here, this 
compound had no effect on FX-mediated cell binding but substantially disrupted 
intracellular transport at 3 h in the absence of toxicity. It was postulated that this effect 
may be due to ER-27319 binding to a viral or cellular ITAM-containing protein involved 
in viral trafficking. Sequence analysis of the Ad capsid proteome for ITAM-like motifs 
((D/E)-x-x-Y-x-x-(L/I)-(xn=6-8)-Y-x-x-(L/I)) identified two motifs on the hexon. However 
neither followed that reported for the FcεRI gamma subunit, instead of the conventional 6-
8 amino acid residues between the two Y-x-x-I/L, the hexon ITAM-like sequences 
expressed 17 or 22 amino acids. Alternatively the ITAM-containing cellular proteins, 
ezrin, radixin and moesin (ERM) were investigated. The ERM family are key regulators of 
the cell cortex, capable of interacting with both the plasma membrane and filamentous 
actin. However, in the time frame imposed by this study this hypothesis could not be 
studied in depth, but warrants further research to investigate whether ERM proteins have a 
novel role in FX-mediated Ad5 intracellular trafficking.  
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A wide range of approaches have been investigated to detarget Ad5 from the liver. In this 
thesis, a pharmacological strategy to preclude FX-mediated liver gene transfer was 
implemented. A high throughput screening platform was developed to identify a novel 
small molecule(s) to manipulate the Ad5:FX infection pathway. In addition to the value of 
such an agent in the gene therapy setting, it may also have potential to treat life-threatening 
disseminated Ad infections in immunocompromised individuals. Using a fluorescence and 
cell-based in vitro high throughput assay 10,240 small molecules were screened using the 
Pharmacological Diversity Drug-like Set library. Initial screening identified 288 
compounds that reduced FX-mediated Ad5 gene transfer by > 75% without causing 
toxicity. Upon further analysis, three compounds, T5424837, T5550585 and T5660138 
were identified as consistently ablating Ad5 transduction both in the absence and presence 
of FX and all had IC50 values < 5.5 µM. These compounds did not directly interfere with 
Ad5 binding to FX, instead they primarily caused a post-binding stage block of the Ad 
infection pathway and all affected optimal virus trafficking to the MTOC, as demonstrated 
by SPR, flow cytometry and confocal microscopy. The candidate molecules have common 
structural features and fall into the “one pharmacophore” model. Focused mini-libraries 
were generated relating to these molecules and structure-activity relationship analysis was 
performed. In vitro screening of the analogues revealed novel hits with similar or improved 
activity, thereby further validating the initial hits and pharmacophore model. Six 
compounds, T5550585, its analogue T5572402, T5660138, its analogue T5660136, 
T5424837 and its analogue T5677956 were tested in vivo. 10 µM T5660138 substantially 
reduced Ad5 liver accumulation 48 h post-injection and, in addition to its closely related 
analogue T5660136, significantly reduced transgene expression at 48 h post-intravenous 
administration of a high viral dose (1 x 1011 vp/mouse). Therefore, this study identifies 
novel small molecule inhibitors of circulating Ad5 infection. 
Through investigation and manipulation of Ad5 interactions with host proteins the work 
presented here, increases the understanding of the key in vivo Ad5:FX tropism determining 
pathway. In summary, in this thesis the mechanism of FX-mediated Ad5 complex binding 
to hepatocytes was dissected and potent inhibitors of this important Ad5 infectivity 
pathway both in vitro and in vivo were identified. This data may contribute to the 
optimisation of Ad vectors for gene therapy applications and potentially the advancement 
of anti-adenoviral drug development.  
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1.1 Introduction 
Gene therapy is a rapidly advancing area of preclinical and clinical research, holding 
immense promise for the future of modern medicine. In the most basic sense, it is a 
technique for correcting defective genes responsible for disease development. This may 
involve substituting the mutated gene with a functional copy, alternatively it can entail the 
delivery of genes to stimulate an immune response, to produce a therapeutic protein or 
suicidal genes to induce cell death. Gene therapy shows exciting potential to provide novel, 
selective, beneficial and even curative treatments for a wide range of inherited and 
acquired diseases which currently lack effective medication. In many respects the ultimate 
success of this approach is defined by the delivery vector, the route of vector 
administration, accessibility of the target cells or tissue and the stability of transgene 
expression. Viruses have evolved sophisticated mechanisms over millennia to deliver their 
genomic payload into host cells. Of the available vectors for gene therapy applications, 
engineered viruses are often the most efficient for the transfer of such genetic material to 
cells. 
The first approved human therapeutic gene therapy clinical trial came in 1990 (Blaese et 
al., 1995). This phase I study was aimed at treating the rare autosomal recessive disorder, 
severe combined immunodeficiency (SCID) caused by a genetic deficiency of adenosine 
deaminase (ADA), a key enzyme in purine metabolism (Blaese et al., 1995; Cristalli et al., 
2001). Lack of ADA leads to the accumulation of the ADA substrate 2’-deoxyadenosine 
and its subsequent conversion to the toxic compound deoxyadenosine triphosphate in T 
cells, thereby disabling the immune system (Cohen et al., 1978; Hirschhorn, 1983). The 
gene therapy clinical study employed a retroviral vector for the ex vivo delivery of ADA 
complementary DNA into the T lymphocytes of two patients suffering from the disorder 
(Blaese et al., 1995). Although the clinical response was limited, in a ten year follow up 
approximately 20% of the first patient's lymphocytes still carried and expressed the ADA 
gene, indicating the long lasting effects in the absence of toxicity (Muul et al., 2003). This 
positive first step highlighted the potential of the therapy (Muul et al., 2003).  
Later, a clinical trial was performed for the treatment of X-linked SCID, an inherited 
disorder caused by mutations in the common cytokine receptor γ chain gene (γc) located on 
chromosome X, preventing T and natural killer (NK) cell differentiation (Fischer, 2000). 
CD34+ bone marrow stem cells were transduced with a retroviral vector, encoding the 
wild-type version of the γc cytokine receptor gene (Cavazzana-Calvo et al., 2000; Hacein-
Chapter 1 | Introduction 
 
3 
Bey-Abina et al., 2002). Patients demonstrated sustained T cell and NK cell reconstitution, 
which were present within normal ranges for the majority of the patients. (Cavazzana-Calvo et 
al., 2000; Hacein-Bey-Abina et al., 2002). However, five of the nineteen participants 
across the two trial centres in London and Paris, developed treatment-related leukaemia 2-
6 years following the trial due to retroviral insertational mutagenesis (Hacein-Bey-Abina et 
al., 2008; Howe et al., 2008). Detailed mapping of the retroviral integration sites indicated 
insertional transactivation of the LIM domain only 2 (LMO2) proto-oncogene, and 
additional sites close to BMI1 (involved in transcriptional control) and CCND2 (a cell-
cycle protein) led to leukaemogenesis (Hacein-Bey-Abina et al., 2008; Howe et al., 2008). 
Whilst this study demonstrated the potential of such an approach to restore T cell 
immunity, it raised serious concerns regarding the toxicity of retrovirus-based vectors for 
gene therapy. The detailed analysis of these adverse effects, the mapping of the retroviral 
integration profiles and the use of safer vectors will help to avoid such events. 
In parallel to the progression of gene therapy, major advances in the field of recombinant 
DNA technology were being made, and there came a greater understanding of our genetic 
makeup. Over a decade has passed since scientists announced the initial draft of the human 
genome (Lander et al., 2001). Mapping over 3 billion base pairs and identifying 25,000 
genes, it was a breakthrough which offered an unrivalled resource for understanding the 
basis of genetic disorders and complex diseases. The human genome project widened the 
scope of genetic targets, meaning the identification of suitable therapeutic genes was no 
longer a limiting factor, and as a result the perspectives broadened. In recent years, a great 
deal of work has focused on the treatment of cancer, currently accounting for 64.6% of 
clinical trials (www.wiley.com//legacy/wileychi/genmed/clinical/), whilst promise has 
been realised for a variety of other conditions, as diverse as cardiovascular disease (Jessup 
et al., 2011), human immunodeficiency virus infection (Barouch et al., 2012) and 
blindness (Vandenberghe et al., 2011) amongst others (Figure 1.1). Recently, a study by 
Nathwani et al. demonstrated the success of a gene therapy approach for the treatment of 
haemophila B, an X-linked bleeding disorder, caused by a mutation in the gene for 
coagulation factor IX (FIX) (Nathwani et al., 2011). Six patients with severe haemophila B 
were administered an adeno-associated virus (AAV) expressing the human FIX transgene, 
resulting in a sufficient increase in FIX expression levels to improve the bleeding 
phenotype with few side effects (Nathwani et al., 2011).  
A major advance in the field of gene therapy was the recent announcement from the 
European Committee for Medicinal Products for Human Use (CHMP), for the 
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recommended approval of the first registered gene therapy product in Europe, alipogene 
tiparvovec (also known as Glybera), which is based on an AAV-1 vector (Miller et al., 
2012, Burnett et al., 2009). Amsterdam Molecular Therapeutics (AMT) developed Glybera 
for the correction of familial lipoprotein lipase deficiency, a rare disorder in which failure 
to metabolise chylomicrons leads to massive hyperlipidaemia and potentially life-
threathening pancreatitis (Miller et al., 2012, Burnett et al., 2009). The approval of the first 
product in Europe represents a very exciting step forward in the development of future 
gene therapy. 
 
Figure 1.1. Gene therapy clinical trials summarised by indication. 
Trials (n = 1714) grouped according to indication; cancer (n =1107, 64.6%), cardiovascular 
diseases (n = 146, 8.5%), monogenic diseases (n = 143, 8.3%), infectious diseases (n = 183, 
8.1%), gene marking (n = 50, 2.9%), healthy volunteers (n = 40, 2.3%), neurological 
diseases (n = 35, 2%), ocular diseases (n = 23, 1.3%) and other (n= 19, 1.1%). Data were 
obtained from the Journal of Gene Medicine 
(http://www.wiley.com//legacy/wileychi/genmed/clinical/). 
While the principle goal of gene therapy, to safely achieve stable transgene expression 
refined to the desired tissue, has not changed throughout its history, the understanding of 
the underlying complexity of just how to achieve this has increased greatly. The desire to 
overcome the outstanding challenges, along with the explosion of interest in the 
biotechnology industry and some major discoveries in the field of virology, has resulted in 
considerable attention and resources being focused on the manipulation of viruses for 
medical treatments. From this, vectors based on adenoviruses (Ad) have emerged as 
promising tools for gene therapy applications (Figure 1.2). 
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Figure 1.2. Gene therapy clinical trials summarised by vector. 
Top ten most commonly used vectors for gene therapy clinical trials; adenovirus (n = 406, 
23.7%), retrovirus (n = 352, 20.5%), naked/plamid DNA (n = 318, 18.6%), lipofection (n = 
109, 6.4%), vaccinia virus (n = 106, 6.2%), adeno-associated virus (n = 81, 4.7%), poxvirus 
(n = 66, 3.9%), herpes simplex virus (n = 57, 3.3%), lentivirus (n = 40, 2.3%) and poxvirus 
with vaccinia virus (n = 28, 1.6%). Data were obtained from the Journal of Gene Medicine 
(http://www.wiley.com//legacy/wileychi/genmed/clinical/). 
 
1.2 Adenoviruses 
Ads are non-enveloped, double-stranded DNA viruses, first isolated in 1953 from human 
adenoid tissue (Hilleman et al., 1954; Rowe et al., 1953). They belong to the Adenoviridae 
family, of which there are at least 57 different serotypes, subdivided into species A to G 
(Table 1.1). Ads are currently classified based on serologic profiles, DNA sequence 
similarity, receptor usage, capacity to agglutinate human, monkey and rat erythrocytes and 
oncogenicity in rodents (Catherine, 2002; Crawford-Miksza et al., 1996). These common 
pathogens are associated with mostly self-limiting infection, causing acute respiratory, 
gastrointestinal and ocular infections. Since the early 1980s these viruses have been 
developed, engineered and partially optimised for use in gene therapy applications. 
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Table 1.1. Classification of Ad serotypes.  
Ad serotypes are divided into species A to G. This classification is related to the Ad 
receptor usage. 
Ad species Ad serotype Receptor usage 
A 12, 18, 31 CAR 
B 3, 7, 11, 14, 16, 21, 34, 35, 50, 55 CD46, HSPG, Desmoglein 2 
C 1, 2, 5, 6 CAR, HSPG, Integrins 
D 8, 9, 10, 13, 15, 17, 19, 20, 22, 23, 24, 
25, 26, 27, 28, 29, 30, 32, 33, 36, 37, 38, 
39, 42, 43, 44, 45, 46, 47, 48, 49, 51, 53, 
54 
CAR, Sialic acid, CD46 
E 4 CAR 
F 40, 41 CAR 
G 52 Unknown 
 
1.3 Adenoviral structure 
The combined application of X-ray crystallography and electron microscopy has provided 
a wealth of information on the architecture of the Ad virion, now determined to a 
resolution of 3.5 angstroms (Liu et al., 2010; Reddy et al., 2010; Saban et al., 2006). The 
Ad particle comprises two major structural elements; the outer capsid and the inner core. 
1.3.1 Outer capsid 
The icosahedral capsid of each Ad particle is approximately 70-90 nm in diameter and 
encloses the viral genome. It is composed of three principle proteins; the hexon, penton 
base and fiber (Figure 1.3). The major capsomer hexon is a pseudo-hexogonal trimer, the 
240 copies of which are situated on the 20 faces of the icosahedron (Benson et al., 1999). 
The homotrimers are composed of three-fold repetitions of two β-barrels at the base of 
each hexon molecule. The two eight stranded β-barrels with ‘jelly roll’ topology and one 
loop at the hexon base are responsible for interacting with adjacent capsomers and 
contribute to the proteins extensive stability (Russell, 2009).There are four different types 
of hexon; H1 (also called peripentonal hexons) which associates with each of the 12 
pentons, while H2, H3 and H4 form the ‘groups of nine’ (GON) on each of the 20 facets of 
the capsid structure (Figure 1.4) (Burnett, 1985). Comparative sequence analysis of 
serotypes has revealed the presence of hypervariable regions (HVRs) within the surface 
exposed regions of the hexon protein (Crawford-Miksza et al., 1996; Rux et al., 2003). 
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These regions relate to serotype-specific antigen recognition (Roberts et al., 2006). At the 
12 capsid vertices, the pentameric penton base protein is located along with the protruding 
trimeric fiber (van Oostrum et al., 1985). In most cases the penton base contains the 
exposed arginine-glycine-aspartic acid (RGD) motif within a flexible loop, which is 
involved in cell internalisation (Wickham et al., 1993). The rigid fiber is composed of 
three distinct regions, the N-terminal tail non-covalently bound to the penton base, the 
intertwined repeating 15-20 amino acid sequences in the shaft and the C-terminal globular 
knob domain (Henry et al., 1994; Zubieta et al., 2005). The capsid also contains several 
minor structural proteins including IIIa (60 copies per virion) (Stewart et al., 1993), VI 
(360 copies) (Stewart et al., 1993), VIII (120 copies) (Fabry et al., 2005) and IX (240 
copies) (Furcinitti et al., 1989), which are implicated in cementing the capsid structure 
(Figure 1.4) (Furcinitti et al., 1989; Stewart et al., 1991).  
 
Figure 1.3. Ad capsid structure. 
The icosahedral Ad capsid, with a core diameter of approximately 90 nm, is composed of 
three principal capsid proteins, the hexon, the penton base and the protruding flexible 
fiber. The Ad type 5 (Ad5) fiber is approximately 37 nm in length and consists of a trimeric 
knob domain, shaft and N-terminus tail attached to the penton base. In addition there are 
several minor capsid proteins, including pIIIa, pVI, pVIII and pIX, which stabilize the virus 
structure.   
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Figure 1.4. Facets of the Ad icosahedron capsid.  
(A) External view - the GON hexons are multicoloured and the H1 peripentonal hexons 
are either lettered in black when they are on the same plane as the GONs or lettered in 
red where they are associated with GONs on a different facet. Similarly, the H2 hexons 
lettered in red are associated with GONs on a different facet. The symbol for protein IX is 
not to scale. (B) Internal view - hexons and associated minor capsid proteins. (C) Internal 
structure at the apex. This figure was taken from Russell (Russell, 2009). 
1.3.2 Inner core 
Protected within the outer Ad capsid is the linear double-stranded DNA, approximately 36 
kb in length. The viral genome is condensed in association with the core proteins, namely 
histone-like protein VII (>800 copies), the capsid-to-core bridging protein V (160 copies), 
µ (100 copies), IVa2, terminal protein and the 23 K virion protease (10-70 copies), 
necessary for the production of the mature virus (Anderson et al., 1989; Rekosh et al., 
1977; Robinson et al., 1973; Russell, 2009; Webster et al., 1989). Inverted terminal repeats 
(ITR) of 100-140 bp in size, flanking both ends of the viral DNA, act as origins of 
replication (Rekosh et al., 1977). Cis-acting packaging elements in the left end of the 
DNA, are required for viral encapsidation (Gräble et al., 1992). The Ad genome comprises 
two main transcription regions, termed the early and late. The early region consists of five 
transcription units (E1A, E1B, E2, E3, E4), two delayed early units (IX and IVa2), and the 
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late region is composed of five units (Figure 1.5) (L1-L5) (Mizuguchi et al., 2001; Russell, 
2000; Warnock et al., 2011).  
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VA RNA
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Figure 1.5. Transcription of the Ad genome. 
The early transcripts are highlighted with yellow boxes, the late in blue and gene products 
are in pink. The arrows indicate the direction of transcription. The gene locations of the 
viral associated (VA) RNAs are denoted in purple. The genes have been mapped by 
superimposing an arbitrary scale of 100 map units. ITR = inverted terminal repeats, ψ = 
the packaging signal, MLP = Major late promoter, RID = Receptor internalisation and 
destruction, Pr = Protease, ADP = Adenovirus death protein, TP = Terminal protein, ORF = 
Open reading frame, DBP = DNA binding protein and Pol = Polymerase. This figure was 
adapted from Russell (Russell, 2000). 
The E1 gene prepares the host cell for viral replication; the E1A region produces two 
transcripts 289R and 243R which promote cell cycle progression whilst synergistically the 
E1B unit prevents apoptosis (Chattopadhyay et al., 2001; Debbas et al., 1993). The 
adenoviral 289R and 243R E1A proteins can induce DNA synthesis and activate the S 
phase of the cell cycle in quiescent cells through the formation of complexes with two 
classes of cellular proteins, the retinoblastoma (Rb) family of growth suppressors and the 
transcriptional modulator p300 and related proteins (Eckner et al., 1994; Howe et al., 
1990). The unscheduled induction of cell proliferation promoted by E1A triggers innate 
cellular tumour suppressor mechanisms (p53) by activating pro-apoptotic pathways 
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(Debbas et al., 1993; Lowe et al., 1993). The adenoviral E1B proteins, E1B-55kDa and 
E1B-19kDa, act to counteract the accumulation of pro-apoptotic p53. The E1B-55kDa 
protein, in conjunction with E4-open reading frame (ORF) 6 and cellular ubiquitination 
proteins, antagonises the ability of p53 to cause apoptosis by inducing its degradation 
(Harada et al., 2002; Querido et al., 1997; Querido et al., 2001). 
The E2 gene encodes the machinery to facilitate replication; DNA polymerase (pol), 
preterminal protein (pTP) and DNA binding protein (DBP) (Hay et al., 1995). E3 codes for 
proteins that block natural cellular responses to viral infection, such as the adenovirus 
death protein (ADP) (Tollefson et al., 1996) and E4 encodes ORF 1-6/7 that perform in 
mRNA transport and further promote replication (Goodrum et al., 1999; Warnock et al., 
2011; Weigel et al., 2000). Ads also transcribe a set of RNAs, termed the virus associated 
(VA) RNAs (I and II), and these play a role in combating cellular defence mechanisms, by 
preventing the interferon antiviral response. RNA-dependent protein kinase (PKR), an 
interferon-inducible serine-threonine protein kinase is activated in infected cells, by the 
presence of double-stranded RNA in the cytoplasm, leading to blockade of cellular mRNA 
translation (O’Malley et al., 1989). VA RNAs can bind directly to and block the actions of 
PKR thereby overcoming this shutdown in protein synthesis (O’Malley et al., 1986).  
Following activation of early genes and viral replication, the major late promoter (MLP) 
(Shaw et al., 1980) leads to the expression of late genes, involved in the expression of viral 
structural proteins required for packaging and maturation, and ultimately in the production 
of infectious viral particles. 
1.4 Ads as gene delivery vectors 
Several features make Ads attractive vectors for gene therapy. Ads are efficient in infecting 
a wide variety of both quiescent and proliferating cell types and exhibiting high level 
transgene expression in target cells. They remain episomal, therefore have minimal-to-no 
risk of insertational mutagenesis. As the vectors are non-integrating their genomes are lost 
in dividing cells and so transgene expression is transient, a factor which may be 
advantageous depending on the clinical applications. Ads have a large packaging capacity 
and can be produced at high titres (up to 1013 virus particles per ml) under Good 
Manufacturing Practice (GMP) conditions, an attribute key for successful development in 
the biotechnology industry.  
Chapter 1 | Introduction 
 
11 
Ads are easy to genetically manipulate to generate replication incompetent viruses or 
conditionally replicating Ads (CRAds). Replication deficient Ads can be classified into 
three categories; first, second and third generation vectors. The first generation vectors 
contain deletions in the early transcription E1 regions, essential for the initiation of viral 
replication, and often also the E3 region, dispensable for replication in cell culture, 
enabling the insertion of a transgene of approximately 8 kb. For vector production, the E1 
functions have to be provided in trans by a complementing producer cell line. The 
development of the human embryonic kidney cell line 293, transfected with sheared Ad5 
genomic DNA to stably express the E1 genes, has aided the efficient production of these 
replication deficient vectors (Graham et al., 1977). A major limitation of first generation 
vectors is that in spite of the E1 deletion, viral genes can be expressed at low levels in cells 
due to transactivation by host transcription factors, causing short duration transgene 
expression and toxicity due to an adaptive cellular immune response against the transduced 
cells (Yang et al., 1994a; Yang et al., 1994b).  
To increase the size of the genetic insert (up to 14 kb), second generation vectors were 
developed and are characterised by additional deletions in the E2 and E4 regions. These 
vectors were complemented by the development of more complex producer cell lines, 
stably co-expressing the E1 region, DNA polymerase, and preterminal proteins 
(Amalfitano et al., 1997). Although some studies did report improved transgene 
persistence and decreased inflammatory responses using second generation vectors 
(Dedieu et al., 1997; Wang et al., 1997), their effects are controversial and may be related 
to tissue type (Lusky et al., 1998; Lusky et al., 1999). Lusky et al generated Ad5 vectors 
with both single deletions (AdE1¯) and double deletions (AdE1¯E2A¯ and AdE1¯E4¯), and 
compared the immunogenicity of these vectors in vitro and in vivo (Lusky et al., 1998). 
AdE1¯E2A¯ demonstrated abolished expression of early and late viral genes, while deletion 
of E1 and E4 also impaired expression of viral genes, although at a lower level than the 
E1/E2A deletion. However, in vivo all vectors produced similar antibody responses and 
showed similar levels of viral genomes in the liver and lung 4 months post-administration 
(Lusky et al., 1998). This study therefore indicates mouse cellular immunity to viral 
antigens plays a minor role in the persistance of the virus genome in vivo (Lusky et al., 
1998). 
Third generation or helper-dependent vectors are devoid of all viral genes except essential 
ITRs and packaging sequences, and can accommodate inserts of 36-38 kb. At present, the 
lack of a suitable cell line to stably express all the viral helper functions make these vectors 
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more difficult to produce and scale-up for clinical applications is therefore a limiting 
factor. Nonetheless, helper-dependent Ads have great potential. Due to the lack of viral 
gene expression, they show promise for reduced immunogenicity and long term transgene 
expression (Brunetti-Pierri et al., 2005; Kim et al., 2001; Morsy et al., 1998; Schiedner et 
al., 1998). One early study reported the life long persistence of a helper-dependent Ad 
vector encoding the apolipoprotein (apo) E gene, which stably corrected 
hypercholesterolemia in apoE-deficient mice (Kim et al., 2001). 
In contrast to replication deficient Ads, conditionally replicating Ads (CRAds) or oncolytic 
Ads can selectively replicate in cancer cells, causing cell lysis and death of the infected cell 
along with the release of progeny virions, which in turn, can infect neighbouring tumour 
cells, thereby amplifying the effect. Oncolytic Ads exploit cancer-specific cellular changes, 
such as transcriptional dysregulation, for the purpose of viral replication. This can be 
achieved by genetic modification of the Ad genome, such as deletion of viral genes 
required for productive infection in normal cells but redundant in tumour cells or by the 
use of tumour specific promoters to drive viral replication (Chen et al., 2011; Heise et al., 
2000; Öberg et al., 2010; Radhakrishnan et al., 2010). In 1996 Bischoff et al. developed 
the first CRAd, ONYX-015 (dl1520), which lacks the E1B-55kDa gene (Bischoff et al., 
1996). It was initially thought that ONYX-015 selectively replicates in tumour cells in 
which the p53 tumour suppressor pathway was dysfunctional (Bischoff et al., 1996). 
However, it was later demonstrated that replication was not due to p53 deficiency and this 
property is now attributed to the unique ability of some tumour cells to compensate for the 
lack of E1B-55kDa-mediated late viral RNA export (O'Shea et al., 2004). Subsequent 
strategies to generate oncolytic vectors included E1A mutant CRAds such as Ad∆24 (Ad5 
containing a 24 base pair deletion within a conserved region (CR2) of E1A) which targeted 
the tumour suppressing Rb pathway defective in some cancer cells (Fueyo et al., 2000).  
1.5 Ad gene therapy – the highs and the lows 
Of the Ads used in gene therapy, the human species C Ad type 5 (Ad5) is the most widely 
studied. However, despite extensive utilisation there are several pitfalls which need to be 
overcome in order to improve the viability of Ad5 as a therapeutic gene delivery vector in 
the broad sense. For many gene therapy targets such as disseminated metastatic tumours 
the optimal and arguably the only route suitable for targeting the multitude of micro-
metastates is intravascular delivery. However, the safety and efficacy of Ad5 by 
intravascular delivery is hampered by the substantial propensity of the virus to transduce 
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the liver, as first documented by Huard et al. (Huard et al., 1995). The resident liver 
macrophages, Kupffer cells (KC), sequester Ad5 and contribute to the host inflammatory 
response (Lieber et al., 1997). Once the reticuloendothelial system is saturated, the virus is 
predominately taken up by hepatocytes (Vrancken Peeters et al., 1996) (Figure 1.6). This 
inherent hepatic tropism greatly reduces the capability of specific targeting to disease sites. 
Increasing the vector dosage can result in toxic side effects (Lozier et al., 2002). Most 
humans are exposed to Ad5 early in life, developing antibodies that efficiently neutralise 
vectorised forms of Ad5 (Sumida et al., 2005). Furthermore, a general sceptism pervades 
the medical community ever since the death of Jesse Gelsinger in 1999, a participant in a 
phase I trial for ornithine transcarbamylase deficiency (Raper et al., 2003; Raper et al., 
2002). Systemic inflammatory response syndrome, disseminated intravascular coagulation 
and multi-organ failure lead to his death 98 h following intravascular administration of 3.8 
x 1013 virus particles. This tragedy highlighted the important deficits in knowledge of 
Ad:host interactions and emphasised the necessity for better understanding of these 
interactions to achieve optimal use of the vector. 
Notwithstanding some of the set-backs in the gene therapy field, remarkable progress has 
been made in recent years with regards to understanding Ad biology. The ongoing 
advances at the lab bench translate into the latest successes observed in the clinic with a 
growing number of trials advancing to phases II and III. An integrated phase II/III, 
randomised and controlled study will commence shortly, investigating the safety and 
efficacy of a conditionally replicating oncolytic Ad (CG0070) expressing granulocyte 
macrophage colony-stimulating factor ((GM-CSF), a cytokine shown to be a potent 
inducer of specific, long-lasting anti-tumour immunity in animal models (Dranoff et al., 
1993; Ramesh et al., 2006)). CG0070 will be tested in patients with non-muscle invasive 
bladder cancer who have failed current forms of treatments (Ramesh et al., 2006). Also 
currently underway is a phase I/II study assessing the use of Ad5 encoding human adenylyl 
cyclase type 6 (functions in cardiac contractility) gene transfer via intracoronary delivery 
for congestive heart failure (Lai et al., 2004). The first phase I/II trial in the UK not based 
on Ad serotype 5, is expected to commence later this year for the treatment of metastatic 
colorectal cancer (Kuhn et al., 2008). This study will employ an oncolytic vector, termed 
ColoAd1, based on subgroup B Ad11p and Ad3 (Kuhn et al., 2008; Kuhn et al., 2005). In 
respect to cancer treatment the use of Ad5 for the delivery of the tumour suppressor gene 
p53 has been the focus of several studies (Bischoff et al., 1996; Gabrilovich, 2006; Heise 
et al., 1997). Gendicine, a replication-deficient Ad5 expressing p53 vector, was the first 
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gene therapy product licensed, in China, for the treatment of head and neck cancers and 
also shows promise for use against other solid tumours (Peng, 2005). 
 
 
 
Figure 1.6. Liver cells and Ad5 hepatic uptake. 
The liver sinusoidal wall is formed by liver sinusoidal endothelial cells and juxtaposed 
Kupffer cells. Whilst Kupffer cells and liver sinusoidal endothelial cells limit hepatocyte 
transduction by Ad5, the presence of fenestrae in liver sinusoidal endothelial cells 
provides a direct access to the space of Disse and the microvillous surface of hepatocytes. 
This figure was taken from Jacobs et al. (Jacobs et al., 2010). 
Chapter 1 | Introduction 
 
15 
In addition to gene replacement and combinations of gene therapy with standard anti-
tumour strategies, the concept of suicide gene therapy is another application under 
investigation (Barton et al., 2011; Freytag et al., 2007a). This refers to the viral delivery of 
enzymes that metabolise systemically administered non-toxic prodrugs into locally active 
anti-cancer agents. A randomised, controlled phase II/III study is currently underway to 
assess the efficacy of replication competent Ad-mediated suicide gene therapy in 
conjunction with radiation treatment for prostate cancer (Barton et al., 2011; Freytag et al., 
2007a; Lu et al., 2011). The virus used in the trial contains a bacterial cytosine deaminase 
(CD)/herpes simplex virus thymidine kinase (TK) fusion gene in the E1 region in place of 
the E1B-55kDa gene, and lacks the adenoviral genes of the E3 region. In addition to the 
oncolytic properties of the virus itself, expression of the CD/TK fusion gene renders 
tumour cells sensitive to 5-fluorocytosine (5-FC) and ganciclovir (GCV) prodrugs (Freytag 
et al., 2007a; Freytag et al., 2007b; Lu et al., 2011). Another study using a similar 
approach has employed a replication deficient Ad vector encoding bacterial nitroreductase 
(NTR) in conjunction with the prodrug CB1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide), 
for the treatment of prostate cancer (Patel et al., 2009). NTR converts the weak alkylating 
agent CB1954 to a highly potent alkylating agent, thereby producing cytotoxic effects 
(Friedlos et al., 1992). 
Whilst local delivery of Ads has proven to be very beneficial, design of a vector which can 
be delivered intravenously and specifically target the desired tissues, without causing an 
immune response (except for certain cancer treatments, in which this may be 
advantageous) remains a challenge for many applications. Future success of systemically 
delivered gene therapy will ultimately be determined by improved understanding and 
modulation of the complex viral interactions with host proteins leading to better prediction 
of in vivo efficacy, pharmacokinetics and toxicity and consequently the development of 
safer, targeted vectors, individualised for defined applications.  
1.6 Ad interactions with host proteins 
1.6.1 Coxsackie virus and adenovirus receptor  
Ad receptor usage greatly influences viral tropism. The extensively studied Ad receptor, 
the 46 kDa coxsackie virus and adenovirus receptor (CAR), was initially identified over 30 
years ago as an attachment receptor for coxsackie B viruses (Lonberg-Holm et al., 1976), 
then later as for Ad2 and Ad5 (Bergelson et al., 1997; Tomko et al., 1997). CAR belongs 
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to the immunoglobulin (Ig) superfamily and is composed of two extracellular Ig-like 
domains (distal variable type - D1 and proximal C2 type - D2) and a single membrane-
spanning sequence connected to the carboxy terminal cytoplasmic domain (Chrétien et al., 
1998; Wang et al., 1999). The major function of CAR is as a cell-to-cell adhesion molecule 
in tight junctions of polarised epithelial cells. It also interacts with junctional adhesion 
molecule-like protein and has a role in T cell activation (Witherden et al., 2010) and 
recruitment of phosphoinositide 3-kinase (PI3K) (Verdino et al., 2010).  
In vitro CAR is a primary cellular attachment receptor for Ads of species A, C, D, E and F, 
but not species B (Roelvink et al., 1998). The CAR D1 domain binds to the side of each 
monomer of the trimeric fiber knob, an interaction which is conserved amongst the CAR 
binding Ads (Kirby et al., 2000; Rolvink et al., 1999). The CAR:knob interaction is 
responsible for the initial binding of the virus to the cell surface. The amino acid residues 
in the Ad fiber essential for CAR binding were identified through alignment of the knob 
domain sequences of those Ads known to interact with CAR (Rolvink et al., 1999). Several 
mutations were found to affect the fiber knob:CAR interaction, including S408E/G, 
P409A, K417G/L (in the AB loop), K420A (B β-sheet), Y477A/T (DE loop), Y491A (FG 
loop), a four amino acid deletion of TAYT or replacement of EGTAY (FG loop) (Figure 
1.7) (Rolvink et al., 1999). Following cell attachment, subsequent virus internalisation is 
mediated by integrins (Wickham et al., 1993). Integrins, cell surface adhesion molecules 
composed of α and β transmembrane subunits, interact with the RGD motif on the Ad5 
penton base, primarily via the integrins αvβ3/αvβ5 (Wickham et al., 1993). Integrins 
interact with a variety of signalling molecules and promote Ad internalisation, principally 
through clathrin-mediated endocytosis (Wang et al., 1998). Once inside the cells and 
following release from the endosomes, the virus travels along microtubules toward the 
microtubule organising centre (MTOC), before binding to nuclear receptors and being 
imported into the nucleus (Greber et al., 1997; Kelkar et al., 2004; Suomalainen et al., 
1999). The intracellular trafficking of Ad from the cell surface to the nucleus and the viral 
uncoating process is described in further depth in Chapter 4. 
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Figure 1.7. Critical features of the Ad fiber. 
The strands of the fiber knob are lettered according to the nomenclature of Xia et al. (Xia 
et al., 1994). The CAR binding site, which is made up mostly by the AB loop (ball and 
stick), lies along the side of the fiber knob trimer. Locations of some mutations that 
abolish CAR binding are indicated by arrows. The HI loop is shown in magenta. The final 
four-repeats of the fiber shaft (18–21) are shown with Roman numerals. This image was 
adapted from Nicklin et al. (Nicklin et al., 2005). 
Although this is a very well defined two step cell tethering and subsequent internalisation 
pathway, detailed by many in vitro studies, there is clear evidence to suggest CAR is not 
the primary attachment receptor in vivo following intravascular delivery of Ad5 vectors. 
Anatomically CAR is localised to tight junctions. Wild-type infection by Ad occurs 
primarily via airway epithelial cells, which release the replicating virus to basolateral and 
apical surfaces, allowing the Ad5 fiber to bind CAR and disrupt tight junction integrity, 
thus facilitating the spread of the virus (Walters et al., 2002). However, tight junctions are 
not readily accessible for circulating Ad5 vectors. In addition, mRNA encoding CAR is 
expressed on a wide range of tissues; most highly in the pancreas, brain, heart, small 
intestine, testes, prostate and to a lesser extent in the liver and lung (Tomko et al., 1997). 
This pattern of expression does not correlate to the pattern of Ad5 tropism in vivo, as 
following intravascular delivery the majority of the vectors are sequestered by the liver, as 
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discussed earlier (Huard et al., 1995). Studies by Einfeld et al. and Koizuma et al. reported 
combined mutations in the fiber knob and the RGD motif of the penton base, to prevent 
CAR and integrin-mediated interactions, significantly reduced liver transduction following 
intravascular delivery (Einfeld et al., 2001; Koizumi et al., 2003). However, a vast number 
of studies employing Ad5 vectors with mutations that ablate CAR binding alone have 
demonstrated no difference in biodistribution, with similar levels of hepatocyte 
transduction to non-modified Ad5 vectors being observed in rodents and non-human 
primates (Alemany et al., 2001; Martin et al., 2003; Smith et al., 2002). Recently, research 
focus has mainly been directed at uncovering alternate Ad pathways that define in vivo 
tropism. 
1.6.2 The role of the immune system 
A major obstacle to the use of Ad5 for gene therapy is the rapid induction of the innate and 
the adaptive immune response towards the vector, which can lead to rapid clearance of the 
virus and severely compromises the envisaged efficacy of the vector (Di Paolo et al., 
2009a; Sumida et al., 2005; Varnavski et al., 2005). The viral capsid proteins possess 
distinct antigenic determinants capable of eliciting cellular and humoral immune responses 
which can result in potent toxicity (Gahéry-Ségard et al., 1997; Lieber et al., 1997; Roberts 
et al., 2006) (Figure 1.8).  
1.6.2.1 Innate immunity 
As previously mentioned, liver macrophages, KCs, can sequester up to 90% of virus 
particles within minutes of intravascular administration in mice (Lieber et al., 1997; 
Worgall et al., 1997). This triggers a rapid destruction of KCs as early as 10 min post-
injection (Manickan et al., 2006). In addition, the same study reported the translocation of 
Ad-positive KCs from the liver to the lungs by 30 min, suggesting KC displacement from 
the liver (Manickan et al., 2006). The acute phase virus-induced KC response has been 
associated with the induction of proinflammatory cytokines and chemokines including 
interleukin (IL)-6, IL-10, IL-8, tumour necrosis factor alpha, gamma interferon and 
macrophage inflammatory proteins 1 and 2, thereby contributing to the extensive liver 
pathology caused by Ad5 (Lieber et al., 1997; Muruve et al., 1999).  
There are several mechanisms involved in the uptake of Ads by KCs. Scavenger receptors 
recognise the negatively charged viral capsid and preinjecting mice with broad spectrum 
inhibitors of scavenger receptors such as dextran or polyinosinic acid (poly(I)) has been 
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shown to decrease Ad uptake by KCs and increase the circulating half-life of the virus in 
vivo (Haisma et al., 2008; Xu et al., 2008). A recent study by Khare et al. reported the 
involvement of HVR 1, 2, 5 and 7 in KC recognition by scavenger receptor SRA-II (Khare 
et al., 2012). Antibody-deficient RAG-1 knockout mice exhibited significantly reduced 
levels of Ad particles within KCs, an effect which could be reversed by preinjection with 
serum from naïve C57BL/6 mice, thus demonstrating a requirement for natural antibodies 
(Xu et al., 2008). Natural immunoglobin M antibodies and complement proteins, in 
particular complement protein C3, opsonize the virus and are involved in KC uptake (Jiang 
et al., 2004; Xu et al., 2008). Pre-existing neutralising antibodies (NAb) of the adaptive 
immune system have also been reported to increase the targeting of Ad to macrophages 
(Zaiss et al., 2009). In vitro, NAbs significantly increased FcR-dependent Ad 
internalisation of macrophages, while in pre-immunised mice, the innate response was 
enhanced, with significantly higher levels of inflammatory gene expression in the liver and 
IL-1β levels in the serum compared to naïve animals (Zaiss et al., 2009). 
As well as cells such as macrophages and serum immune mediators, intra- and extra-
cellular innate receptors, termed host pattern recognition receptors (PRR), can recognise 
the antigenic viral capsid, double-stranded genome or viral proteins (Zhu et al., 2007). 
Activation of IL-1α in splenic marginal zone macrophages in response to the Ad5 RGD 
motif binding to αvβ3 integrins has also been elegantly shown (Di Paolo et al., 2009a). Ad5 
RGD activation of IL-1α is required for the expression of IL1-RI dependent cytokines and 
chemokines including CXCL1 and CXCL2 and this occurs independently of genomic 
nucleic acid recognition by PRRs (Di Paolo et al., 2009a).  
Several successful strategies to deplete or inactivate KCs have been described including 
intravascular injection of gadolinium chloride (Lieber et al., 1997), clodronate 
encapsulated liposomes (Van Rooijen et al., 1996; Wolff et al., 1997) or predosing animals 
with a null Ad vector (Tao et al., 2001). Clodronate liposomes are ingested by the KCs, 
which are then killed following phospholipase-mediated disruption of the liposomal 
bilayers and release of the clodronate (van Rooijen et al., 2003). Similarly, gadolinium 
chloride forms a colloidal precipitate in the bloodstream which is phagocytosed by the 
macrophages, resulting in cell destruction (Hardonk et al., 1992). These methods provide a 
therapeutic window in which the vector can be delivered whilst bypassing clearance by 
KCs and decreasing liver damage. Whilst these methods are valuable for studying Ad host 
interactions in the laboratory setting, they are not likely to be of clinical relevance and the 
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multitude and complexity of the immune response to Ad5 remains a hurdle for clinical 
applications. 
1.6.2.2 Adaptive immunity  
An important consideration which must be taken into account is the lack of natural pre-
existing neutralising antibodies in animals which may underestimate the importance of the 
human immune response. In the United States the seroprevalence to Ad5 is reported to be 
50%, whilst in sub-Saharan Africa this number rises to 80% (Sumida et al., 2005). The 
high seroprevalence of pre-existing NAb to the Ad5 capsid proteins, in particular the 
hexon, which has been shown by Sumida et al. to have NAb titers up to 10-fold higher 
than fiber-specific NAb titers, is a major hurdle for Ad5 gene therapy applications (Sumida 
et al., 2005). A study by Roberts et al., in which the seven HVRs of Ad5 were replaced 
with that of Ad48 (a so called “rare serotype”), demonstrated the vectors ability to largely 
evade Ad5 specific NAb in pre-immunised mice, therefore indicating a major role for the 
hexon HVRs in activating the adaptive immunity (Roberts et al., 2006). Chimeric Ad5 
vectors in which subsets of the HVRs were exchanged (Ad5HVR48(1-3), Ad5HVR48(4), 
and Ad5HVR48(5)) were generated to look more closely at the role of individual regions 
(Bradley et al., 2012b). The Ad5HVR48(1-3) vector resulted in intermediate NAb titres 
compared  to Ad5HVR48(1-7) and Ad5, and Ad5HVR48(4), and Ad5HVR48(5) were 
unable to bypass pre-existing Ad5 immunity in preimmunised mice, thereby indicating 
NAb target multiple HVRs (Bradley et al., 2012b).  
NAb responses have also been reported against the fiber protein (Bradley et al., 2012a; 
Gahéry-Ségard et al., 1998; Hong et al., 2003; Parker et al., 2009). Parker et al. 
pseudotyped the Ad5 fiber with a fiber from the less prevalent serotype Ad45 (Parker et 
al., 2009). The Ad5f45 vector partially bypassed neutralisation in vitro, indicating a 
significant proportion of NAbs identified by these assays are directed against the fiber 
(Parker et al., 2009). In a separate study, the fiber knob of Ad5 and Ad5HVR48(1-7) were 
replaced with that of the chimpanzee adenovirus AdC68 (AdC68 rarely causes infection in 
humans) (Bradley et al., 2012a; Xiang et al., 2006). Ad5KC68 demonstrated lower NAb 
titres in pre-immunised mice (preimmunised with two injections of 1010 vp of Ad5 
separated by 4 weeks) compared to Ad5, and Ad5HVR48(1-7)KC68 demonstrated a 
further decrease in Ad5-specific immunity compared to Ad5HVR48(1-7), thereby 
indicating the presence of antibodies directed against the fiber knob (Bradley et al., 2012a). 
It has been suggested that Ad5-specific NAbs are directed to different components of the 
Chapter 1 | Introduction 
 
21 
virion, depending on the route of infection (Cheng et al., 2010). Following natural 
infection they were directed primarily against fiber, whereas Ad5-specific NAbs following 
Ad5 vector vaccination were directed primarily against hexon (Cheng et al., 2010). 
Following natural Ad infection in airway epithelial cells, the fiber protein is produced in 
substantial excess to access CAR located in the tight junctions (Walters et al., 2002), 
however this does not occur following intramuscular injection of Ad vectors and hence 
may explain the different anti-fiber (native) versus the anti-hexon (vaccine) host response. 
In summary, the use of rare Ad serotypes which are less seroprevalent (Abbink et al., 
2007) is an attractive prospect, however the caveat being they are less well studied and 
their tropism defining interactions are not always understood, necessitating further 
research.  
1.6.3 Blood components 
Efforts to elucidate the infectivity mechanisms of Ad5 vectors in vivo have lead 
researchers to evaluate the role of the blood in determining the Ad tropism. It is perhaps 
unsurprising that Ads have evolved a multitude of methods by which to harness host cells 
and proteins for their benefit, whilst in parallel the immune system exhibits a range of 
defense mechanisms upon contact with the virus. Following intravascular administration, 
Ads have been shown to interact directly with a variety of blood cells, plasma proteins and 
coagulation factors (summarised in Figure 1.8 (page 27)). 
1.6.3.1 Erythrocytes 
Following a 30 min incubation with blood ex vivo, 90% of Ad5 are bound to human 
erythrocytes, increasing to 98.8% after 1 h co-incubation (Cichon et al., 2003; Lyons et al., 
2006). Ad5 interacts with and agglutinates human and rat erythrocytes, but not murine or 
rabbit (Carlisle et al., 2009; Cichon et al., 2003; Nicol et al., 2004). Incubation of human 
erythrocytes with free RGD peptide did not prevent Ad5 binding, nor did Ad5∆RGD (Ad5 
vector in which the RGD motif is deleted) decrease binding compared to Ad5 (Lyons et 
al., 2006). In the presence of human blood very low levels of virus transduction were 
observed in CAR positive cells in vitro, compared to Ad5 alone, indicating blood cells can 
prevent infection of epithelial cells (Lyons et al., 2006). Furthermore when virus was 
allowed to bind to carcinoma cells for short incubation times (< 5 min), prior to washing 
with blood, Ad5 infection was significantly reduced demonstrating the ability of human 
blood cells to inhibit infection by viral particles prebound to epithelial cells, an important 
factor for Ad gene therapy applications (Lyons et al., 2006). When the distribution of viral 
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genomes in blood samples from clinical trial patients injected intra-tumourally with 1 x 109 
Ad5 particles were studied, 99% of viral DNA detected in the bloodstream was associated 
with blood cells. This is in contrast to the situation observed in mice following intravenous 
injection, in which 99% of Ad5 genomes remain free in plasma, highlighting the caution 
required when extrapolating data from animal studies for human trials (Lyons et al., 2006). 
More recently, two important studies demonstrated that human erythrocytes express CAR 
(Carlisle et al., 2009; Seiradake et al., 2009). Anti-CAR antibodies decrease the binding of 
Ad5 to human erythrocytes in plasma by less than 25%, indicating a dependency on CAR 
but also implicating additional mechanisms (Carlisle et al., 2009). Furthermore, whilst the 
use of a CAR-binding ablated vector prevents binding to erythrocytes in phosphate 
buffered saline (PBS), it does not alter binding in human plasma (Carlisle et al., 2009; 
Nicol et al., 2004). Human erythrocytes also present complement receptor 1 (CR1), which 
binds Ad5 in the presence of antibodies and complement. The mechanism that the virus 
adopts to bind erythrocytes influences Ad5 circulation kinetics. Intravascular 
administration of Ad5 into CR1 transgenic mice resulted in a bloodstream half-life of less 
than 2 min, whilst injection into CAR transgenic mice resulted in up to 70% of Ad5 still 
detectable in the circulation at 6 h (Carlisle et al., 2009). In a separate study, Ad5 was 
administered to GATA1-CAR (that express CAR on erythrocytes) and control C57BL/6 
(CAR-negative erythrocytes) mice, resulting an 1000-fold higher viral load in the blood of 
GATA1-CAR versus control mice during the first 72 h post-injection (Seiradake et al., 
2009). Notably, viral genomes in the liver of GATA1-CAR mice were substantially lower 
compared to controls (Seiradake et al., 2009). Although reducing liver transduction, 
sequestration of Ad by erythrocytes limits biodistribution and prevents specific targeting to 
desired tissues. Conversely, the study by Nicol et al., showed no difference in liver 
transduction following intravascular delivery using Ad5 or non-CAR-binding Ad5 in rats, 
with erythrocytes expressing CAR (Nicol et al., 2004). These data strongly support a role 
for erythrocytes in determining Ad tropism, however the effect of virus binding to 
erythrocytes on biodistribution and blood kinetics in non-transgenic animals warrants 
further detailed investigation. 
Evidently, the complexity of Ad5 interactions with host factors is extensive but existing 
animal models may only provide limited information. The differences in the expression 
patterns of cellular receptors, such as the lack of CAR expression on mouse erythrocytes, 
may bypasses the very relevant sequestration mechanism observed in human blood. 
Another example is the expression of the Ad species B receptor, CD46, which is localised 
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to the testes in rodents, whereas it is widespread in humans. Whilst the use of transgenic 
models can help combat some of these problems, such as the recently reported desmoglein 
2 transgenic mouse model for the study of species B Ads (Wang et al., 2012), they will not 
aid the discovery of Ad:human host factor interactions which are currently undefined. A 
restraint to the successful development Ad gene therapy not to be underplayed is the 
species variation amongst the currently used animal models and humans. 
1.6.3.2 Platelets 
Ad5 can also bind to and activate circulating platelets (Othman et al., 2007; Stone et al., 
2007). A study in which mice were administered via the tail vein with Ad5, demonstrated 
platelet counts were significantly reduced after 5 and 24 h (Othman et al., 2007). The 
interaction between Ad and platelets initiates a cascade of events, as reported by Othman et 
al. Ad5 activates platelets and causes the rapid exposure of P-selectin, which is capable of 
binding to P-selectin glycoprotein ligand-1, detected on the majority of leukocytes and also 
present to a lesser extend on platelets, resulting in the formation of platelet-leukocyte 
aggregates (Othman et al., 2007). This causes the release of platelet and leukocyte 
microparticles, which are cell vesicles with inflammatory and coagulatory potency 
(Othman et al., 2007). P-selectin has been reported to mediate the tethering of leukocytes 
to endothelial cells (McEver, 1995). This study indicated that endothelial cells are 
activated after Ad5 administration (Othman et al., 2007). Additionally, Ad5 injection into 
mice resulted in an acute, significant increase in plasma von Willebrand factor (vWF), 
which originated from the activated endothelial cells. vWF is reported to mediate the 
binding of platelets to the endothelium (Sadler, 1998). Furthermore, Ad administration in 
mice deficient in vWF did not result in thrombocytopenia by 24 h. Platelets exhibit 
significantly less P-selectin expression and platelet-leukocyte aggregate formation after 1 
h, compared to vWF positive mice. Therefore these data indicate a role for P-selectin and 
vWF in mediating Ad induced thrombocytopenia. As 72% of human platelets are positive 
for CAR (Othman et al., 2007), Ad5 may bind to platelets via this receptor, thereby acting 
as a ‘sink’ for systemically delivered Ads as well as causing endothelial activation, 
thrombocytopenia and leukocyte infiltration (Othman et al., 2007; Stone et al., 2007).  
In a study by Stone et al., immunohistochemistry performed on livers harvested at 5 min 
post-injection, indicated triple co-staining with hexon, macrophage and platelet markers 
(Stone et al., 2007). Aggregates containing degranulated, virus-containing platelets were 
observed in the liver sinusoids, in the vicinity of KCs, implicating a role for platelets in 
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virus sequestration by KCs. Mice treated intravenously with an antibody against platelets, 
caused an approximate 66% reduction in platelet counts prior to Ad5 administration and 
viral genomes in the liver were significantly reduced at 5 min post-injection (Stone et al., 
2007). This suggests virus platelet aggregates may be rapidly captured in the hepatic 
reticuloendothelial system and degraded. 
However, the role of platelets in reticuloendothelial system uptake remains controversial. 
A study by Xu et al. reported that platelets were not required for virus sequestration by 
KCs, as platelet depletion in mice did not result in any significant difference in Ad uptake 
by KCs at 10 min post-injection (Xu et al., 2008). Therefore additional studies are required 
to confirm the importance of this interaction. 
1.6.3.3 Lactoferrin 
Lactoferrin, a multifunctional iron-binding glycoprotein produced at areas of inflammation 
and present at mucosal sites and in many bodily fluids (Masson et al., 1966), has been 
shown to enhance Ad5 cell binding to corneal epithelial cells (Johansson et al., 2007). 
Using monoclonal antibodies to block CAR caused no effect on human lactoferrin-
mediated infection in vitro. Furthermore, human lactoferrin from tear fluid promoted Ad5 
binding to CAR negative T cells more efficiently than T cells transfected to express CAR, 
thereby indicating cellular binding in a CAR-independent manner (Johansson et al., 2007). 
Replacing the Ad5 fiber with that of Ad35 resulted in significantly lower levels of 
transgene expression compared to an Ad5 control vector, suggesting a role for the fiber in 
lactoferrin-mediated infection (Johansson et al., 2007). 
A study by Adams et al. reported the ability of human and bovine lactoferrin to enhance 
Ad5-mediated transduction of human primary antigen expressing cells, such as dendritic 
cells, in a dose-dependent manner independently of CAR (Adams et al., 2009). The C-type 
lectin receptor dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN) facilitated entry of Ad5 complexed with bovine lactoferrin in dendritic 
cells, however the receptor for human lactoferrin remains elusive (Adams et al., 2009; 
Günther et al., 2011). 
1.6.3.4 Complement proteins 
The human complement component C3, a central component of the complement pathway, 
has also been shown to bind to Ad5 (Jiang et al., 2004). In complement C3 knockout mice, 
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administration of a relatively low dose Ad5 (2.3 x 109 vp) caused ~100-fold reduction in 
hepatocyte transduction after 3 days, in comparison to wild-type control mice (Zinn et al., 
2004). As the dose of Ad5 administered was increased (highest dose of 1.3 x 1010 vp) the 
difference between wild-type and C3-/- mouse liver targeting was decreased, as shown by 
bioluminescence imaging over a 35 day period, independently of antibody responses 
against Ad (Zinn et al., 2004). Preincubation of Ad5 with wild-type, C1q-/-, or factor B 
(protein components of the alternative complement system) deficient mouse sera for 5 min 
significantly increased transduction of mouse liver hepatoma cells in vitro, as compared to 
preincubation with C3-/- sera, indicating Ad-induced C3 activation is via a C1q or FB 
dependent mechanism (Zinn et al., 2004). Tsai et al. demonstrated the ability of 
complement protein Cq1 to mediate Ad infection in a CAR-negative cell line (Tsai et al., 
2008). In a separate study, injection of high dose (1.5 x 1011 vp/mouse) Ad5 resulted in 
similar levels of hepatocyte transduction in wild-type and C3 knockout mice at 48 and 72 
h. However thromocytopenia and the acute inflammatory response was significantly 
reduced (Kiang et al., 2006). Whilst these results indicate a dose-dependent role for C3 in 
determining liver gene transfer, they suggest it may have a pivotal role in determining the 
host immune response.  
A study by Seregin et al. performed genetic engineering of Ad5 to ‘capsid display’ the 
human complement inhibitor decay-accelerating factor (DAF) following insertion into the 
C-terminus of Ad protein IX (Seregin et al., 2010). The vector resulted in reduced 
complement activation in vitro and complement dependent immune responses in vivo, 
including decreased levels of pro-inflammatory cytokines, chemokine responses, 
thrombocytopenia and minimized endothelial cell activation compared to Ad5 (Seregin et 
al., 2010). Ad5 capsid-displaying DAF vectors also reduced transgene and capsid specific 
adaptive immune responses, after intravascular and intramuscular delivery in Ad5-naïve 
and Ad5 immune mice (Seregin et al., 2011).  
1.6.3.5 Blood factors 
In 2005, Shayakhmetov et al. were the first to describe a potential role of blood factors in 
determining Ad5 tropism (Shayakhmetov et al., 2005). Using an in situ liver perfusion 
technique, they analysed gene delivery to the liver in the absence of blood. Hepatocyte 
transduction of Ad5 and the non-CAR binding vectors, Ad5 containing the Ad35 knob 
domain, and Ad5*F (which has a single point mutation at position Y477 in the fiber knob, 
ablating the CAR interaction) were assessed. In the absence of blood, hepatocyte 
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transduction by the non-CAR binding vectors was significantly decreased compared to 
Ad5, indicating the involvement of an alternative mechanism for Ad5 infection that are 
dependent on blood factors (Shayakhmetov et al., 2005). To investigate the cellular 
receptor responsible for this novel pathway, mice were preinjected with competing ligands 
for hepatocellular receptors, including polymerised bovine serum albumin (saturates the 
scavenger receptor SR-BI), asialofetuin (saturates the asialoglycoprotein receptor), human 
low density lipoprotein (LDL) (saturates the LDL receptor) or lactoferrin (saturates low-
density lipoprotein receptor-related protein (LRP) and heparan sulphate proteoglycans 
(HSPGs)). A 50-fold reduction of Ad5*F, a 600-fold reduction of Ad5/35 and an 8-fold 
reduction in Ad5 liver gene transfer in the presence of lactoferrin indicated cellular binding 
through LRP and HSPGs (Shayakhmetov et al., 2005). Injection of heparinase I, resulting 
in enzymatic digestion of heparan sulphate side-chains, prior to vector administration 
resulted in significantly lower levels of liver transduction in wild-type mice, implicating 
HSPGs as the major cellular receptors (Shayakhmetov et al., 2005). Consequently, tandem 
mass spectrometry and slot blot assays were used to identify blood factors capable of 
interacting with Ad. Coagulation factor IX and complement component C4-binding protein 
were shown to directly interact with the Ad fiber knob and mediate Ad infection in vitro 
(Shayakhmetov et al., 2005). In addition, mouse livers perfused with saline containing FIX 
showed increased hepatocyte transduction of Ad5/35 and Ad5*F, reaching levels 
comparable to Ad5. However, injection of Ad5/35 and Ad5*F into FIX knockout mice 
resulted in no significant difference in liver gene transfer compared to wild-type mice 
(Shayakhmetov et al., 2005). Whilst this data suggested a role of FIX and C4-binding 
protein in mediating Ad5 hepatic transduction, further studies supported the involvement 
of additional blood factors key to determining the Ad5 inherent liver tropism. 
 
  
 
Figure 1.8. In vivo Ad5 interactions with host factors.  
Ad5 binds to coagulation FX due to a high affinity interaction between the Ad5 hexon HVR domains and the FX Gla domain. FX subsequently bridges 
the complex to HSPGs on the surface of hepatocytes. Opsonisation by IgM antibodies, complement and scavenger receptors can promote Kupffer 
cell uptake. Ad5 fiber knob can bind to CAR-expressing erythrocytes or in the presence of complement and antibodies the virus binds to CR1 on the 
surface of erythrocytes. Ad5 can also interact with lactoferrin. Ad5 binding to platelets can induce the formation of platelet-leukocyte aggregates, a 
process dependent on von Willebrand factor and P-selectin. 
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1.7 A critical role for coagulation factor X in determining the 
Ad5 liver tropism 
Several other vitamin-K dependent zymogens were subsequently found to enhance 
transduction of Ad5 in HepG2 cells (Parker et al., 2006). These blood coagulation factors 
FVII, FIX, FX and protein C are zymogens of serine proteases. The vitamin-K dependent 
coagulation factors are structurally very similar and likely to be derived from a common 
ancestral gene via gene duplication and exon shuffling (Davidson et al., 2003). They have 
a light chain consisting of a γ-carboxylated glutamic acid (Gla) rich domain and two 
epidermal growth factor-like domains which are disulfide linked to the serine protease (SP) 
heavy chain (Figure 1.9).  
 
Serine protease
EGF2
EGF1
Gla
 
Figure 1.9. Coagulation factor X. 
The domain structure of FX, highlighting the γ-carboxylated glutamic acid, the epidermal 
growth factor (EGF) 1-like, EGF2-like and serine protease domains. The green balls 
indicate calcium ions. This figure has been adapted from Venkateswarlu et al. 
(Venkateswarlu  et al., 2002). 
To investigate whether zymogen activation was required to increase Ad infection, FX was 
incubated with recombinant tick anticoagulant protein (TAP), a highly specific direct FXa 
inhibitor, or fondaparinux, which inhibits FXa indirectly through antithrombin III. Neither 
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inhibitor had an effect on FX-mediated Ad transduction in HepG2 cells and pretreating 
mice with fondaparinux prior to injection of a CAR-binding ablated Ad5 vector (AdKO1) 
caused no effect on levels of liver transduction. Therefore, this demonstrated that zymogen 
activation was not necessary (Parker et al., 2006). The authors went on to assess whether 
FX could interact with Ad5 and AdKO1 directly. Surface plasmon resonance (SPR) 
analysis revealed a strong association between each virus and FX in a dose-dependent 
manner, however upon the addition of ethylenediamine tetra-acetic acid (EDTA) the virus 
readily dissociated, indicating a dependency on calcium. In an attempt to investigate 
whether FX-mediated transduction was relevant in vivo, Parker et al., first assessed the 
ability of FX to restore gene transfer of AdKO1 to levels of Ad5 in an ex vivo liver 
perfusion model. FX not only increased AdKO1 liver transduction to levels comparable to 
Ad5, but substantially increased hepatocyte transduction by both vectors, causing a 25-fold 
increase in Ad5 and an equivalent 250-fold increase in AdKO1 transgene expression 
(Parker et al., 2006). Moreover, following intravascular delivery, Ad-mediated liver gene 
transfer was greatly reduced in warfarin pretreated mice demonstrating the requirement for 
vitamin-K dependent coagulation factors (Parker et al., 2006; Waddington et al., 2007). 
Warfarin inhibits the effective synthesis of vitamin K-dependent coagulation factors by 
preventing efficient γ-carboxylation of the Gla domain, thus reducing levels of functional 
circulating factors (Mosterd et al., 1992; Stanton et al., 1992). Despite FVII, FIX and 
protein C being effective enhancers of Ad5-mediated gene transfer in vitro only 
intravascular injection of physiological concentrations of FX, 30 min prior to AdKO1 or 
Ad5 administration, was reported to completely restore Ad hepatic transduction in 
warfarin-treated mice (Parker et al., 2006; Waddington et al., 2007). Another study 
investigated whether warfarin could block Ad liver sequestration by KCs, an effect which 
can occur within minutes after Ad administration (Waddington et al., 2007). Warfarin 
treatment did not effect Ad5 virion levels in the liver and spleen at 1 h post-injection, 
however at 48 h virion accumulation was decreased, suggesting coagulation factors do not 
effect KC uptake but selectively influence hepatocyte transduction (Di Paolo et al., 2009b; 
Waddington et al., 2007). Together these data demonstrated a pivotal role for FX in 
determining the targeted liver gene transfer of Ad5 via a CAR-independent mechanism.  
1.8 FX Gla domain mediates binding to Ad5 
In order to identify the region of FX responsible for binding to Ad5, Waddington et al., 
utilised SPR to demonstrate the ability of the monoclonal antibody HX-1, directed against 
the light chain (Gla-EGF1-EGF2) of FX, to block binding to Ad5 and inhibit AdKO1 
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transduction, in the presence of physiological levels of FX, in HepG2 cells (Waddington et 
al., 2008). In addition, SPR analysis revealed that Ad5 failed to bind to Gla domainless FX 
(Kalyuzhniy et al., 2008; Waddington et al., 2008). In vivo, Gla domainless FX did not 
restore Ad5 liver gene transfer in warfarin-treated mice (Waddington et al., 2008), thereby 
demonstrating the importance of the Gla domain in the Ad5:FX interaction. Factor X-
binding protein (X-bp), an anticoagulant isolated from Deinagkistrodon acutus (the 
hundred pace snake), is a high affinity Gla domain binding protein (Atoda et al., 1998). X-
bp blocked Ad5 binding to FX as shown by SPR and preincubation of human FX with 
eqimolar concentrations of X-bp inhibited FX-mediated Ad5 infection in HepG2 cells 
(Waddington et al., 2008). Preinjection of X-bp resulted in significantly lower levels of 
Ad5 liver transduction in mice. Moreover, preincubation of FX with X-bp prior to injection 
into warfarin-treated mice blocked the ability of FX to restore Ad5 hepatic gene transfer 
(Waddington et al., 2008). These data demonstrate the FX Gla domain is critical for FX-
mediated Ad5 liver transduction.  
1.9 FX binds directly to the Ad5 hexon  
Initially it was proposed that coagulation factor mediated hepatic gene transfer was as a 
result of FIX binding to the Ad5 fiber (Shayakhmetov et al., 2005). A study using a panel 
of Ad5 vectors pseudotyped with fibers from species D, including f17, f24, f30, f33, f45 
and f47, investigated the capacity of each vector to bind to coagulation factors (Parker et 
al., 2007). SPR analysis indicated that all vectors directly bound to FX in a calcium-
dependent manner, indicating bridging of FX to an alternative capsid protein or to a highly 
conserved region in the fiber. FX caused a significant increase in HepG2 cell binding and 
transgene expression for all vectors (Parker et al., 2007). FX-mediated Ad infection was 
demonstrated to occur via HSPGs, as shown by the enhanced levels of transduction in 
Chinese hamster ovary (CHO) cells expressing HSPGs compared to the significantly 
reduced levels in genetically modified CHOpgsA745 cells, which have a defect in 
xylosyltransferase and do not produce glycosaminoglycans, therefore have no surface 
expression of the receptors (Parker et al., 2007). Injection of Ad5/f47 into coagulation 
depleted mice significantly reduced levels of hepatic transduction (Waddington et al., 
2007), hence the effects of FX were relevant not only for Ad5 but also for Ad5 fiber 
pseudotyped vectors. 
An unexpected finding was observed when SPR studies demonstrated that fully fiberless 
Ad5 virions bound to FX as efficiently as wild-type Ad5 (Waddington et al., 2008). 
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Deletion of the Ad5 fiber had no effect on FX-mediated Ad5 cellular binding, thus 
confirming the binding of FX to an alternative capsid protein (Waddington et al., 2008). 
Previously, hexon was thought to act principally as a structural protein. However, SPR 
analysis showed the FX Gla domain bound to the Ad5 hexon protein in a high affinity, 
calcium-dependent manner (Kalyuzhniy et al., 2008; Waddington et al., 2008). Both 
human and mouse FX bound to the Ad5 hexon with picomolar affinity (Kalyuzhniy et al., 
2008; Waddington et al., 2008).  
1.10 FX binds to hexon HVRs 
Waddington et al. employed cryoelectron microscopy to generate a three-dimensional 
reconstruction of the Ad5:FX interaction (Figure 1.10). Cryoelectron microscopy revealed 
that the FX molecule binds within the central cavity formed by each hexon trimer, a region 
characterised by the presence of HVRs (Kalyuzhniy et al., 2008; Waddington et al., 2008). 
Ads have seven HVRs on the hexon which differ amongst Ad types. In addition to binding 
to the Ad5 HVRs, SPR studies demonstrated the ability of FX to bind Ads from species A, 
B, C, D, E and F with varying degrees, indicating that the Ad:FX interaction is highly 
conserved (Kalyuzhniy et al., 2008; Waddington et al., 2008).  
Previously the hexon was thought not to be directly related to tropism determination. In 
1999, a study by Vigne et al., reported the inclusion of a RGD-containing peptide, targeted 
to αv integrins, in HVR5 of the hexon significantly increased transgene expression in 
human vascular smooth muscle cells, naturally refractory to Ad infection due to a lack of 
CAR expression (Pasqualini et al., 1997; Vigne et al., 1999). Vigne et al. demonstrated the 
ability of hexon HVR-modified capsids to be efficiently internalised by cells lacking the 
virus primary receptors and this was one of the earliest studies to imply a function of the 
HVRs in Ad cell entry (Vigne et al., 1999). Intravenous delivery of the vector resulted in 
~98% lower hepatic transgene expression after 48 h compared to control Ad5 and its 
counterpart containing the RGD peptide in the fiber (Vigant et al., 2008). Vigant et al. also 
demonstrated substantially reduced liver transduction and hepatoxicity using an Ad5 vector 
in which HVR5 was replaced by non-targeting peptides containing 8 or 24 glycine-alanine 
residues (Vigant et al., 2008). 
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Figure 1.10. Analysis of Ad5 hexon binding to FX by cryoelectron microscopy. 
The image on the left hand side is an overlay of three-dimensional cryoelectron 
microscopy reconstructions of uncomplexed Ad5 (blue) and the Ad5:FX complex (purple) 
and the image on the right hand side is a close-up view of FX-labelled hexon. This figure 
has been  adapted from Waddington et al. (Waddington et al., 2008).  
A study using an engineered Ad5 vector, Ad5HVR48, in which all the amino acids of the 
HVRs in Ad5 were replaced with those of Ad48 (a species D Ad which does not bind FX), 
abolished FX binding (Waddington et al., 2008). FX did not enhance Ad5HVR48 cellular 
binding or transduction in vitro and a 600-fold reduction of liver transgene expression 
compared to Ad5 was observed in mice depleted in KCs, due to preinjection with 
clodronate liposomes (Waddington et al., 2008). In a separate study, FX binding was 
decreased using an Ad5 vector in which a 71 amino acid biotin acceptor peptide (BAP) 
was inserted into HVR5 (Kalyuzhniy et al., 2008; Shashkova et al., 2009). Incubation of 
coagulation factors with Ad5BAP did not enhance gene transfer in vitro and preinjection of 
FX failed to increase Ad5BAP liver transduction in warfarin-treated mice 48 h post-
injection (Kalyuzhniy et al., 2008), again confirming the importance of the HVRs for the 
Ad5:FX interaction. 
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Figure 1.11. Model view of Ad5:FX interaction. 
The Gla domain of one FX molecule bound within the cavity formed by the hexon trimer, 
whilst the FX SP domain is orientated outwards from the Ad5 capsid. This model was 
taken from Waddington et al. (Waddington et al., 2008). 
In order to dissect the hexon:FX interaction Alba et al. modelled it by fitting the published 
crystal structure of hexon (Rux et al., 2003) and a molecular model of FX (Venkateswarlu 
et al., 2002) to the cryoelectron microscopy model (Waddington et al., 2008) in order to 
identify the relevant contact residues (Alba et al., 2009). These were found to be HVR5 
and HVR7 (Alba et al., 2009). Phylogenetic analysis of HVR sequences of FX binding 
Ads, in comparison to those that do not bind FX, identified a glutamic acid residue at 
position 451 as common amongst FX binding Ads, which was replaced by a glutamine in 
non-binding Ads (Waddington et al., 2008). Subsequently, the authors manipulated the 
viral capsid using point mutagenesis of two amino acids in HVR5 (T270P and E271G), 
four amino acids in HVR7 (I421G, T423N, E424S and L426Y) or a single mutation at 
position 451 in HVR7, swapping these residues with sequences of the species D, non-FX 
binding, Ad26. The mutations did not affect virus production. Ad5 with mutations in 
HVR5 resulted in decreased FX-mediated Ad5 cell binding and transduction in vitro, as 
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well as liver gene transfer in mice (Alba et al., 2009). Ad vectors with HVR7 mutations 
showed profound inhibition of FX binding by SPR, ablated the enhancement in binding 
and transduction in cell lines and mouse hepatic transduction in the presence of FX. 
Furthermore, intravenous administration of the HVR5 (T270P and E271G) and HVR7 
(I421G, T423N, E424S, L426Y and E451Q) mutated vector (Ad5-HVR5*7*E451Q) into 
non-human primates, microcebus murinus, substantially reduced hepatocyte transgene 
expression compared to control Ad5 (Alba et al., 2012). Ad5 was also detected in the 
spleen, heart, lung, kidney, and to a lesser extent in the thymus, pancreas, intestines and 
lymph nodes. Whilst the FX-binding ablated vector genomes were found in the spleen, 
negligible amounts were detected in the other tissues (Alba et al., 2012). This indicates a 
role for the FX pathway in mediating virus transduction and genome accumulation not 
only in the liver but also in several other organs. Heparin, which acts as a competitive 
inhibitor of HSPGs, blocked FX-mediated Ad5 binding to non-human primate livers ex 
vivo, showing a dependency on HSPGs and indicating conservation of this pathway across 
diverse species (Alba et al., 2012). In addition to HVR5 and HVR7, Kalyuzhniy et al. used 
cryoelectron microscopy and sequencing alignment to implicate a site at the sequence TDT 
in HVR3 as a potential contact point between Ad and FX (Kalyuzhniy et al., 2008), 
however the role of this motif is yet to be verified. 
1.11 Ad:FX complex binding to hepatocytes 
HSPGs are composed of a core protein to which one or more heparan sulphate (HS) 
glycosaminoglycan side-chains (linear polysaccharides composed of alternating N-
acetylated or N-sulphated glucosamine units and uronic acids) are covalently linked (Esko 
et al., 2001). Bradshaw et al. demonstrated the ability of heparinase III, a heparin lyase that 
specifically cleaves N-acetylated domains of HS, to inhibit Ad5 cellular binding and gene 
transfer in vitro in the presence of FX, hence indicating that the HS side-chains mediate 
attachment of Ad5:FX complexes to the cell surface  (Bradshaw et al., 2010). Experiments 
employing sodium chlorate, a selective inhibitor of sulfation (Safaiyan et al., 1999), 
demonstrated that Ad5 uptake via the FX pathway is dependent on HS sulfation. The study 
showed inhibition of N-linked, and particularly inhibition of O-linked sulphate groups, 
which are highly expressed in the liver, attenuated FX-mediated Ad5 cell binding and 
transduction in vitro, in a dose-dependent manner (Bradshaw et al., 2010). Attachment of 
fluorescently labelled Ad5 in the presence of FX to mouse liver sections ex vivo was 
significantly reduced in the presence of heparin, however neither de-O-sulphated heparin, 
which lacks O-sulphate groups, nor de-N-sulphated heparin, which lacks N-sulphated 
Chapter 1 | Introduction 
 
35 
groups had any effect on Ad5 attachment. Moreover, heparin substantially reduced FX-
mediated Ad5 accumulation in the liver 1 h after intravascular administration in 
macrophage depleted mice, whilst no effect was observed with de-O-sulphated heparin and 
de-N-sulphated heparin (Bradshaw et al., 2010).  
1.12 Post-binding events via the FX infectivity pathway 
Using non-CAR binding and/or αv integrin mutants Bradshaw et al. (Bradshaw et al., 
2010) showed a dependency on an intact penton base RGD motif for efficient post-
attachment cell entry and intracellular transport via the FX pathway, thus indicating the 
interaction with cellular integrins as co-receptors for internalisation is retained. Whilst 
fluorescently-labelled Ad5 and AdKO1 resulted in similar levels of accumulation at the 
MTOC after 1 h in the presence of FX in vitro, accumulation of the penton base RGD 
mutant vectors were significantly delayed. In addition, using a short hairpin RNA approach 
to knockdown αv integrin expression in a CAR low expressing cell line, Ad5 trafficking to 
the perinuclear area was substantially reduced, thereby confirming the importance of 
integrin engagement for transport via the FX-mediated pathway. 
After cell surface attachment via HSPGs, the fiber also plays a role in cell entry and 
subsequent intracellular trafficking. A study investigating the role of FX in Ad5, Ad35, 
Ad5/fiber 35 and Ad5/penton 35/fiber 35 chimeric vector gene transfer, used SPR to first 
show that all of the vectors could bind to the coagulation factor, with pseudotypes having 
FX-binding affinities similar to other vectors possessing the same serotype hexon (Greig et 
al., 2009). In the absence of the native species B CD46 receptor, the vectors use FX to 
bridge the complex to HSPGs, thereby enhancing cell surface binding and internalisation, 
however in the presence of FX, transduction of all viruses capable of binding CD46 i.e. 
Ad5/f35, Ad5/p35/f35, and Ad35, was substantially reduced in CHO-BC1 cells, which 
express CD46 (Corjon et al., 2011; Greig et al., 2009). FX increased intracellular uptake of 
vectors in both CD46 and CD46 negative cells, indicating the decrease in gene transfer did 
not involve the endocytosis step of the infectivity pathway (Corjon et al., 2011; Greig et 
al., 2009). This suggests that FX limits post-internalisation mechanisms that lead to 
cellular transduction by viruses containing the Ad35 fiber. The negative effect of FX on 
Ad5/35 vector transduction in vitro was shown to be due to inefficient intracellular 
trafficking and accumulation of virus in the late endosomal compartment, resulting in a 
delayed release from vesicles and nuclear import (Corjon et al., 2011; Greig et al., 2009). 
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These studies, implying a functional role for the fiber protein, show some overlap with the 
well known classical CAR-mediated pathway, for which the fiber is critical.  
Corjon et al. investigated whether or not FX was internalised with Ad5, using fluorescently 
labelled Alexa Fluor-555 FX and Alexa Fluor-488 Ad vectors (Corjon et al., 2011). In 
HSPG expressing CHO cells, control FX alone was endocytosed, with signals observed 
intracellularly after 15 min. Following coincubation, fluorescent signals for both FX and 
Ad5 were detected colocalised within the cell at the same time point, as shown by confocal 
microscopy, thereby indicating co-endocytosis (Corjon et al., 2011). By 1 h, Ad5 particles 
trafficked to the nucleus, resulting in reduced colocalisation with FX, which remained in 
the cell periphery. In the case of Ad5f35, at 3 h post-infection the FX:Ad5f35 complexes 
remained colocalised in the cytoplasm, again indicating inefficient intracellular trafficking 
compared to Ad5 (Corjon et al., 2011). 
1.13 Methods of manipulation of the Ad:FX interaction 
In vivo kinetics and Ad biodistribution are defined by a range of host interactions. Many 
years of research have been focused on altering the tropism of Ad5, the majority of the 
early studies concentrating on targeting the vector to alternative receptors. A great deal of 
these efforts were not as successful as anticipated. In hindsight, this is perhaps unsurprising 
and can be explained by the recent discoveries regarding the role of blood coagulation FX 
in liver transduction and other tropism determining pathways of Ads (Nilsson et al., 2011; 
Waddington et al., 2008; Wang et al., 2011), as well as having a more detailed knowledge 
of the Ad-induced immune response. Gaining a better understanding of Ad biology allows 
for a more informed progression and rationale design of optimised systems. Here a variety 
of methods to manipulate FX-mediated Ad gene transfer are discussed (Figure 1.12). 
1.13.1 Genetic modification of the Ad hexon to prevent FX binding 
Genetic manipulation of capsid proteins, designed to bypass host interactions and improve 
infectivity of desired tissues, is a frequently used targeting approach for Ad5. Mutagenesis 
strategies aimed at adapting viral tropism include pseudotyping with rare Ad types, non-
human or those devoid of FX binding, hexon or fiber ‘swapping’ or incorporation of 
targeting moieties (reviewed extensively by Coughlan et al. (Coughlan et al., 2010)). In the 
context of FX-mediated transduction, modification of the hexon protein is an attractive 
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strategy to prevent the virus interaction with FX following intravascular delivery, thereby 
reducing Ad hepatic gene transfer.  
Several studies genetically modifying the HVR5 and HVR7 domains demonstrated 
significantly decreased hepatic transgene expression in both rodents and non-human 
primates (Adams et al., 2009; Alba et al., 2012; Kalyuzhniy et al., 2008; Vigant et al., 
2008; Waddington et al., 2008). As previously mentioned, a study by Alba et al. showed 
the levels of liver gene transfer were greatly reduced using FX-binding ablated vectors, 
point-mutated at HVR5 (T270P and E271G) and HVR7 (I421G,T423N,E424S, L426Y and 
E451Q), a so called Ad5HVR5*7*E451Q vector (Alba et al., 2010; Alba et al., 2011). 
This occurred regardless of macrophage depletion. At high viral doses (1 x 1011 vp/mouse 
or 4 x 1012 vp/kg), significantly higher quantities of Ad5HVR5*7*E451Q viral genomes 
were detected in the spleens of macrophage-depleted mice, compared with Ad5 (Alba et 
al., 2010). This suggests that Ad clearance by macrophages significantly reduces splenic 
uptake independently of FX. At this high viral dose Ad5 and Ad5HVR5*7*E451Q caused 
an increase in several chemokines and cytokines including IL-12, monokine-induced by 
interferon γ and 10-kDa interferon γ-induced protein, all of which were elevated following 
FX-ablated vector administration compared to Ad5, whilst IL-6 was significantly 
decreased (Alba et al., 2010). At such high doses (4 x 1012 vp/kg) it is difficult to predict 
whether such toxicities would be relevant in humans, as the dose administered in clinical 
trials is much lower (e.g. 2 x 1011 vp/person) (Au et al., 2006; Hamid et al., 2003; Small et 
al., 2006). Attempts at retargeting the vector involved the generation of a non-FX binding 
Ad5 vector containing the Ad35 fiber (Ad5HVR5*7*E451/F35++) (Alba et al., 2010). This 
Ad35 fiber (Ad35++) contains two amino acid changes, inducing a 60-fold higher affinity 
to the subgroup B receptor CD46 compared to native Ad35 (Wang et al., 2008). 
Intravascular injection of Ad5HVR5*7*E451/F35++ in macrophage-depleted CD46 
transgenic mice showed increased gene transfer in the lung, coupled with reduced 
transduction in the liver and spleen (Alba et al., 2010). In these animals the 
Ad5HVR5*7*E451/F35++ lung/liver ratio was approximately 800:1, resulting in a 16,000-
fold increase in lung transduction compared to Ad5HVR5*7*E451Q (Alba et al., 2010). 
A separate study by Short et al., in which the Ad5 hexon was replaced with that of the 
species B Ad3 (Ad5H3), reduced vector binding to FX as demonstrated by SPR (Short et 
al., 2010). Incubation with physiological levels of FX caused no enhancement of Ad5H3 
infectivity in vitro and caused a 100-fold decrease in liver gene transfer. This was 
comparable to Ad5 in warfarin-treated mice. Substitution of the fiber knob domain with 
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that of CD46 binding Ad3 enhanced tumour transduction and anti-tumour efficacy by a 
conditionally replicating version of the vector (Short et al., 2010).  
Khare et al. adopted a different strategy to genetically manipulate the Ad:FX interaction 
(Khare et al., 2011). As hexon is reported to be a major antigenic capsid protein (Sumida et 
al., 2005), generating hexon-chimeric vectors utilising rare Ads may also be beneficial for 
overcoming pre-existing immunity (Roberts et al., 2006; Youil et al., 2002). Replacing the 
HVR domains of Ad5 with those of Ad6 (to create an Ad5/6 vector), another species C 
virus which is less seroprevalent and previously shown to evade KC uptake (Shashkova, 
May et al. 2009), this group achieved 10-fold higher transduction in the liver following 
intravenous delivery (Khare et al., 2011). Both Ad5 and Ad6 retain the glutamic acid at 
position 451 in HVR7 that is conserved in all tested FX-binding Ads (Waddington et al., 
2008). Ad6 binds to FX in vivo, but in this instance the interaction was exploited in order 
to attain targeted hepatic delivery while escaping KC uptake. Liver transduction was 
significantly reduced for Ad5 and Ad5/6 in warfarin-treated animals indicating a 
sensitivity to vitamin K dependent coagulation factor depletion (Khare et al., 2011). Ad5/6 
is less efficiently phagocytosed by macrophages in vitro, and this is suggested to be due to 
the block of Ad5 HVR 1, 2, 5 and 7 binding to scavenger receptor SRA-II (Khare et al., 
2012). Therefore without induction of KC activation in vivo and subsequent virus 
sequestration, the vector can more efficiently target the liver, features desirable for liver 
gene therapy applications (Khare et al., 2011; Khare et al., 2012). 
1.13.2 Polymer-conjugated Ad complexes shield the vector from FX 
Chemical modification of Ads using polymers to ‘shield’ the hexon protein from FX is an 
alternative strategy. This has the additional advantage of also precluding other host 
interactions e.g. complement, neutralising antibodies. Polyethylene glycol (PEG) is an 
uncharged, hydrophilic, non-immunogenic polymer synthesised of repeating CH2CH2O 
subunits, with a molecular weight ranging from 200 to 40,000 Da. In general, chemical 
modifications based on monovalent PEG or also commonly used multivalent N-(2-
hydroxypropyl methacrylamide) (HPMA) involves covalent attachment to the Ad surface 
by the use of activated tresyl-monomethoxy PEG (TMPEG), succinimidyl succinate-
monomethoxy PEG (SSPEG) or monomethoxy PEG (MPEG) (Croyle et al., 2000; 
O'Riordan et al., 1999). The activated PEG reacts preferentially with the epsilon-amino 
groups of lysine residues, the most abundant functional group on the Ad capsid, present on 
the hexon, fiber and penton (O'Riordan et al., 1999). Coating the Ad capsid in HPMA 
Chapter 1 | Introduction 
 
39 
molecules prevents virus binding to FX via the hexon (Subr et al., 2009) and has been 
shown to improve pharmacological profiles by protecting from proteolytic degradation and 
extending plasma kinetics.   
In the study by Subr et al. Ad5 was coated with HPMA modified to contain positively 
charged quaternary amine groups (N,N,N-trimethylammonium ethyl) (Subr et al., 2009). 
As Ad5 possesses an overall negative charge, this improved the yield of the coating 
reaction by enhancing the electrostatic interaction of the positive coating polymer with 
negatively charged groups on the surface of the virus. Coincubation of the modified 
vectors with FX caused no increase in Ad transduction in a CARlow expressing cell line in 
vitro, indicating that the FX-binding residues within the HVRs of the hexon are shielded 
by the polymer (Subr et al., 2009).  
Prill et al. combined genetic manipulation techniques, by mutagenesis of a single amino 
acid in HVR5 to introduce a surface accessible cysteine, with covalent chemical coupling 
to protein moieties at the site of genetic modification (Prill et al., 2011). Coupling the 
vector to PEG molecules, ranging in sizes 750 to 5,000 Da, abolished transduction 
mediated by FX in vitro. Coupling to a 20,000 PEG moiety resulted in variability in its FX 
shielding efficiency due to only 50% coverage of the hexon. Intravenous administration of 
the 750, 2,000 or 20,000 Da PEGylated vectors resulted in significantly decreased liver 
transduction compared to Ad5, and to similar levels of Ad5 in warfarin-treated mice (Prill 
et al., 2011).  
Biodistribution characteristics of polymer coated Ad complexes are reported to be affected 
by the density of the PEG shield (Doronin et al., 2009). Decreased liver transgene 
expression could be due to the size restrictions imposed by the liver sinusoid fenestrae and 
not solely due of the virus being masked from FX (Hofherr et al., 2008). The presence of 
fenestrae allows the virus to navigate through the space of Disse and rapidly reach their 
receptors on the surface of hepatocytes. However, the size of fenestrae, varying 
significantly across species, ranging from 150-175 nm in rats (Wisse et al., 1985) and ~140 
nm in mice (Snoeys et al., 2007), the two most commonly used animal models, whilst only 
~107 nm in healthy human livers (Wisse et al., 2008), may act as a sieve preventing entry 
depending on the dimensions of the vectors. This was highlighted when Hofherr et al. 
revealed Ad5 conjugated with 20 and 35 kDa PEG, but not 5 kDa markedly reduced liver 
transduction despite maintaining the ability to bind coagulation FX (Hofherr et al., 2008). 
In the study by Prill et al. addition of 5 kDa PEG to the Ad vector resulted in an 11-fold 
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increase in hepatocyte transduction, an effect which was independent of FX and more 
likely due to vector shielding from KCs (Prill et al., 2011). This may be a valuable 
approach for liver directed gene therapy. PEGylated Ad complexes are an attractive and 
viable targeted therapeutic gene therapy approach which will no doubt be improved by 
advances in polymer chemistry.   
1.13.3 Adaptor molecules 
Developing adaptor molecules, which consist of a capsid binding domain genetically or 
chemically fused to a specific cell targeting domain e.g. bispecific antibodies, single-chain 
antibody variable fragments (scFv) or growth factors, is another method which has been 
employed to manipulate the Ad5:FX interaction. Ad vectors conjugated to adaptor 
molecules serve a dual function; the antibody selectively retargets the Ad complex to the 
desired tissues whilst simultaneously blocking binding to the native receptors.  
Chen et al. exploited the high affinity interaction between Ad5 and FX by generating FX 
fusion proteins (Chen et al., 2010). As it is the Gla domain of FX which binds to the virus, 
plasmids were constructed that removed the FX SP domain and instead fused the Gla-
EGF1 domain with scFv directed against the tumour markers Her2, EGFR or the stem cell 
marker ATP-binding cassette protein G2 (ABCG2) (Chen et al., 2010). The Ad-scFv 
fusions caused increased targeting and cytotoxicity of cancer cells in vitro and in vivo. 
Although an effective method of targeting, levels of liver transduction were unaffected 
with Ad-scFv fusions suggesting Ad5 binding to Gla-scFv may not be stable in vivo and is 
displaced by the greater levels of FX in the bloodstream (Chen et al., 2010). 
1.13.4 Pharmacological agents to prevent Ad transduction 
Recent advances in the understanding of the precise mechanisms involved in Ad5 binding 
to FX points to a target suitable for drug discovery. Ad5 in combination with 
pharmacological agents has already proven effective for mediating systemically delivered 
gene therapy in animal models. Factor X binding protein (X-bp), which binds with high 
affinity to the FX Gla domain preventing the Ad5:FX interaction (Waddington et al., 
2008), the use of warfarin to decrease circulating levels of functional blood factors (Parker 
et al., 2006) or heparin to block HSPGs (Bradshaw et al., 2010), have all reduced FX-
mediated Ad5 liver transduction. These agents however are sub-optimal for administering 
to patients about to undergo a therapeutic gene therapy procedure due to anticoagulant 
properties (O'Donnell, 2012). The feasibility of viral/drug combination gene therapy 
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strategies to block redundant Ad infection whilst maintaining the integrity of the virus is 
yet to be fully realised. 
The potential of novel pharmacological compounds to specifically block Ad interactions 
with their native receptors was elegantly illustrated by Spjut et al (Spjut et al., 2011). A 
recent study demonstrated that species D Ad37 infection causes epidemic 
keratoconjunctivitis by binding of the Ad fiber knob protein to glycoproteins containing 
two terminal sialic acid moieties on the surface of epithelial cells in the cornea or 
conjunctiva (Nilsson et al., 2011). A combination of molecular modelling, nuclear 
magnetic resonance and X-ray crystallography dissected the interaction to reveal that the 
two sialic acids dock into two sialic acid binding sites in the trimeric Ad37 knob (Nilsson 
et al., 2011). This finding led to Spjut et al. synthesizing tri- and tetravalent sialic acid 
compounds which effectively block Ad37 infection of human ocular cells. SPR and 
crystallography techniques demonstrated the trivalent sialic acid conjugate, ME0322, binds 
directly to the sialic acid-binding sites in the fiber knob, with similar affinity to GD1a 
hexasaccharide, and is a potent inhibitor of Ad37 infection (Spjut et al., 2011). Although 
these studies are not directly focused on gene therapy applications, they underline the 
importance of a thorough understanding of virus interactions with the host and a 
subsequent development of chemical inhibitors. The detailed analysis of crystal structures 
of Ad capsid-host protein complexes allows the study of specific interactions at the atomic 
level and contributes immensely to rational drug design.  
As well as taking advantage of the well defined Ad structure (Reddy et al., 2010), known 
to near atomic resolution, along with the electron cryomicroscopy and the three-
dimensional reconstructions of the Ad5:FX complex, an array of diverse in vitro assays 
exist to study Ads and manipulate their interactions for drug development. Many of these 
are cell-based including cytopathic effect or plaque formation assay, cell viability, 
haemagglutination, FX-mediated cell binding, gene transfer or intracellular transport 
assays etc. These assays can be time consuming but are flexible and could be adapted to 
investigate Ad5 infectivity in the presence of FX in a high throughput manner. High 
throughput screening of pharmacologically favourable small molecules in search of safe 
inhibitors of the Ad5 interaction with FX or FX-mediated gene transfer is an attractive 
prospect. This technique is commonly used in the anti-viral drug field (Campagnola et al., 
2011; Hoffmann et al., 2011; Jegede et al., 2011), emphasising the plausibility of this 
approach for enhancing the efficacy of therapeutic gene adenoviral delivery.  
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• Genetic engineering e.g. fiber/hexon pseudotyping 
• Polymer coating e.g. PEG >20 kDa
• Pharmacological inhibitors e.g. warfarin, heparin, 
clodronate liposomes 
Block Ad5:FX gene transfer
• Genetic engineering
• Adaptor molecules e.g. antibodies
• Tissue specific promoters
 
Figure 1.12. Tropism modifying strategies. 
A range of potential strategies have been employed to block FX-mediated Ad5 gene 
transfer and detarget the virus from its inherent liver tropism Bypassing such host 
interactions would result in increased Ad circulation times and allows for specific vector 
targeting to the desired cells or tissues. 
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1.14 Future of Ad-based gene therapy 
The transition from relevant Ad in vitro pathways to key in vivo mechanisms has taken 
three decades of study and will no doubt continue for many more years. Better 
understanding the intricacies of Ad pathways through the use of shrewd in vitro or cell-
based assays, along with the correlation of these results in relevant in vivo models, has had 
major implications for Ad based gene therapy. Discovering the role of FX in determining 
the substantial hepatic transduction of Ad5 upon contact with the blood was a major 
advance toward achieving the long desired goal of effective liver detargeting for systemic 
gene therapy applications. In many ways, this finding has redefined several tropism 
modifying strategies, and changed the focus of those previously concentrated on bypassing 
Ad binding to CAR. Building on this result and gaining a greater depth of knowledge of 
the FX-mediated infectivity pathway will help piece together the precise sequence of 
complex events which define the Ad5 tropism in vivo and aid in the design of pioneering 
strategies to manipulate FX-mediated Ad5 gene transfer. This will no doubt ultimately 
contribute to the development of more efficient vectors targeting defined tissues with 
reduced toxicity, and holds great promise for improving the therapeutic viability of Ads for 
targeted delivery following intravascular administration. The promise of pre-clinical results 
will hopefully soon be converted into triumphs in the clinical setting and the true appeal of 
Ad based gene therapy will begin to be fulfilled in the coming years. 
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1.15 Aims of this thesis 
The principle aims of this thesis were to gain a greater understanding of FX-mediated Ad5 
infection and to use several strategies to manipulate Ad5:FX gene transfer. To this end, 
three approaches were employed. These focused on different aspects of the FX-mediated 
Ad5 pathway, from the initial stages to cellular binding, intracellular transport to 
preventing effective Ad transgene expression. This thesis is divided into three studies, each 
with an individual aim. 
 
• Investigation of the mechanism by which Ad5:FX complexes bind to the cell 
surface.  
This was performed using mutagenesis techniques to genetically modify amino acid 
residues within the FX SP domain and subsequent examination of the effects of the 
mutations using in vitro and ex vivo assays. 
 
• Investigation of cellular and signalling events occurring during Ad5 
transduction in the presence of FX.  
This involved the use of pharmacological agents to interfere with efficient virus cell 
binding, internalisation, trafficking and transduction. 
 
• Identification of a small molecule inhibitor of FX-mediated Ad5 gene transfer.  
This was carried out using a high throughput approach to screen a library of over 10,000 
compounds in search of one which prevented virus transduction.  
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Materials 
2.1 Chemicals 
The Pharmacological Diversity Drug-like Set compound library was purchased from 
Enamine (Kiev, Ukraine). Analogue compounds of the hits from the high throughput 
screen were also purchased from Enamine. The Tocris Kinase Inhibitor Toolbox, a kind 
gift from Dr. Jo Mountford (University of Glasgow, Glasgow, UK), was originally 
obtained from Tocris Bioscience (Bristol, UK). Oligonucleotides were obtained from 
MWG-Biotech (Edersberg, Germany). All other chemicals unless otherwise indicated were 
obtained from Sigma-Aldrich (Poole, UK). 
2.2 Proteins 
Purified human plasma derived (pd) blood coagulation FX and activated FX were 
purchased from Haematologic Technologies (Vermont, USA).  
2.3 Plasmid DNA constructs 
The wild-type FX cDNA cloned into the mammalian expression pCMV4 vector (human 
prothrombin signal sequence and propeptide followed by the sequence for the FX 
derivative - pCMV4-ss-pro-II-FX) was a kind gift from Prof. John McVey (Thrombosis 
Research Institute, London, UK). The pMK-RQ_FX SP mutant plasmid was purchased 
from GeneArt (Invitrogen, Paisley, UK). 
2.4 Antibodies  
Primary rabbit polyclonal antibodies raised against pericentrin and ezrin, and rabbit 
monoclonal antibodies against radixin and moesin were obtained from Abcam (Cambridge, 
UK). The mouse monoclonal antibody raised against intact heparan sulphate (clone 10E4) 
was obtained from AMS Biotechnology (Oxford, UK). The monoclonal mouse antibody 
raised against spleen tyrosine kinase (Syk) was obtained from Antibodies-online GmbH 
(Aachen, Germany). IgGs and secondary antibodies were obtained from Invitrogen 
(Paisley, UK) unless otherwise stated. The mouse monoclonal antibody against human FX 
(clone HX-1) was obtained from Sigma-Aldrich. The hybridoma expressing the 
monoclonal anti-human FX antibody 4G3 was a kind gift of Dr R. Camire (Children's 
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Hospital of Philadelphia, USA). The 4G3 antibody was purified by protein G affinity 
chromatography by Prof. John McVey (Thrombosis Research Institute, London, UK). 
2.5 Cell culture materials 
All tissue culture reagents were purchased from Invitrogen (Paisley, UK) unless otherwise 
stated.  
Methods 
2.6 Tissue culture 
Tissue culture was performed under sterile conditions using biological safety class II 
vertical laminar flow cabinets. Cells were grown as a monolayer in 150 cm2 tissue culture 
flasks in 37ºC, 5% CO2 and 95% air incubators. Tissue culture experiments involving Ad 
vectors were performed in a dedicated tissue culture laboratory and maintained in separate 
incubators.  
2.7 Maintenance of established cell lines 
Cells were routinely passaged at approximately 80% confluence to prevent overgrowth and 
loss of surface contact in culture flasks. The cells and media used are described in Table 
2.1. To passage, cells were washed twice in Dulbecco’s calcium and magnesium free PBS 
and incubated with 3 ml trypsin-ethylenediamine tetra-acetic acid (trypsin-EDTA) 
(Invitrogen) at 37ºC for approximately 5 min. Once detached, cells were collected in 5 ml 
complete media (media supplemented with 10% (v/v) fetal calf serum (FCS), 1% (v/v) 
penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine) which inactivates the trypsin. 
Cells were centrifuged at 480 g for 5 min. Media and trypsin-EDTA were poured off and 
the cell pellet resuspended in complete media for passaging or plating. To accurately seed 
cell culture dishes or plates with a known number of cells, cells were counted using a 
haemocytometer (Hausser Scientific, PA, USA). 
2.8 Cryopreservation 
For cryopreservation cells were collected as described in section 2.7. Cells from a 80% 
confluent 150 cm2 tissue culture flask were resuspended in 2 ml complete media 
supplemented with 10% dimethyl sulphoxide (DMSO) and aliquoted into cryo-
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preservation vials. Vials were cooled at a constant -1ºC/min to -80ºC using isopropanol. 
Cells were transferred for long term storage in liquid nitrogen. When recovering cells from 
liquid nitrogen, vials were thawed at 37ºC and then the cell suspension was carefully added 
dropwise to 10 ml complete media in a universal container. Cells were pelleted by 
centrifugation at 480 g for 5 min. The cell pellet was resuspended in complete media, 
transferred to a 150 cm2 tissue culture flask and incubated in a 37ºC, 5% CO2 and 95% air 
incubator. 
Table 2.1. Cell lines and media used. 
 
Cell type Description Cell culture medium 
SKOV3 Human ovary 
adenocarcinoma   
cell line  
RPMI 1640 media supplemented with 10% (v/v) 
FCS, 1% (v/v) penicillin, 100 µg/ml streptomycin and 
2 mM L-glutamine.  
A549 Human lung 
adenocarcinoma 
epithelial cell line 
RPMI 1640 media supplemented with 10% (v/v) 
FCS, 1% (v/v) penicillin, 100 µg/ml streptomycin and 
2 mM L-glutamine. 
HepG2 Human 
hepatocellular 
carcinoma cell line 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10 % FCS, 1% (v/v) penicillin, 
100 µg/ml streptomycin and 2 mM L-glutamine. 
SW 620 Human colon 
cancer cell line 
RPMI 1640 media supplemented with 10% (v/v) 
FCS, 1% (v/v) penicillin, 100 µg/ml streptomycin and 
2 mM L-glutamine. 
293 Human embryonic 
kidney cell line 
DMEM supplemented with 10% FCS, 1% (v/v) 
penicillin, 100 µg/ml streptomycin and 2 mM L-
glutamine. 
293T 
 
Transformed 
human embryonic 
kidney cell line 
DMEM supplemented with 10% FCS, 1% (v/v) 
penicillin, 100 µg/ml streptomycin and 2 mM L-
glutamine. 
 
2.9 Cloning procedures 
2.9.1 Plasmid preparation 
Bacterial stock culture containing plasmid DNA from a glycerol stock was spread on to an 
ampicillin (100 µg/ml) containing agar plate and incubated at 37ºC overnight to allow the 
bacteria to grow. Single bacterial colonies were then picked from the agar plate and used to 
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inoculate a starter culture of 5 ml (for small scale preparation of plasmid DNA) or 10 ml 
Luria-Broth (LB) containing ampicillin. This was incubated at 37ºC for 8 h whilst shaking. 
For large scale preparation of plasmid DNA the starter culture was transferred to 500 ml of 
LB in a 2 L flask and incubated at 37ºC overnight whilst shaking. 
2.9.2 Small scale preparation of plasmid DNA 
Plasmid DNA was extracted from bacteria on a small scale using the QIAprep Spin 
Miniprep Kit (QIAGEN, Crawley, UK) according to the manufacturer’s instructions. 
Briefly, bacterial cells were harvested by centrifugation for 5 min at 16,000 g. The pellet 
was resuspended in 250 µl of Buffer P1 (50 mM tris(hydroxymethyl)aminomethane (Tris)-
HCl, pH 8, 10 mM EDTA, 100 µg/ml RNase A). The EDTA in this buffer chelates 
divalent metals (primarily magnesium and calcium). Removal of these cations destabilises 
the cell membrane, resulting in the lysis of the bacterial cells. The RNase A is a 
ribonuclease which degrades RNA. 250 µl of Buffer P2 (200 mM NaOH, 1% sodium 
dodecyl sulphate (SDS)) was added and the sample was mixed thoroughly. The NaOH in 
this buffer denatures chromosomal DNA and the SDS disrupts the cell membranes. The 
lysis step was neutralised by 350 µl Buffer N3 (4.2 M guanidinium chloride, 0.9 M 
potassium acetate, pH 4.8), which causes the precipitation of genomic DNA, proteins, cell 
debris and SDS. The precipitated samples were centrifuged at 16,000 g for 10 min. The 
supernatant was transferred to an equilibrated QIAGEN-tip 20 column, which contains a 
silica membrane to which the plasmid DNA binds, and centrifuged for 1 min. The DNA 
bound to the column was washed with 500 µl Buffer PB (5 M guanidinium chloride, 30% 
(v/v) isopropanol) to remove endonucleases and the column centrifuged for 1 min. 750 µl 
Buffer PE (10 mM Tris-HCl pH 7.5, 80% (v/v) ethanol) was added to further wash and 
remove salts and the column centrifuged for 1 min. DNA was eluted from the column by 
adding 50 µl dH2O, allowed to stand for 1 min and then centrifuged for 1 min. The amount 
of DNA in each sample was quantified by measuring absorbance at 260 nm (NanoDrop, 
ND-1000 spectrophotometer (Labtech International, Ringmer, UK)). 
2.9.3 Large scale preparation of plasmid DNA 
Plasmid DNA was extracted from bacteria on a large scale using the Plasmid Maxi Kit 
(QIAGEN) according to the manufacturer’s instructions. Briefly, bacterial cells were 
harvested by centrifugation at 6000 g for 15 min at 4ºC. The pellet was resuspended in 10 
ml of Buffer P1. 10 ml of Buffer P2 was added, the sample was mixed thoroughly and 
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incubated at room temperature for 5 min. The lysis step was neutralised by 10 ml Buffer 
P3 (3 M potassium acetate, pH 5.5). The potassium acetate in this buffer allows for the 
precipitation of genomic DNA, proteins, cell debris and potassium dodecyl sulphate. The 
samples were centrifuged at 20,000 g for 30 min at 4ºC. The supernatant containing the 
plasmid DNA was collected and transferred to an equilibrated QIAGEN-tip 500 column. 
The sample was allowed to pass through the resin of the anion-exchange column by gravity 
flow. During this step the plasmid DNA selectively binds to the resin. The QIAGEN-tip 
500 was washed with 30 ml Buffer QC (1 M NaCl, 50 mM 3-(N-
morpholino)propanesulfonic acid pH 7, 15% (v/v) isopropanol) twice. This is a medium-
salt wash to remove RNA, proteins, metabolites and other low-molecular-weight 
impurities. The plasmid DNA was eluted from the column by the addition of 15 ml Buffer 
QF (1.25 M NaCl, 50 mM Tris pH 8.5, 15% (v/v) isopropanol). The plasmid DNA was 
concentrated and desalted by precipitation with 10.5 ml isopropanol and centrifuged 
immediately at 15000 g for 30 min at 4°C. 5 ml 70% (v/v) ethanol was added to wash the 
DNA pellet, which was then centrifuged again at 15,000 g for 10 min. The supernatant was 
removed and the DNA pellet left to air dry for 20 min prior to resuspension in 200 µl 
dH2O. The concentration of DNA in each sample was quantified by measuring absorbance 
at 260 nm (NanoDrop, ND-1000 spectrophotometer). 
2.9.4 Generation of glycerol stocks 
Plasmid DNA glycerol stocks were generated for long term storage. 200 µl of sterile 
glycerol was added to 800 µl of bacterial culture containing the plasmid DNA in a 1.5 ml 
Eppendorf. Stocks were stored at -80ºC. 
2.9.5 Site-directed polymerase chain reaction mutagenesis  
Polymerase chain reaction (PCR) is a technique used to amplify a specific DNA sequence. 
Single (R125A)) or double  (R93A_K96A, R165A_K169A or K236A_R240A) amino acid 
residues mutations in the WT FX (pCMV4-ss-pro-II-FX) plasmid were generated by 
substituting basic residues with alanine using site-directed PCR mutagenesis (amino acids 
are numbered from the amino terminal residue of the mature FX). For this the QuikChange 
Site-Directed Mutagenesis Kit (Agilent Technologies, Edinburgh, UK) was used as per 
manufacturer’s instructions (for overview of the method see Figure 2.1). The procedure 
utilised the WT FX plasmid and two synthetic mutagenic oligonucleotide primers (forward 
and reverse) containing the desired mutation. For primer design see section 2.9.6.  
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Step 1           
Plasmid preparation Gene in plasmid with target 
site     for mutation
Step 2          
Temperature cycling
Step 3         
Digestion
Step 4        
Transformation
Denature the plasmid and 
anneal the oligonucleotide
primers     containing the 
desired mutation x
Using the nonstrand-displacing 
action of Pfu Turbo DNA 
polymerase, extend and 
incorporate the mutagenic primers 
resulting in nicked circular strands
Digest the methylated, nonmutated
parental DNA template with Dpn I
Transform the circular, nicked dsDNA
into XL1-Blue supercompetent cells
After transformation, the XL-1 cells 
repair the nicks in the mutated 
plasmid
Parental DNA plasmid
Mutagenic primer
Mutated DNA plasmid
 
Figure 2.1. Overview of the QuikChange site-directed mutagenesis method. 
This figure was adapted for the Stratagene QuikChange Site-Directed Mutagenesis 
instruction manual. 
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2.9.5.1 Step 1: Plasmid preparation 
In order to test the mutagenesis efficiency of the mutant plasmid generation, a pWhitescript 
4.5 kb control plasmid was used. The control reaction was prepared as follows, 5 µl of 10 x 
reaction buffer (100 mM KCl, 100 mM (NH4)2SO4, 200 mM Tris-HCl (pH 8.8), 20 mM 
MgSO4, 1% Triton X-100, 1 mg/ml nuclease-free bovine serum albumin (BSA)), 2 µl (10 
ng) of pWhitescript 4.5 kb control plasmid, 1.25 µl (125 ng) of oligonucleotide control 
forward primer #1, 1.25 µl (125 ng) of oligonucleotide control reverse primer #2, 1 µl 
dNTP mix and 39.5 µl of double distilled water (ddH20) to a final volume of 50 µl. Then 1 
µl of PfuTurbo DNA polymerase was added. The forward and reverse primers contain the 
desired mutations and are complementary to opposite strands of the vector and each other. 
The primers are extended during the temperature cycling step by using PfuTurbo DNA 
polymerase. PfuTurbo DNA polymerase replicates both plasmid strands with high fidelity 
and without displacing the mutant oligonucleotide primers. Incorporation of the 
oligonucleotide primers generates a mutated plasmid with staggered nicks. The sample 
reaction was prepared as follows, 5 µl of 10 x reaction buffer, 2.5 µl (25 ng) of WT FX 
plasmid, 1.25 µl (125 ng) of the forward mutagenic oligonucleotide primer, 1.25 µl (125 
ng) of the corresponding reverse mutagenic oligonucleotide primer #2, 1 µl dNTP mix and 
39 µl of ddH20 to a final volume of 50 µl. Then 1 µl of PfuTurbo DNA polymerase was 
added. 
2.9.5.2 Step 2: Temperature cycling 
The temperature cycling used for synthesis and amplification was in accordance with the 
type of mutation desired. In the first step, the plasmid gets denatured. Following 
denaturation, the oligonucleotide primers containing the desired mutation(s) anneal to the 
vector and are then incorporated to the synthesised strand of DNA, resulting in two nicked 
circular DNA strands. The first segment is one cycle at 95ºC for 30 sec, the second 
segment is 16 (for single amino acid change of residue R125A of FX) or 18 cycles (for 
double amino acid changes of R93A_K96A, R165A_K169A or K236A_R240A) of 95ºC 
for 30 sec, 55ºC for 1 min and 68ºC for 6 min (1 min/kb of plasmid length, WT FX is 6405 
base pairs). The control reaction was run under the same conditions. Following 
temperature cycling the reaction was placed on ice for 2 min.  
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2.9.5.3 Step 3: Digestion 
The next step was to digest the amplification products. 1 µl of the Dpn I restriction enzyme 
(10 U/µl) was added directly to each amplification reaction. Dpn I is an enzyme specific 
for methylated and hemimethylated DNA and is used to digest the parental DNA template 
and select for the mutation-containing synthesised DNA. DNA isolated from E.coli is dam 
methylated and therefore susceptible to Dpn I digestion. The samples were incubated at 
37ºC for 1 h to digest the parental (i.e. non-mutated) supercoiled dsDNA. 
2.9.5.4 Step 4: Transformation 
The final step was the transformation of Epicurian Coli® XL1-Blue Supercompetent Cells. 
1 µl of the DpnI treated DNA (circular nicked vector DNA containing the desired 
mutations) from each sample reaction was added to 50 µl of the cells in separate 
polypropylene tubes and incubated on ice for 30 min. The transformations were heat 
shocked for 45 sec at 42ºC and then placed on ice for 2 min. 500 µl of LB broth was added 
and the mix incubated at 37ºC for 1 h with shaking. 250 µl of each transformation reaction 
was spread on to LB ampicillin agar plates and incubated overnight at 37ºC. The 
pWhitescript 4.5 kb control plasmid contains a stop codon (TAA) at the position where a 
glutamine (CAA) would normally appear in the β-galactosidase gene. XL1-Blue cells 
transformed with this control plasmid appear white in ampicillin agar plates containing 
IPTG (isopropyl-beta-thio galactopyranoside, a lactose analog which binds and inhibits the 
lac repressor and thereby strongly induces β-galactosidase production) and X-gal (5-
bromo-4-chloro-indoly-β-D-galactoside, stain used in the detection of β-galactosidase) 
since β-galactosidase activity is removed. The oligonucleotide control primers mutate the 
T residue in the stop codon to a C residue, changing the stop codon to a glutamine codon 
found in the WT sequence thus restoring β-galactosidase activity and forming blue 
colonies on the ampicillin agar plates, thereby testing the mutagenesis efficiency of this 
protocol. 
2.9.6 Design of mutagenic oligonucleotide primers 
Mutagenic oligonucleotide primers with either single (for mutagenesis of amino acid 
residue R125) or double (for mutagenesis of amino acid residues R93 and K96, R165 and 
K169 or K236 and R240) amino acid changes were designed. Both the mutagenic primers 
(forward and reverse) for each set of mutations contain the desired mutation(s) and anneal 
to the same sequence on the opposite strands of the plasmid. All primers were between 28 
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and 49 bases in length and had a melting temperature below 78ºC. The desired mutation(s) 
were located near the middle of each primer with approximately 8-15 bases of correct 
sequence on both sides. All primers terminate in G or C bases. See Table 2.2 for primer 
sequences. 
Table 2.2. Mutagenic oligonucleotide primers. 
 
Primer Sequence 
R93A_K96A Forward 
5’-GGTGGTCATCAAGCACAACGCGTTCACAGCGGAGACCTATGACTTCGAC-3’ 
Reverse 
5’-GTCGAAGTCATAGGTCTCCGCTGTGAACGCGTTGTGCTTGATGACCACC-3’ 
R125A Forward 
5’-CTGCCTCCCCGAGGCTGACTGGGCCGAG-3’ 
Reverse 
5’-CTCGGCCCAGTCAGCCTCGGGGAGGCAG-3’ 
R165A_K169A Forward 
5’-CCCTACGTGGACGCCAACAGCTGCGCGCTGTCCAGCAG-3’ 
Reverse 
5’-CTGCTGGACAGCGCGCAGCTGTTGGCGTCCACGTAGGG-3’ 
K236A_R240A Forward 
5’-GTCACCGCCTTCCTCGCGTGGATCGACGCGTCCATGAAAACCAGG-3’ 
Reverse 
5’-CCTGGTTTTCATGGACGCGTCGATCCACGCGAGGAAGGCGGTGAC-3’ 
 
2.9.7 Cloning FX SP mutant cDNA into pcDNA3.1+zeocin 
The FX SP mutant cDNA coding sequence within the pMK-RQ_FX SP mutant plasmid 
(Invitrogen) was firstly cloned into a pSCb plasmid and then into a pcDNA3.1+zeocin 
plasmid (Figure 2.2). Cloning into the pSCb plasmid allows the FX SP mutant to be 
sequence verified, as well as providing a plasmid to easily transform and make large scale 
preparations of the DNA. 
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2.9.7.1 Step 1: Excision of FX SP mutant cDNA from the pMK-RQ_FX SP mutant 
plasmid  
Oligonucleotides were designed to amplify the FX SP mutant cDNA from the pMK-RQ 
plasmid, adding an AflII site at the 5’ end and amplifying through HindIII at the 3’ end. 
AflII-FX SP mutant-HindIII was amplified by polymerase chain reaction (PCR) using the 
two oligonucleotides (MWG-Biotech) described in Table 2.3 and Herculase II proof 
reading polymerase. To 25 ng of pMK-RQ_FX SP mutant plasmid DNA, 1 µl  Herculase 
II fusion DNA polymerase (Agilent Technologies), 10 µl  5x Herculase II reaction buffer 
(Agilent Technologies), 0.5 µl dNTP mix (Agilent Technologies), 10 µM of forward and 
reverse primers were added and made up to a final volume of 50 µl with dH2O. Thermal 
cycling steps were as follows; 1 cycle at 95°C for 2 min, 30 cycles at 95°C for 20 sec, 
50°C for 20 sec and 72°C for 45 sec, followed by 1 cycle at 72°C for 3 min. 
Table 2.3. Primer design. 
FX SP mutant forward (containing AfIII sequences (highlighted in blue)), reverse and 
sequencing primers were designed and commercially synthesised. 
Primer Sequence 
pMK-RQ_ FX SP mut_AfIII Forward 
5’-GAATCTTAAGAGGAAGGCCGTCA-3’ 
pMK-RQ_FX SP mut_rv Reverse 
5’-GGCCCATGAGGCCCAGG-3’ 
FX SP mutant #1 5’-CCATGGCCCACGTGCG-3’ 
FX SP mutant #2 5’-GCCTGCATCCCTACCG-3’ 
FX SP mutant #3 5’-ACTGCGACCAGTTCTGCCA-3’ 
FX SP mutant #4 5’-TGGTCATCAAGCACAACGC-3’ 
 
The PCR products were electrophoresed on a 1% agarose gel in 1x Tris/Borate/EDTA 
(TBE) (10 mM Tris, 10 mM boric acid, 10 mM EDTA, pH 8.3) and ethidium bromide (10 
ng/ml). Gels were electrophoresed at a constant voltage of 100 V with TBE as running 
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buffer. Bands were visualised and photographed on a molecular imager ChemiDocTM 
XRS+ Imaging System (Bio-Rad Laboratories, Hemel Hempstead, UK).  
The band for FX SP mutant was gel extracted and placed in a microcentrifuge tube. Gel 
extraction of DNA was used to excise DNA fragments following restriction endonuclease 
digestion to eliminate excess primers, nucleotides or enzyme reaction reagents. The 
Wizard SV Gel and PCR Clean-Up System (Promega, South Hampton, UK) was used to 
extract plasmid DNA according to the manufacturer’s instructions. Briefly, 10 µl of 
membrane binding solution (4.5 M guanidine isothiocyanate, 0.5 M potassium acetate, pH 
5) was added per 10 µg DNA. The sample was vortexed and incubated at 50-65°C for 10 
min, when the band was fully dissolved. The sample was transferred to a SV Minicolumn 
and centrifuged at 16,000 g for 1 min at 4°C. The SV Minicolumn was washed twice with 
700 µl and 500 µl Membrane Wash Solution (10 mM potassium acetate pH 5, 16.7 mM 
EDTA pH 8, 80% (v/v) ethanol). After each wash samples were subjected to centrifugation 
at 16,000 g for 1 min and 5 min at 4°C. Gel purified DNA was eluted with 40 µl dH2O and 
centrifuged at 16,000 g for 1 min. DNA was stored at -20°C. 
2.9.7.2 Step 2: Ligation of the FX SP mutant cDNA into the pSCb plasmid 
The purified FX SP mutant PCR product was ligated into a pSCb plasmid using the 
StrataClone Blunt PCR Cloning Kit (Agilent Technologies) as per manufacturer’s 
instructions. Briefly, the ligation reaction mixture was produced by adding (in order) 3 µl 
StrataClone Blunt Cloning Buffer, 2 µl (32 ng) FX SP mutant PCR product and 1 µl 
StrataClone Blunt Vector Mix ampicillin. The mixture was incubated at room temperature 
for 5 min, then placed on ice. 1 µl of the mixture was added to a tube of thawed 
StrataClone SoloPack Competent Cells and mixed gently. The transformation mixture was 
incubated on ice for 20 min and then heat-shocked at 42°C for 45 sec, followed by 
incubation on ice for 2 min. 250 µl of prewarmed LB was added and the cells were allowed 
to recover at 37°C for 2 h with gentle shaking. Either 5 µl or 100 µl of the transformation 
mixture was plated on agar plates and incubated at 37°C overnight. The next day, colonies 
were picked and small scale preparation of DNA performed as described in section 2.9.1. 
The samples were sequenced as described in section 2.10 and using the sample with the 
correct DNA sequence, large scale preparation of DNA was performed as described in 
section 2.9.3. Sequencing primers are described in section Table 2.3. 
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2.9.7.3 Step 3: Excision of the FX SP mutant cDNA from the pSCb plasmid and 
ligation into pcDNA3.1+zeocin 
Restriction endonuclease digestion is a procedure to cut double-stranded DNA using a 
restriction endonuclease. 20 µg pSCb_FX SP mutant or pcDNA3.1+zeocin plasmid was 
digested overnight at 37°C with 5 µl enzyme EcoRI (Promega) and 5 µl enzyme EcoRI 
buffer (Promega), made up to a final volume of 50 µl with dH2O. The pSCb_FX SP mutant 
and pcDNA3.1+zeocin restriction endonuclease digests were electrophoresed on a 1% 
agarose gel. Bands for FX SP mutant and pcDNA3.1+zeocin were gel extracted. To 
prevent recircularisation of the digested pcDNA3.1+zeocin DNA in the ligation reaction, 
the 5’ phosphates from digested DNA were removed using 5 U shrimp alkaline 
phosphatase (SAP) (Promega) by incubation at 37°C for 15 min. SAP was inactivated by 
incubation at 65°C for 15 min. Dephosphorylated pcDNA3.1+zeocin and FX SP mutant 
DNA were ligated using T4 DNA ligase (Promega). Ligation reactions were performed at a 
1:3 molar ratio (pcDNA3.1+zeocin_FX SP mutant). The DNA, 1 µl T4 DNA ligase and 1 
µl T4 DNA ligase buffer were made up to a final volume of 10 µl with dH2O and 
incubated at 4°C for 2 h. The mixture was then transformed into competent E.coli JM109 
(Promega) and the transformation mixture streaked on to agar plates. The next day, 
colonies were picked and small scale preparation of DNA was performed as described in 
section 2.9.1. 
2.9.7.4 Step 4: Investigating the efficiency of FX SP mutant cDNA ligation into 
pcDNA3.1+zeocin 
In order to ensure the FX SP mutant DNA was successfully ligated a diagnostic digest was 
performed. To 5 µl (500 ng DNA) of the miniprep sample, 2 µl enzyme BglII, 1 µl BglII 
buffer, 0.2 µl 10x BSA were added and made up to a final volume of 20 µl with dH2O. 
Samples were incubated at 37°C for 3 h before being electrophoresed on a 1% agarose gel 
as previously described in Step 1. The samples showing the band for FX SP mutant were 
sequenced and, using the sample with the correct DNA sequence, large scale preparation of 
DNA was performed as described in section 2.9.3. Sequencing primers are described in 
section Table 2.3. 
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FX SP mutant
EcoRI
AflII
FX SP mutant
FX SP mutant
Figure 2.2. Strategy for cloning FX SP mutant into pcDNA3.1+zeocin. 
Firstly the SP mutant fragment was amplified from the pMK-RQ construct by adding an 
AflIII site at the 5’ end and amplifing through the HindIII site on the 3’ end. The purified 
PCR product was ligated into a pSCb construct. The pSCb_FX SP mutant and the 
pcDNA3.1+zeocin plasmid were digested with EcoRI. The FX SP mutant fragment was 
ligated into pcDNA3.1+zeocin. A diagnostic digestion was performed cutting at BgIII sites, 
one present in the pcDNA3.1+zeocin backbone and one in the FX SP mutant insert, to 
ensure the insert was present. 
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2.10 DNA sequencing 
To confirm the sequence of plasmid DNA generated from small or large scale preparations 
dideoxy sequencing was performed. This process takes advantage of the ability of DNA 
polymerase to incorporate 2′, 3′-dideoxynucleotides, nucleotide base analogs that lack the 
3′-hydroxyl group essential in phosphodiester bond formation. It requires a DNA template, 
a sequencing primer, a thermal stable DNA polymerase, nucleotides (dNTPs), 
dideoxynucleotides (ddNTPs) (provided in the Ready Reaction mix (Applied Biosystems) 
see below), and buffer. Devised from Sanger sequencing, the Applied Biosystems 
fluorescence-based cycle sequencing system used here employs fluorescent dyes to label 
the extension products and the components are combined in a reaction that is subjected to 
cycles of annealing, extension, and denaturation in a thermal cycler. Thermal cycling the 
sequencing reactions creates and amplifies extension products that are terminated by one of 
the four dideoxynucleotides, resulting in the formation of extension products of various 
lengths. The sequencing products are then separated based on size by capillary 
electrophoresis.  
2.10.1 Sequencing PCR  
300 ng DNA was used as a template for sequencing using specific forward and reverse 
primers. Each sequencing reaction contained 1.6 nM primer (forward or reverse), 0.5 µl 
v3.1 Ready Reaction mix (Applied Biosystems), 4 µl v3.1 sequencing buffer (Applied 
Biosystems, MA, USA) made up to a final volume of 20 µl with dH2O. The cycle 
conditions were 25 cycles to denature at 96°C for 50 sec, anneal at 50°C for 20 sec and 
extend the DNA fragment at 60°C for 3 min. 
2.10.2 Sequencing reaction purification 
Sequencing reactions were purified to remove reaction constituents and unincorporated 
nucleotides and primers using CleanSEQ (Agencourt Bioscience Corporation, MA, USA) 
according to the manufacturer’s instructions. Briefly, 10 µl of CleanSEQ reagent was 
added to each sequencing reaction, followed by 62 µl of 85% ethanol. Plates were vortexed 
briefly and centrifuged for 30 sec to collect the liquid in the bottom of the wells. Plates 
were placed on a SPRIPlate (Beckman Coulter, UK) for 2 min. The plate was turned 
upside down to empty the liquid from it. Wells were washed in 150 µl of 85% ethanol and 
plates were vortexed briefly and placed on a SPRIPlate for 2 min. Wells were emptied as 
much as possible by centrifugation of inverted plates for 1 sec. Plates were removed from 
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the SPRIPlate and air dried for 10 min. 40 µl of dH2O was added to each well and the plate 
returned on to the SPRIPlate for 2 min. 20 µl of sequencing products were loaded into 
optically clear barcoded 96 well plates and plates were sealed to prevent evaporation. DNA 
sequencing was performed using a 96-capillary ABI 3730 automated sequencer (Applied 
Biosystems). The sequences were analysed using Applied Biosystems SeqScape software 
version 2. 
2.11 Recombinant FX production 
2.11.1 Differential pH transient transfections 
293T cells were seeded in 10 cm2 culture dishes and incubated at 37°C overnight to reach 
approximately 70% confluence. Cells were gently washed once in PBS. 4.5 ml media A 
(DMEM, high glucose, GlutaMAX (Invitrogen), 10% (v/v) FCS, 2 mM L-glutamine, 1% 
(v/v) penicillin-streptomycin, 25 mM HEPES, pH 7.9) was added to each dish. 100 mM 
CaCl2 and 21 µg plasmid DNA were added to 960 µl media B (DMEM, high glucose, 
GlutaMAX (Invitrogen), 2 mM L-glutamine, 1% (v/v) penicillin-streptomycin, 25 mM 
HEPES, pH 7.1) in a universal tube. 1 ml of this mixture was added per dish, volumes 
were scaled up for multiple transfections. The mixture was added on to the cells in a drop-
wise fashion, whilst the dishes were gently shaken. The cells were incubated at 37°C 
overnight. The next day cells were washed once in PBS and 15 ml fresh media was added 
per dish. 
2.11.2 Determining optimal concentration of zeocin  
To determine the optimal concentration of zeocin for use in the generation of stable cell 
lines i.e. the minimum concentration of zeocin required to kill the untransfected host cell 
line, cells were firstly seeded in 24-well plates at 1 x 105 cell/well and incubated at 37°C 
overnight. 100, 200, 300, 400 or 500 µg/ml of zeocin in 10% media was added to the cells. 
Cells were incubated at 37ºC. Zeocin containing media was replenished every 2 days. Cell 
death was visually assessed after 7 days.  
2.11.3 Generation of FX stable cell lines  
Stable cell lines were generated based on zeocin resistance. 293T cells were seeded in 10 
cm2 culture dishes and incubated at 37°C overnight to reach approximately 70% 
confluence. Cells were transfected using the differential pH transfection method as 
Chapter 2 | Materials & Methods 
61 
described in section 2.11.1 with either the pcDNA3.1+zeocin/FX SP mutant plasmid, 
cotransfected with the plasmid encoding WT FX and the pcDNA3.1+zeocin or 
cotransfected with the control green fluorescent protein (GFP) and the pcDNA3.1+zeocin 
plasmid. Cotransfection was performed at a 1:10 molar ratio (pcDNA3.1 zeocin:WT FX or 
GFP). Cells were incubated at 37°C for 24 h then the media was replaced with 10% media 
supplemented with 5 µg/ml vitamin K and 200 µg/ml zeocin. Cell growth was observed 
every 2 to 3 days and the media was replenished every 3 to 4 days, taking care not to 
pipette directly on to the cells. After 2 weeks there was mass cell death, leaving stable cell 
colonies behind. To pick colonies, 24-well plates with 1 ml 10% media supplemented with 
5 µg/ml vitamin K and 200 µg/ml zeocin in each well were prepared. The 10 cm2 dishes 
were washed once with PBS to remove any cell debris. Using a 1 ml wide bore pipette tip, 
the tip was lowered to the surface of the colony of interest and media was added gently 
through the tip secured over the colony. The colony was transferred to a well of a 24-well 
plate. This was repeated with other colonies. Cells were grown until 90% confluent in the 
presence of 200 µg/ml zeocin. Conditioned media was collected from individual wells and 
FX enzyme-linked immunosorbent assay (ELISA) (Affinity Biologicals, Canada) was 
preformed to identify the highest producing cells. The high producing cells were grown 
and expanded into 6-well plates, 25 cm2, 75 cm2 and finally 150 cm2 tissue culture flasks.  
2.12 Human FX ELISA 
Protein was quantified using a matched-pair antibody set for ELISA of human FX antigen 
(Affinity Biologicals, Canada). The affinity purified polyclonal antibody to FX was diluted 
1/100 in coating buffer (50 mM Carbonate, 15 mM Na2CO3 and 35 mM NaHCO3 in 1 L 
dH2O, pH 9.6) and 100 µl was added to each well of a 96-well plate. The plate was 
incubated at 4°C overnight. The contents of the plate were emptied and 150 µl of blocking 
buffer (2.5 g BSA in 200 ml PBS, pH 7.4) was added to each well. The plate was incubated 
at room temperature for 60 min. The plates were washed three times with 0.1% Tween. 
The commercially bought pd FX was diluted in sample diluent (5.95 g HEPES, 1.46 g 
NaCl, 2.5 g BSA, 0.25 ml Tween-20 in 250 ml dH2O, pH 7.2).  The pd FX dilutions (20, 
10, 5, 2.5, 1.25, 0.625, 0.3125, 0.1516, 0.078, 0.039, 0.0195 and 0.00976 µg/ml) were used 
as controls in this experiment. Conditioned media from cells stably or transiently 
transfected with FX plasmids were added neat or diluted 1/10 or 1/50 in the sample diluent. 
100 µl of control or samples were added to the plate and incubated at room temperature for 
90 min. The antibody coated on the plate captured any FX in the samples. The plates were 
washed three times with 0.1% Tween-20 to remove any unbound material. A peroxidase 
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conjugated polyclonal FX antibody was diluted 1/100 in sample diluted and 100 µl added 
to each well. The plate was incubated at room temperature for 90 min. The plates were 
washed three times with 0.1% Tween-20 to remove any unbound conjugated antibody. The 
peroxidase activity is expressed by adding 100 µl o-phenylenediamine (OPD) substrate (5 
mg OPD in 12 ml substrate buffer (2.6 g citric acid and 6.9 g Na2HPO4 in 500 ml dH2O) 
and 12 µl 30% H2O2) to each well. After 15 min incubation at room temperature the 
reaction was quenched with the addition of 50 µl/well of 2.5 M H2SO4. The colour 
produced was measured using a Wallac VICTOR2 plate reader (Wallac) at a wavelength of 
490 nm.  
2.13 rFX purification 
rFX was affinity purified from conditioned serum free cell culture media using a 
chromatographic approach employing the AKTAexploror chromatography system (GE 
Healthcare) and the 4G3 mouse monoclonal antibody coupled to sepharose as previously 
described (Kim et al., 1994). Briefly, the conditioned media was dialysed in 4 L of buffer 
HBS-Ca2+ (10 mM HEPES, pH 7, 150 mM NaCl, 5 mM CaCl2) twice, for 12 h each. The 
buffered cell culture media was applied to the 4G3 sepharose column and the column was 
extensively washed in buffer HBS-Ca2+. Bound proteins were eluted by applying a linear 
gradient of buffer HBS-E (10 mM HEPES, pH 7, 150 mM NaCl and 10 mM EDTA) to the 
column. The bound fractions were collected and further analysed or stored at -20ºC. 
2.14 Activation of rFX 
The amidolytic activity of samples was measured in a two stage process. Firstly, the FX 
was activated to factor Xa (FXa) in the presence of tissue factor, factor VIIa and calcium.
 
In the second stage, the generated FXa hydrolyses the chromogenic substrate Z-D-Arg-
Gly-Arg-pNA (S-2765 (Quadratech, Surrey, UK)), thus liberating the chromophoric group 
pNA (p-nitroaniline).
 
rFX, commercially bought pd FX and FXa (Haematologic 
Technologies) were diluted in TBSA (50 mM Tris-HCl, 150 mM NaCl, 1 mg/ml albumin, 
pH 7.4).  rFX and pd FX were used at 10, 5 and 1 µg/ml. The FXa dilutions (0.5, 0.2, 0.1, 
0.05, 0.02 and 0.01 µg/ml) were used as controls in this experiment. 40 µl of each sample 
or standard was added to each well of a 96-well plate, followed by 160 µl of the mastermix 
containing 1 mM chromogenic substrate S-2765 (Quadratech), 100 nM tissue factor, 100 
nM factor VIIa (Novo Nordisk Ltd., Crawley, UK) and 6 mM CaCl2. Samples were 
incubated at room temperature for 15 min.
 
The colour produced was measured using a 
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Wallac VICTOR2 plate reader (Wallac) at a wavelength of 405 nm. The generated FXa 
(and thus the intensity of colour) is directly proportional to the FX activity of the sample.
 
2.15 Surface plasmon resonance analysis  
SPR was performed using a Biacore T100 (GE Healthcare, London, UK).  
2.15.1 Analysis of purified FX fractions 
Briefly, the monoclonal anti-human FX 4G3 antibody was covalently immobilised on to 
the flowcell of a CM5 biosensor chip by amine coupling according to the manufacturer’s 
instructions. Sensorgrams were generated at a flow rate of 30 µl/min using 10 mM HEPES 
pH 7.4, 150 mM NaCl, 5 mM CaCl2, 0.05% Tween-20 as running buffer and regeneration 
between injections with HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% Tween-20. 
Injections of WT rFX or SP mutant rFX fractions eluted from the 4G3 affinity column 
diluted in running buffer were passed over the chip. This was followed by regeneration of 
the sensorchip surface. Subtracted sensorgrams were generated by subtracting the signal 
from a surface subjected to a blank amine immobilisation. Data was analysed using 
Biacore T100 Evaluation software. 
2.15.2 Analysis of rFX binding to Ad5 hexon 
Briefly, virus was biotinylated using sulfo-NHS-LC-biotin (Pierce, Rockford IL, USA). 
Ad5 hexon was covalently immobilised on to the flowcell of a CM5 biosensor chip by 
amine coupling according to the manufacturer’s instructions. The immobilisation density 
of the Ad5 hexon was 1036 response units. Sensorgrams were generated at a flow rate of 
30 µl/min using 10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM CaCl2, 0.05% Tween-20 as 
running buffer and regeneration between injections with HEPES pH 7.4, 150 mM NaCl, 3 
mM EDTA, 0.05% Tween-20. Injections of pd FX, WT rFX or SP mutant rFX conditioned 
media diluted in running buffer were immediately followed by injections of the 
monoclonal anti-FX antibodies HX-1 and 4G3 prior to regeneration of the biosensor chip 
surface. Subtracted sensorgrams were generated by subtracting the signal from a surface 
subjected to a blank amine immobilisation.  
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2.15.3 Analysis of pharmacological compounds binding to FX and Ad5 
binding to FX in the presence of compounds 
Briefly, human FX was covalently immobilised on to the flowcell of a CM5 biosensor chip 
by amine coupling according to the manufacturer’s instructions. Sensorgrams were 
generated at a flow rate of 30 µl/min using 10 mM HEPES pH 7.4, 150 mM NaCl, 5 mM 
CaCl2, 0.05% Tween-20 as running buffer and regeneration between injections with 
HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% Tween-20. Injections of 10 µM 
compound T5550585, T5424837, T5660138, T5677956, T5660136 or T5572402 from the 
Pharmacological Diversity Drug-like Set (Enamine, Ukraine) or an equivalent volume of 
DMSO in the absence and presence of Ad5 diluted in running buffer were passed over the 
chip. This was followed by regeneration of the biosensor chip surface. DMSO subtracted 
sensorgrams were generated and data analysed using Biacore T100 Evaluation software.  
2.16 Protein extraction 
Protein was extracted from SKOV3, A549 and SW620 cells in 6-well plates by first adding 
lysis buffer (20 mM Tris pH 7.5, 150 mM NaCl, 2.5 mM sodium pyrophosphate, 1 mM β-
glycerophosphate, 1 mM sodium orthovanadate (Na3VO4), 1 mM 
ethylenediaminetetraacetic acid (EDTA), 1 mM ethylene glycol tetraacetic acid (EGTA), 
1% (v/v) Triton X, 1 µg/ml leupeptin and 1 mM phenylmethylsulfonyl fluoride (PMSF)). 
Each well was scraped, the lysed cells collected in 1.5 ml Eppendorfs and centrifuged to 
pellet the cells. The supernatant was discarded.  
2.17 Determination of protein concentration in cells 
The concentration of protein in cell lysates was determined using the bicinchoninic acid 
assay (BCA) Protein Assay Kit (Pierce), a colorimetric detection and quantification 
protocol, as per manufacturer’s instructions. A protein standard curve was generated using 
BSA at concentrations of 2000, 1500, 1000, 750, 500, 250, 125 and 25 µg/ml. 200 µl of 
BCA working reagent was added to 25 µl of cell lysate or standard, in duplicate in a 96-
well plate. PBS was used as the blank control. The plate was incubated at 37°C for 1 h in 
the dark. The absorbance was measured at 570 nm on the Wallac Victor2 plate reader 
(Wallac). 
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2.18 Electrophoresis 
2.18.1 SDS-PAGE  
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE), Coomassie 
blue staining and western immunoblotting were used to detect specific proteins. Protein 
concentration in the samples were quantified as described in section 2.17 and samples 
prepared with equal concentrations in 5x loading buffer (10% (v/v) Tris-HCl pH 6.8, 10% 
(w/v) SDS, 30% (v/v) glycerol, 0.1% (w/v) bromophenol blue and 2% (v/v) β-
mercaptoethanol). In order to denature the protein, samples were heated at 95°C for 5 min 
prior to loading on to the gel. 40 µl rainbow ladder (Amersham Bioscience UK Ltd, 
Buckingham, UK) was also added to the gel as a marker of protein size. The 
polyacrylamide gel consisted of a 4% stacking gel containing 13.3% (v/v) polyacrylamide 
30%, 12.5 mM Tris pH 6.8, 0.1% (v/v) SDS, 1% ammonium persulphate (APS) and 0.1% 
N,N,N’,N’,- Tetramethylethylenediamine (TEMED) and a 10% polyacrylamide gel, 
consisting of 33.3% (v/v) polyacrylamide 30%, 37.5 mM Tris pH 8.8, 0.1% (v/v) SDS, 1% 
APS and 0.1% TEMED. Samples were electrophoresed at 200 V in running buffer (0.025 
M Tris-HCl, 0.2 M glycine, 0.001 M SDS) for approximately 5 h. The gel was then either 
subjected to Coomassie blue staining (section 2.18.2) or to further processing and western 
immunoblotting (section 2.18.3). 
2.18.2 Coomassie blue staining 
The SDS-PAGE gel was washed in dH2O three times, for 5 min each. The gel was then 
stained in Coomassie Simply Blue Safe Stain (Invitrogen, Paisley, UK) at room 
temperature with gentle shaking for 1 h. The stain was discarded and the gel washed in 
dH2O twice, for 1 h each, with gentle shaking. The stained gel was visualised using an 
Odyssey infra-red imaging system (LI-COR, Nebraska, USA). 
2.18.3 Western immunoblotting 
The proteins from the SDS-PAGE (section 2.18.1) were transferred to Hybond-P 
membrane (Amersham Bioscience UK Ltd, Buckingham, UK) using 80 mV in transfer 
buffer (0.2 M glycine, 0.025 M Tris, 20% (v/v) methanol, 0.1 M SDS) overnight at 4°C. 
After transferring, the membrane was blocked in TBS-T (150 mM NaCl, 50 mM Tris, 
0.1% (v/v) Tween-20) and 10% (w/v) fat free milk powder (blocking buffer) for 3 h at 
room temperature. The membrane was either incubated with primary antibody for 1 h at 
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room temperature (for the monoclonal human anti-FX clone HX1 antibody (1:1000 
dilution in blocking buffer)) or overnight at 4°C (for the rabbit polyclonal antibody anti-
ezrin (1:750 dilution), the rabbit monoclonal anti-radixin (1:1000 dilution), rabbit 
monoclonal anti-moesin (1:2500 dilution) or the mouse monoclonal anti-Syk (1:500) 
antibodies) whilst shaking. The membrane was washed twice in blocking buffer, for 5 min 
and incubated with the appropriate secondary antibody; goat anti-mouse IR dye 800CW 
labelled secondary antibody (1:1000 dilution) (LI-COR, Nebraska USA), rabbit anti-mouse 
HRP (1:1000 dilution) or swine anti-rabbit HRP (1:1000 dilution) (Neomarkers, Fremont, 
CA, USA), for 1 h at room temperature, whilst shaking. The membrane was washed six 
times for 15 min each at room temperature whilst shaking, four times with blocking buffer 
and twice in TBS-T. The blot was visualised using either an Odyssey infra-red imaging 
system (LI-COR) or Enhanced Chemiluminescent (ECL) Detection System (Amersham 
Biosciences UK Limited) following the manufacturer’s instructions. Briefly, equal 
quantities of the two solutions from the ECL kit were mixed and poured on to the 
membrane. After 1 min, the excess ECL was drained off and films were exposed for 
various lengths of time ranging from 30 sec to overnight.  
2.19 Adenovirus production 
2.19.1 Recombinant Ad5 production 
High titre stocks of recombinant E1/E3-deleted Ad5 were produced by large-scale 
expansion of a plaque pure stock of Ad5 in 293 cells. AdKO1 was previously generated in 
house as described by Bradshaw et al. (Bradshaw et al., 2010). Ad5KO1 is based on the 
Ad5 vector and contains a two-amino acid substitution in the fiber knob domain (S408E, 
P409A) that ablates CAR binding. For recombinant Ad5 production, cells were grown to 
approximately 80% confluence and infected with virus with a multiplicity of infection of 1 
plaque forming unit (pfu) per cell. After 3 to 4 days the cytopathic effect (CPE) of the virus 
caused the cells to detach from the base of the tissue culture flask. The media containing 
the cells was collected and the cells were harvested by centrifugation at 850 g for 10 min. 
The supernatant was removed and the cells were resuspended in 8 ml PBS. Next, 8 ml 
Arklone P (trichlorotrifluoroethane) was added to the cells and the mixture gently shaken 
and inverted several times. The mixture was centrifuged at 1900 g for 15 min. The top 
aqueous layer containing the virus was removed and stored at -80˚C.   
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2.19.2 Ad5 purification using caesium chloride (CsCl) gradient 
Clear ultracentrifuge tubes (Beckman Coulter, London, UK) were sterilised with 70% 
ethanol and sterile H2O. A CsCl gradient was produced by adding, in order, 2.5 ml of CsCl 
with a density of 1.4 g/ml and 2.5 ml of CsCl with a density of 1.25 g/ml to an 
ultracentrifuge tube. The crude Ad5 stock was gently poured on top and the remaining 
volume in the tube was filled with PBS. The tube was placed in a Sorvall Discovery 90 
rotor container (Sorvall Centrifuges, Connecticut, USA) and subjected to 
ultracentrifugation at 90,000 g for 1.5 h at 4°C with maximum acceleration and zero 
deceleration. On completion of this step a distinct, opalescent band containing the virus 
was observed between the CsCl 1.4 g/ml and CsCl 1.25 g/ml density layers in the tube 
(Figure 2.3). The virus band was removed by piercing the tube below the band using a 21 
gauge needle and removing the band in the minimal volume possible whilst taking care not 
to disrupt the other bands. The extracted virus was gently added to a fresh ultracentrifuge 
tube containing 5 ml of CsCl with a density of 1.34 g/ml and the remaining volume in the 
tube was filled with PBS. The tube was placed in a Sorvall Discovery 90 rotor container 
and subjected to ultracentrifugation at 90,000 g for 18 h at 4°C with maximum acceleration 
and zero deceleration. The distinct, opalescent band containing the virus visible above the 
CsCl 1.34 g/ml density layer was removed as before (Figure 2.3). The virus was 
transferred to a SlideA-Lyzer Dialysis Cassette (molecular weight cut-off of 10,000 Da) 
(Perbio Science, Cramlington, UK) for dialysis after hydration of the cassette for 1 min in 
dialysis solution. The virus was dialysed in 2 L 0.01 M Tris pH 8 and 0.001 M EDTA 
twice, first for 2 h then overnight in fresh buffer, and for a further 2 h in fresh buffer 
supplemented with 10% (v/v) glycerol. The virus was extracted from the cassette and 
stored at -80˚C. 
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Figure 2.3. Purification of Ad5 by CsCl gradient. 
(A) After the first ultracentrifugation step a distinct, opalescent band containing the virus 
forms between the CsCl 1.4 g/ml and CsCl 1.25 g/ml density layers (B) After the second 
ultracentrifugation step a band containing virus is visible above the CsCl 1.34 g/ml density 
layer in the tube. 
2.20 Virus titration by end-point dilution assay 
Ten-fold serial dilutions of viral stocks were titrated on 293 cells (~60% confluent), seeded 
in a 96-well plate with ten replicates of each titration on the plate. The next day the media 
was replaced with 200 µl complete media. Media was replenished every 2-3 days. Infection 
was detected by induction of CPE. Once the CPE was apparent in a well, that well was 
marked and the media no longer replaced. The cells were incubated at 37°C for 8 days, at 
which point the number of wells containing plaques were counted and results fitted into the 
following equations in order to obtain the titre of the adenoviral stocks in pfu/ml. The 
proportionate distance = (% positive above 50% - 50%) / (% positive above 50% - % 
positive below 50%). The log ID50 (infectivity dose) = (log dilution above 50% + 
(proportionate distance x -1) x dilution factor). Viral tissue culture ID50 (TCID50) values 
were then adjusted (1 x TCID50 = 0.7 pfu) to enable viral titres to be expressed as pfu/ml. 
2.21 Quantification of virus particles 
Virus particle titre was determined based on the protein content of the virus stock using a 
Micro BCA Protein Assay Kit (Pierce) according to the manufacturer’s instructions. 
Briefly, BSA standards at concentrations of 200, 40, 20, 10, 5, 2.5, 1 and 0.5 µg/ml were 
prepared in PBS and 150 µl of each were pipetted in duplicate into a 96-well plate. 150 µl 
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PBS was used as a blank control. 1, 3 and 5 µl of the virus stock were added in duplicate 
and each well was made up to 150 µl with PBS. 150 µl working reagent (made up of 
25:24:1 part Reagent A, B, C supplied with the kit) was added to each well. The plate was 
incubated at 37˚C for 2 h. The absorbance was measured at 570 nm using a Wallac 
VICTOR 2 plate reader (Wallac). Background or the blank control absorbance was 
subtracted from all samples and standards. The amount of protein present in each virus was 
determined from the standard curve. The virus particle titre was calculated using the 
established formula, 1 µg protein = 1 × 109 viral particles (Von Seggern et al., 1998).  
2.22 Adenovirus infection 
2.22.1 Virus cell binding 
Cells were seeded in 24-well plates at a density of 2 x 105 cells/well and incubated 
overnight at 37ºC. Cells were washed in ice cold PBS and incubated with 1000 vp/cell of 
Ad5 in serum free media for 1 h on ice in the absence or presence of 1 µg/ml pd FX, WT 
or SP mutant rFX. Cells were then washed three times in PBS before cells were 
mechanically dislodged into 500 µl PBS. The cell suspension was collected in a 1.5 ml 
Eppendorf. The cells were pelleted by centrifugation at 16000 g for 3 min at room 
temperature. The supernatent was removed and the cell pellet was resuspended in 200µl 
PBS. 
2.22.2 DNA extractions 
Viral and genomic DNA was extracted from samples using the QIAmp DNA mini kit 
(QIAGEN) according to the manufacturer’s instructions. Briefly, to the cell pellet 
resuspended in 200µl PBS, 20 µl proteinase K and 200 µl buffer AL were added and the 
mixture was vortexed. Samples were incubated for 10 min at 56°C. Next, 200 µl 100% 
ethanol was added to the samples, mixed and the complete sample was loaded on to a 
QIAamp Spin Column. Samples were centrifuged at 6000 g for 1 min at room temperature 
to allow the DNA to adsorb on to the silica-gel membrane of the spin column. The spin 
column was then washed with 500 µl buffer AW1 and centrifuged at 6000 g for 1 min at 
room temperature, followed by a second wash step with 500 µl buffer AW2 and 
centrifuged at 16000 g for 3 min at room temperature. Finally the DNA was eluted in 50 µl 
dH2O by centrifugation at 6000 g for 1 min. The amount of DNA in each sample was 
quantified by measuring absorbance at 260 nm (NanoDrop, ND-1000 spectrophotometer). 
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2.22.3 Quantitative PCR for quantifying Ad genomes 
Virus particles remaining bound to cells from the virus cell binding experiment were 
quantified by quantitative polymerase chain reaction (qPCR). This quantitative 
measurement is based on the detection of a fluorescent signal produced proportionally 
during the amplification of a PCR product. The amount of fluorescence released during the 
amplification cycle is proportional to the amount of product generated in each cycle and 
can be measured directly. Acquisition of data occurs when PCR amplification is in the 
exponential phase. The Power SYBR Green detection system (Applied Biosystems, 
Warrington, UK) was used. Power SYBR Green PCR master mix with 0.2 µM hexon 
primers, forward (5’-CGCGGTGCGGCTGGTG-3’) and reverse (5’-
TGGCGCATCCCATTCTCC-3’) were used to amplify the DNA. A standard curve was 
produced from serial dilutions of Ad5 (102-107 vp). For each reaction 125 ng of total DNA 
was used. The following conditions were used; 95°C for 10 min for denaturation, 95°C for 
15 sec for amplification, 60°C for 1 min (repeated for 50 cycles) for annealing, 95°C for 15 
sec, 60°C for 15 sec and 95°C for 15 sec for dissociation. Total adenoviral genomes were 
calculated using the SDS 2.3 software.  
2.22.4 Fluorescence activated cell sorting (FACS) analysis of virus:cell 
binding 
SKOV3 cells were detached from culture vessels using a 1 x citric saline solution and 
seeded at a density of 2 x 105 cell/tube in 50 µl of ice cold serum free media. Cells were 
incubated with 50 µl ice cold serum free media containing 5000 vp/cell of Alexa Fluor-488 
fluorescently-labelled Ad5 in the absence or presence of FX plus 10 µM compound 
T5550585, T5424837, T5660138, T5677956, T5660136 or T5572402 from the 
Pharmacological Diversity Drug-like Set or ER-27319 (Tocris Bioscience). The cells:virus 
mixes were incubated at 4˚C for 1 h, in the dark, whilst shaking. Samples were washed 
twice in serum free media, undergoing centrifugation at 498 g for 3 min each time and 
resuspended in a final volume of 150 µl ice cold serum free media. Alexa Fluor-488 
fluorescently-labelled virus bound to the cells was detected on FACS Canto II flow 
cytometer (Beckton Dickinson, Oxford, UK) using FACS DIVA software. Viable cells 
were gated on the basis of forward and side light scatter profiles, with a minimum of 5000 
gated events analysed per sample. Results are expressed as geometric mean x percentage 
positive cells per condition.  
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2.22.5 Virus cell transduction in the presence of rFX 
Cells were seeded in 96-well plates at a density of 2 x 104 cells/well and incubated 
overnight at 37ºC. Cells were washed with PBS and incubated with 1000 vp/cell Ad5 in 
serum free media in the absence or presence of 1 µg/ml FX, WT, SP mutant rFX and 100 
µg/ml soluble heparin or for transduction experiments involving the single and double 
mutants of rFX in the absence or presence of 10 ng/ml FX, WT, SP mutant rFX, or rFX 
with mutations R93A_K96A, R125A, R165A_K169A, K236A_R240A for 3 h at 37°C. 
Cells were then washed once in serum free media and 200 µl complete media added. Cells 
were incubated at 37°C for a further 45 h.  
2.22.6 Virus cell transduction in the presence of pharmacological agents 
Cells were seeded in 96-well plates at a density of 2 x 104 cells/well and incubated 
overnight at 37ºC. Cells were washed with PBS and for experiments involving the kinase 
inhibitors, were preincubated with 20 µM compound at 37ºC for 30 min. Cells were 
incubated with 1000 vp/cell Ad5 in serum free media in the absence or presence of 10 
µg/ml FX with or without kinase inhibitors or compounds from the Pharmacological 
Diversity Drug-like Set for 3 h at 37°C. 100 µl of complete media containing 20% serum 
was added to cells and they were incubated at 37°C for a further 45 h.  
2.22.7 β-galactosidase transgene quantification  
Expression of β-galactosidase was quantified using Tropix Galacto-Light Plus (Applied 
Biosystems). Briefly, cells were washed in PBS and 70 µl 1 x Reporter Lysis Buffer (5 x 
Reporter Lysis Buffer stock (Promega) diluted in PBS) was added. The plate was freeze 
thawed to ensure complete lysis of cells. 10 µl of each sample was transferred to a black 
96-well plate and 70 µl of Tropix Galacton Plus:β-gal diluent mix (1:100 dilution of Tropix 
Galacton Plus in 100 mM NaH2PO4 and 1mM MgCl2, pH 8) was added. Cells were 
covered in tinfoil to protect from light and incubated at room temperature for 1 h. 100 µl of 
Tropix Accelerator II was added to each well and incubated for 2 min. Luminescence was 
measured using a Wallac VICTOR2 plate reader (Wallac). β-Galactosidase activity was 
then normalised to total protein content of the samples, measured by BCA assay (section 
2.17) producing relative light units per milligram protein (RLU/mg protein). 
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2.22.8 GFP transgene quantification 
Cells were washed in PBS and 50 µl 1 x Reporter Lysis Buffer was added. Cells were 
placed on ice and mechanically dislodged from each well of the plate. A standard curve of 
recombinant GFP ranging from 0.01 to 1 µg/ml was produced and 100 µl of each dilution 
was added in duplicate to the plate. 100 µl of PBS was added in duplicate as a blank 
control. 20 µl of each sample was transferred to the plate and 80 µl 1 x Reporter Lysis 
Buffer was added. The plate was incubated at room temperature for 10 min. Luminescence 
was measured using a Wallac VICTOR2 plate reader (Wallac). GFP activity was then 
normalised to total protein content of the samples, measured by BCA assay (section 2.17) 
producing relative light units per milligram protein (RLU/mg protein). 
2.22.9 Luciferase transgene quantification 
Expression of luciferase transgene was quantified using Luciferase Assay System 
(Promega, Madison, WI, USA) and recombinant luciferase protein (Promega, Madison, 
WI, USA) was used as the standard. Briefly, cells were washed with PBS and 50 µl 1 x 
Reporter Lysis Buffer was added. The plate was freeze/thawed to ensure complete lysis of 
the cells. 10 µl of each sample was transferred to a white 96-well plate and 90 µl 1 x 
Reporter Lysis Buffer was added to each well. Standard curves of recombinant luciferase 
ranging from 0-100 pg/ml and 0-1 pg/ml were produced and 100 µl of each dilution was 
added in duplicate. Luciferase Assay Buffer was added to Luciferase Assay substrate and 
100 µl was then added to each well. Luminescence was measured using a Wallac 
VICTOR2 plate reader (Wallac). Luciferase activity was then normalised to total protein 
content of the samples, measured by BCA assay (section 2.17) producing relative light 
units per milligram protein (RLU/mg protein). 
2.23 Investigating intracellular Ad5 transport 
2.23.1 Fluorescently labelling vectors 
Ad5 was fluorescently labelled using an Alexa Fluor-488 Protein Labeling Kit (Invitrogen, 
Paisley, UK) according to the manufacturer’s instructions. This kit can be used to label 100 
µg of protein per reaction and as 1 µg = 4 x 109 vp, using the established formula (Von 
Seggern et al., 1998), 4 x 1011 vp were used per labelling reaction. The vector was 
transferred to a SlideA-Lyzer Dialysis Cassette (molecular weight cut-off of 10000 Da) 
(Perbio Science) for dialysis after hydration of the cassette for 1 min in dialysis solution. 
Chapter 2 | Materials & Methods 
73 
The vector was dialysed twice in 2 L of PBS, for 3 h each. The dialysis removes any 
glycerol which the vector was stored in, as this may interfere with labelling efficiency. The 
vector was removed from the cassette and added to the reaction tube (Component C) 
supplied by the kit.  A 1 M sodium bicarbonate solution (pH ~8.3) was prepared by adding 
1 ml dH2O to the vial of sodium bicarbonate (Component B) supplied by the kit.  A 1/10 
volume of 1 M sodium bicarbonate was added to the reaction tube (Component C) and the 
sample was mixed. 10 µl dH2O was added to one vial of Alexa Fluor® 488 TFP ester 
(Component A) and mixed to ensure the contents of the vial were completely dissolved. 10 
µl of the reactive dye solution was added to the reaction tube and mixed thoroughly. A 3:1 
ratio for dye:virus was used. The reaction mixture was incubated at room temperature in 
the dark for 15 min. The reaction mixture was transferred to a SlideA-Lyzer Dialysis 
Cassette for dialysis after hydration of the cassette for 1 min in dialysis solution. The 
labelled vector was dialysed in 2 L of 0.01 M Tris pH 8 and 0.001 M EDTA for 3 h in the 
dark. The buffer was then replaced with 2 L of 0.01 M Tris pH 8, 0.001 M EDTA and 10% 
(v/v) glycerol and the vector dialysed overnight in the dark. Labelled vectors were 
removed from the cassette, aliquoted and viral titre was reassessed as in section 2.21. 
Infectivity of labelled adenoviruses was verified by in vitro gene transfer assay as 
described in section 2.23.2. Labelled vectors were stored in the dark at -80ºC. 
2.23.2 Cell trafficking of fluorescently-labelled vectors 
Cells were seeded in 8-well chamber slides at 4 x 104 cells/well and incubated at 37ºC 
overnight. Cells were washed with PBS and for experiments involving the kinase 
inhibitors, were preincubated with 20 µM compound at 37ºC for 30 min. Cells were then 
washed and incubated with 1 x 104 vp/cell of fluorescently-labelled Ad5 in 150 µl serum 
free media for 1 h on ice in the absence or presence of 1 µg/ml pd FX, WT or SP mutant 
rFX or in the presence of 10 µg/ml pd FX with or without pharmacological compound. 
Cells were either immediately washed in PBS and fixed in 4% paraformaldehyde (PFA) 
for 15 min at room temperature or incubated at 37ºC for 15, 60 or 180 min prior to 
fixation. Prolong Gold Antifade Reagent with DAPI (Invitrogen) was added to counterstain 
the nuclei or cells were subjected to immunocytochemistry (section 2.24). Coverslips were 
added. The mounting agent was allowed to set overnight before viewing on the Zeiss 
confocal imaging system LSM 500 (Carl Zeiss Ltd., Germany).  
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2.24 Immunocytochemistry 
Cells were treated as described in section 2.23.2. After fixation, cells were washed twice in 
PBS and permeabilised with 0.1% (v/v) Triton X for 10 min at room temperature. Cells 
were washed three times in PBS and incubated in 10% (v/v) goat serum (Vector 
Laboratories Inc., Burlingame, CA) for 30 min. Cells were washed in 0.1% (v/v) Triton X 
and incubated overnight at 4ºC with the primary antibody or relevant IgG negative control 
(diluted in PBS and 10% (v/v) goat serum, for concentrations see Table 2.4). The primary 
antibody was removed and cells washed three times in PBS for 5 min each. Next cells were 
incubated with a secondary fluorescein isothiocyanate (FITC)- or tetramethyl rhodamine 
isothiocyanate (TRITC)-labelled antibody for 1 h in the dark. Cells were washed three 
times in PBS for 5 min each to remove the secondary antibody. Prolong Gold Antifade 
Reagent with DAPI (Invitrogen) was added to counterstain the nuclei. Coverslips were 
added. Images were taken using the Zeiss confocal imaging system LSM 500 (Carl Zeiss 
Ltd.).  
Table 2.4. Antibodies used in experimental procedures. 
 
Antibody Species 
raised in 
Cross reactivity Clone Final 
concentration 
Mouse IgG  
(isotype matched) 
Mouse Human, rat, 
rabbit 
N/A Equivalent to 
primary 
antibody 
Rabbit IgG 
(isotype matched) 
Rabbit Human, mouse, 
rat,  
N/A Equivalent to 
primary 
antibody 
Goat-anti-rabbit Goat Rabbit                                                                           N/A 4 µg/ml
 
Goat-anti-mouse Goat Mouse N/A 4 µg/ml 
 
Pericentrin Rabbit Human, mouse, 
rat, rabbit 
Polyclonal 5 µg/ml 
 
Radixin Rabbit Human, mouse, 
rat 
Monoclonal 
-  # EP1862Y 
0.34 µg/ml 
 
Moesin Rabbit Human, mouse, 
rat 
Monoclonal 
-  # EP1863Y 
1.15 µg/ml 
 
Ezrin Rabbit Human, mouse, 
rat 
Polyclonal 5 µg/ml 
 
Pan-heparan 
sulphate 
Mouse Human Monoclonal 
-  # 10E4 
5 µg/ml 
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2.25 Quantification of Ad5 colocalisation with the MTOC 
Cells from virus trafficking assays were fixed and stained using the rabbit polyclonal 
pericentrin antibody as described in section 2.24. The pericentrin antibody stains the 
MTOC of cells. Colocalisation of fluorescently-labelled Ad5 with the MTOC was 
quantified by counting the number of cells with fluorescently-labelled virus and pericentrin 
co-staining using the Zeiss confocal imaging system LSM 500 (Carl Zeiss Ltd.). Data were 
averaged from five 40 x microscope fields per experimental condition. 
2.26 Analysis of Ad5 attachment ex vivo 
Liver sections from MF-1 mice were embedded in Tissue-Tek Optimum Cutting 
Temperature (OCT) compound (Sakura Finetek, The Netherlands) in intermediate Tissue-
Tek cryomolds (Sakura Finetek) on dry ice. Cryostat sections 4 µm thick were cut and 
mounted on Tissue Tek AutoWrite StarFrost Adhesion Microscope Slides with Cut Edges 
(Sakura Finetek). Slides were stored at -80 ºC until required. Liver sections were air dried 
at room temperature for 20 min and fixed in 4% PFA. The sections were incubated with 2 
x 109 vp of Alexa Fluor-488 fluorescently-labelled Ad5 in serum free media in the 
presence of 7 µg/ml WT or SP mutant rFX for 1 h on ice followed by 1 h at 37°C. Sections 
were washed twice in PBS, fixed and the nuclei stained using Prolong Gold Antifade 
Reagent with DAPI. Sections were imaged using an Olympus Cell M imaging system. To 
quantify adherent Alexa Fluor-488 fluorescently-labelled Ad5 particles, 40x images were 
captured using an Olympus Cell M imaging system and processed using Image J counting 
software. At least six captured images were analysed per experimental condition. 
2.27 MTT assay 
Cells were plated at a seeding density of 2 x 104 in 96-well plates and incubated at 37ºC 
overnight. Cells were transduced with virus in the presence of pharmacological compounds 
as described in section 2.22.6. 48 h post-infection, media on the cells was replaced with 
100 µl complete media and 15 µl of dye solution containing terazolium. MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is a pale yellow substrate that 
produces a dark blue formazan product when incubated with live cells and is commonly 
used to measure cell death (Tim, 1983). Cells were incubated for 4 h at 37ºC. Next, 100 µl 
of Solubilization Solution/Stop Mix was added to each well to solubilise the formazan 
product. Cells were incubated for a further 1 h at 37ºC. The colour produced was measured 
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using a Wallac VICTOR2 plate reader (Wallac) at a wavelength of 570 nm and was 
directly proportional to the amount of live cells in the sample. 
2.28 RNA extractions 
A549, SKOV3 or SW620 were plated at 4 x 105 cells/well in 6-well plates and incubated at 
37ºC overnight. Total RNA was extracted from cells using the RNeasy Mini Kit (Qiagen). 
Briefly, cells were lysed, collected in a 1.5 ml Eppendorf and centrifuged at 16,000 g for 5 
min to pellet the cells. 600 µl RLT buffer was added to the cell pellet and the mixture was 
vortexed. RLT buffer contains denaturing guanidine isothiocyanate. This immediately 
inactivates RNases and ensures extraction of intact RNA. In order to facilitate binding to 
the spin column, 600 µl 70% ethanol was added and the sample was then loaded on to the 
spin column. This was subjected to centrifugation at 8,000 g for 15 sec to allow the RNA 
to bind to the silica-gel membrane of the spin column. To wash the spin column 700 µl 
buffer RWT was added and the spin column was centrifuged at 8,000 g for 15 sec. This 
was followed by two further wash steps with 500 µl RPE buffer, the first wash centrifuged 
at 8,000 g for 15 sec and the second wash centrifuged at 8,000 g for 2 min. This eliminates 
contaminants. To elute the purified RNA, 30 µl RNase-free water was added and the spin 
column centrifuged at 8,000 g for 1 min.  
2.29 DNase treatment of RNA 
DNase treatment of RNA samples was performed using the TURBO DNA-free kit 
(Applied Biosystems) according to the manufacturer’s instructions. This removes 
contaminating DNA from RNA extractions. Briefly, to 40 µl of the RNA sample, 0.5 µl 
10x TURBO buffer and 1 µl TURBO DNase were added and the mixture was incubated at 
37ºC for 30 min. DNase inactivation reagent (0.1% v/v) was added and the mixture was 
incubated at room temperature for 2 min. This was followed by centrifugation at 10,000 g 
for 1.5 min. The supernatant was kept as a DNA-free RNA sample. RNA was quantified 
by measuring absorbance at 260 nm (NanoDrop, ND-1000 spectrophotometer). The 
samples were stored at -80ºC. 
2.30 cDNA synthesis 
The Reverse Transcription Kit (Applied Biosystems, Warrington, UK) was used to convert 
mRNA into complementary DNA (cDNA) as per the manufacturer’s instructions. To 1 µg 
RNA, 2 µl RT buffer, 5.5 mM MgCl2, 4 µl deoxyribonucleotide triphosphates (dNTPs) 
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mix, 1 µl random hexamers, 1 µl RNase inhibitor and 0.5 µl Multiscribe Reverse 
Transcriptase were added in a final volume of 20 µl. The samples were incubated at 25ºC 
for 10 min for preannealing, at 48ºC for 30 min to allow reverse transcription to occur and 
at 95ºC for 5 min for reverse transcription inactivation. The samples were stored at -20ºC. 
2.30.1 QPCR for quantification of cellular genes 
QPCR (as described in section 2.22.3) was used to detect expression of Syk, ezrin, moesin 
and radixin in SKOV3, A549 and SW620 cells. The Power SYBR Green detection system 
(Applied Biosystems, Warrington, UK) was used with the QuantiTect Primer Assay kit 
containing forward and reverse primers (QIAGEN, UK) for human Syk (Hs_SYK_2_SG, 
catalogue QT01886521), ezrin (Hs_EZR_1_SG, catalogue number QT00078127), moesin 
(Hs_MSN_1_SG, catalogue number QT00015169) or radixin (Hs_RDX_1_SG, catalogue 
number QT00047397) to amplify the cDNA. To 2.5 µl of the cDNA, 6.25 µl SYBR Green 
master mix, 1.25 µl primer mix and 2.5 µl dH2O were added. The following thermal 
cycling conditions were used; 95°C for 10 min for denaturation, 95°C for 15 sec for 
amplification, 60°C for 1 min for annealing (repeated for 50 cycles), followed by 95°C for 
15 sec, 60°C for 15 sec and 95°C for 15 sec for dissociation.  
2.31 High throughput screening 
2.31.1 Compound library 
The Pharmacological Diversity Drug-like Set (Enamine, Kiev, Ukraine) library consisted 
of 10,240 compounds preplated in columns 3 to 22 of 32 Matrix 384-well, clear, V-bottom, 
polypropylene plates (catalogue number 4312, Thermo Scientific, Surrey, UK) as single 
compounds at a concentration of 10 mM in 100% DMSO. Each plate had an individual 
barcode and sample ID for tracking purposes. Plates were sealed and compounds stored 
under nitrogen (BOC, Glasgow, UK) using the Platesealer SILVERseal, aluminium 
(Greiner Bio One, Gloucestershire, UK). Compounds were stored at -80ºC. Information 
about the library including compound I.D., molecular weight and structure can be found on 
the Enamine website, following the link 
www.enamine.net/index.php?option=com_content&task=view&id=83. All compounds 
were assured by the vendor (Enamine, Kiev, Ukraine) to be at least 90% pure as assessed 
by liquid chromatography-mass spectrometry and proton nuclear magnetic resonance 
spectrometry.  
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2.31.2 Production of compound library dilution plates 
Three individual replicate plates of each compound library plate were generated, each with 
a barcode and sample ID related to the parent plate. Using the Biomek FXP 96 
multichannel pipetting head (Beckman Coulter) 3 µl from each well of the compound 
library plate was directly dispensed into a 384 deep well, small volume, polypropylene 
plate (catalogue number 784201, Greiner Bio One, Gloucestershire, UK) previously loaded 
with 27 µl of DMSO using the Multidrop Combi (Thermo Scientific). This was preformed 
in triplicate. These plates, in which compounds were at a concentration of 1 mM, were 
named mother plates. All robotics protocol designing and scheduling was performed using 
Biomek Software (Beckman Coulter) and SAMI Workstation EX Software (Beckman 
Coulter) (Figure 2.4). Plates were sealed, compounds stored under nitrogen using the 
Platesealer SILVERseal, aluminium (Greiner Bio One) and stored at -80ºC. 
2.31.3 Seeding cells  
Following optimisation, SKOV3 cells were seeded at a density of 1500 cells per well in 50 
µl complete media in 384 µ-clear flat bottom, black, cell culture microplates (catalogue 
number 781091, Greiner Bio One, Gloucestershire, UK) using the Multidrop Combi 
(Thermo Scientific). These plates were termed assay plates. Each plate had an individual 
barcode and sample ID for tracking purposes. Cells were tested prior to use to ensure they 
were mycoplasma free. Cells were incubated in 37ºC, 5% CO2 and 95% air incubators 
overnight. All tissue culture procedures for robotic screening experiments was performed 
under sterile conditions using biological safety class II vertical laminar flow robotics 
enclosure cabinets (Bigneat Containment Technology, Bigneat Ltd, Waterlooville, UK). 
2.31.4 Screening the compound library 
Plates were loaded on to the Cytomat Hotel (Thermo Scientific), a microplate stacking and 
handling system integrated with the liquid handling robotics. As plates were imported from 
the hotel, the barcodes were scanned and sample IDs read, this was to ensure all liquid 
aspirations from one plate were dispensed in the corresponding daughter or assay plate. 
Using the Biomek FXP 96 multichannel pipetting head 2 µl of each well in columns 3 to 22 
of the mother plate was directly dispensed into a 384 deep well, small volume, 
polypropylene plates (Greiner Bio One) in which all wells were previously loaded with 8 
µl of serum free media using the Multidrop Combi (Thermo Scientific). Using the Span-8 
(Beckman Coulter) 2 µl of DMSO was added into every second well of column 2 (starting 
Chapter 2 | Materials & Methods 
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with 2A) and 23 (starting with 23B) as vehicle controls. The Span-8 configuration allows 
for independent well access. 1000 vp/cell of Ad5GFP was added to columns 2 to 23 in a 
final volume of 20 µl using the Multidrop Combi. Compounds were at a concentration of 
100 µM. This plate was referred to as the daughter plate. Cells in the assay plate were 
washed once in 50 µl of serum free media using the Biomek FXP 96 multichannel pipetting 
head. 22.5 µl of serum free media was added to each well in columns 1, 2, 23 and 24 and 
22.5 µl of serum free media containing FX was added to each well in columns 3 to 22 
using the Multidrop Combi.  
Controls: Each compound was tested in triplicate, with each replicate on a separate plate. 
This allowed for interplate and intraplate controls. Columns 1 and 24 contained the 
untreated control samples. To each well in columns 1 and 24, 2.5 µl of serum free media 
was added using the Span-8 (Beckman Coulter). Columns 2 and 23 contained the positive 
and negative control samples. Into every second well of column 2 (starting with 2A) and 
23 (starting with 23B) 2.5 µl of serum free media containing FX was added (+FX negative 
controls (final concentration of 10 µg/ml FX and 1% (v/v) DMSO vehicle) and into every 
other well of those columns, 2.5 µl of serum free media was dispensed (-FX positive 
controls) using the Span-8. 
From each well in columns 2 to 23 of the working plate, 2.5 µl of virus and compound 
mixture was added to the cells in the corresponding wells in columns 2 to 23 of the assay 
plate. All wells in columns 3 to 22 had a concentration of 10 µM compound, 10 µg/ml FX 
and 1% (v/v) DMSO. Daughter and assay plates were returned to the Cytomat Hotel. 
Daughter plates were disposed of and assay plates were incubated in 37ºC, 5% CO2 and 
95% air for 3 h. After this incubation, 25 µl of complete media containing 20% (v/v) FCS, 
1% (v/v) penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine was added to all wells 
using the Multidrop Combi. Assay plates were further incubated in 37ºC, 5% CO2 and 95% 
air for 45 h. 
2.31.5 Fixing cells from the HTS screen 
Assay plates were loaded on to the Cytomat Hotel. Cells were washed once in 50 µl PBS 
and 50 µl 4% PFA was added to each well using the Plate Washer (Beckman Coulter). 
Cells were incubated at room temperature for 15 min and washed in 50 µl PBS using the 
Plate Washer. The Biomek FXP 96 multichannel pipetting head was employed to dispense 
10 µg/ml Hoechst 33342 (Sigma Aldrich) and 10 µg/ml propidium iodide (Sigma Aldrich) 
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on to cells in a final volume of 25 µl. Cells were incubated at room temperature for 20 min 
and washed in 50 µl PBS twice using the Plate Washer (Beckman Coulter). Assay plates 
were either analysed immediately or stored at 4˚C in the dark. 
 
Figure 2.4. SAMI Workstation EX Software screening protocols. 
Screen shot from the SAMI Workstation EX Software, in which liquid handling assay 
protocols were designed, from simple media additions (top panel), to more complex 
protocols with multiple steps such as those designed for cell fixation (middle panel) and 
compound additions (bottom panel).  
Chapter 2 | Materials & Methods 
81 
2.31.6 Using the IN Cell Analyser 2000 to capture screen images 
Assay plates were imaged using the IN Cell Analyser 2000 (GE Healthcare). A single 
image of the central field of view in each well was captured using the Nikon 10x objective 
(Figure 2.5). Preview scans of 5 random wells were preformed prior to starting the 
acquisition run (Figure 2.6). Imaging conditions were as follows, filter sets were matched 
to each fluorophore; 350excitation (ex) and 455 emission (em) for Hoechst 33342 nuclear staining 
and an exposure time of 40 millisec (ms), 490ex and 525em for GFP expression and an 
exposure time of 60 ms; 579ex and 624em for propidium iodide non-viable nuclear staining 
and an exposure time of 45 ms. The short exposure times contributed to the speed of 
acquisition. Hardware and laser autofocus options were chosen to optimise the quality of 
the images. 
 
Figure 2.5. Determining the field of view using the IN Cell Analyser 2000. 
A single image of the central field of view in each well of a 384-well plate was captured 
using a 10x objective. 
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Figure 2.6. IN Cell Analyser 2000 preview scan.  
Screen shot from the IN Cell Analyser 2000 software program. A random well from the 
384-well plate was chosen and a preview scan was performed to ensure imaging 
conditions were correct prior to starting the acquisition run.  
2.31.7 Analysing the screen images and acquiring screen data 
To quantify the amount of GFP expression per viable cell per field of view the images 
were analysed using IN Cell Developer Toolbox V1.6 software (GE Healthcare). The 
screen images were of high quality and provided sufficient resolution for effective 
segmentation of cellular components and GFP expression. Nuclei were segmented based 
on Hoeschst 33342 staining and shape, GFP expression was outlined based on its intensity 
and cell shape was estimated based on previous measurements outlined from brightfield 
images. Non-viable cell segmentation was related to propidium iodide staining. Nuclei, 
GFP expression and cells were termed targets and the targets were linked. An algorithm 
was designed to measure the total number of cells per field of view, to quantify all viable 
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cells per field of view, to quantify all GFP expression per field of view and then to measure 
the amount of GFP expression per viable cell per field of view;  
[DxA<Sum:/Cell Nuc GFP/GFP] / [Count<Sum:/Cell_Nuc/Cell] 
or 
 
[Intensity of total GFP per field of view] / [Total number of viable cells per field of view] 
 
This resulted in a numerical output enabling the calculation of results. All untreated control 
values were zero. All data were normalised to intraplate positive (Ad5-FX (low level Ad5 
transduction)) and negative (Ad5+FX and vehicle (high levels of Ad5 transduction 
mediated by FX)) controls and expressed as percentage inhibition of FX-mediated 
Ad5GFP expression.   
% Inhibition = (Negative control – compound) / (Negative control – Positive control) 
Data were pooled for each compound from the three replicate plates. Any compounds 
causing greater than 75% inhibition of FX-mediated Ad5GFP expression were selected for 
second round screening analysis. Preliminary candidate compounds from the library were 
selected manually and directly dispensed into columns 3 to 22 of a 384 deep well, small 
volume, polypropylene plates. Compounds were retested as described in section 2.31.4 to 
2.31.7. 
2.32 Animals 
All animals were housed under controlled environmental conditions. Temperature was 
maintained at ambient temperature with 12 h light/dark cycles. Mice were fed standard 
chow and water was provided ad libitum. All animal experiments were approved by the 
University of Glasgow Animal Procedures and Ethics Committee and performed under UK 
Home Office licence (PPL 60/3752) in strict accordance with UK Home Office guidelines.  
2.32.1 In vivo administration of Ad5 
In vivo Ad5 administration was performed in 8 week old, male, MF1 mice. Mice were 
injected via lateral tail vein injection with PBS or 1 x 1011 vp/mouse of Ad5 expressing a 
luciferase transgene in the absence or presence of 0.1% DMSO, 10 µM compound 
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T5550585, T5424837, T5660138, T5677956, T5660136 or T5572402 from the 
Pharmacological Diversity Drug-like Set.   
2.32.2 Quantification of adenoviral transgene expression  
Mice were injected subcutaneously with 300 µl of XenoLight D-Luciferin (Caliper, Life 
Sciences, Hopkinton, MA, USA) 48 h post-administration of Ad5. Luciferin becomes 
oxidised under the catalytic effects of luciferase and ATP, and a bluish-green light is 
produced. This was measured using the IVIS Imaging System (IVIS Spectrum, Caliper). 
Mice were subject to whole body bioluminescence quantification (IVIS Spectrum, Caliper 
Life Sciences). 48 h post-Ad5 injection mice were sacrificed for tissue analysis. Tissue 
homogenates were produced from 25 mg liver tissue using TissueLyser II (QIAGEN, 
Crawley, UK). DNA was isolated from tissue homogenates using QIAamp DNA mini kit 
(QIAGEN, Crawley, UK). 50 ng of total DNA was subject to qPCR analysis as described 
in section 2.22.3. 
2.33 Statistical analysis 
Results presented are representative data from a minimum of three separate experiments 
with at least three experimental replicates per group, unless otherwise stated. High 
throughput screening of the complete Pharmacological Diversity Drug-like Set compound 
library was performed once. Statistical analysis was performed in Prism version 4.0 (Graph 
Pad Software, San Diego, CA, USA). Data are shown as mean ± standard error of the 
mean. Comparisons were made using one way ANOVA or paired Student’s t-test. p<0.05 
after Dunnett’s or Bonferroni’s post-analysis were considered statistically significant. 
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3.1 Introduction 
Hepatic transduction of Ad5 following intravascular administration is due to a high affinity 
interaction between the Ad5 hexon and coagulation FX (Kalyuzhniy et al., 2008; Vigant et 
al., 2008; Waddington et al., 2008). FX is synthesised in the liver and circulates in the 
blood at a concentration of 8-10 µg/ml, as a two chain glycoprotein, with a molecular 
weight of 59,000 Da. The light chain consists of the Gla rich domain with 11 Gla residues, 
which are important for calcium-dependent binding, and two EGF-like domains, with an 
additional calcium binding site in EGF-1 (Nelsestuen et al., 1976). The light chain is 
linked to the heavy chain by a disulphide bond. The heavy chain contains the SP domain 
which features the active site of the catalytic triad; histidine 57, aspartic acid 102 and 
serine 195. Whilst the Gla domain of FX binds with high affinity within the cup formed by 
each hexon trimer (Waddington et al., 2008), the SP domain has been reported to be 
responsible for mediating the Ad5:FX complex interaction with HSPGs (Bradshaw et al., 
2010; Parker et al., 2006; Waddington et al., 2008). However the exact mechanism by 
which the FX SP domain binds to HSPGs has not been fully elucidated.  
The physiological function of FX is as a plasma zymogen, central to the blood coagulation 
cascade, a complex, multi-step process leading to the initiation of blood clotting, 
localisation at the injured vasculature, fibrin clot formation and generation of the platelet 
plug (Figure 3.1). During the clotting process FX is converted to its active enzyme, FXa, 
via cleavage of an arginine-isoleucine (Arg51-Ile52) peptide bond in the heavy chain, 
releasing a 52 amino acid activation peptide fragment (Fujikawa et al., 1974; Furie et al., 
1988). This process occurs at the point of convergence of the intrinsic and extrinsic 
pathways, either via FIXa and FVIIIa or tissue factor and FVIIa complexes, which 
assemble on phospholipid membranes, in the presence of calcium (Bom et al., 1990). FXa 
then participates with FVa to activate prothrombin to thrombin, which in turn converts 
fibrinogen to fibrin (Figure 3.1) (Davie et al., 1964; Macfarlane, 1964; Osterud et al., 
1977).  
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Figure 3.1. Coagulation cascade. 
Summary of the blood coagulation cascade, showing the intrinsic pathway (yellow), the 
extrinsic pathway (orange) and the common pathway (red). 
Despite the great homology between the serine proteases in the blood coagulation cascade, 
they exhibit narrow and distinctive specificity to their own protein substrates. Substrate 
recognition by several surface exposed residues in the catalytic domain, in addition to 
those surrounding the active site exist. Studies have shown that the basic residues Arg-93, 
Lys-96, Arg-125, Arg-165, Lys-169, Lys-236 and Arg-240 constitute an exosite in the SP 
domain of FXa which can bind to heparin, a highly sulphated glycosaminoglycan which 
serves as an anticoagulant (Figure 3.2) (Hirsh et al., 2001; Rezaie, 2000). Mutagenesis 
studies, in which each of these amino acids were substituted with a neutral alanine in 
separate Gla domainless FXa (GDFXa) constructs, investigated the contribution of 
individual residues for binding heparin (Rezaie, 2000). Elution with NaCl of each of the 
seven mutants from a heparin-sepharose column was assessed. As FXa binds to heparin via 
ionic forces, elution was accomplished by a stepwise gradient of increasing ionic strength 
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i.e. the higher the concentration of NaCl required to elute the protein, the stronger the 
binding and the lesser the effect of the mutation. The relative decrease in concentration of 
NaCl for elution was reported for GDFXa and R125A (0.4 M NaCl), R93A and K96A 
(0.38 M), R165A and K169A (0.35 M), K236A (0.28 M) and R240A (0.24 M) (Rezaie, 
2000). In addition, the effects of antithrombin on FXa inactivation were analysed. 
Antithrombin acts as an inhibitor of FXa and thrombin, an effect which is accelerated in 
the presence of heparin-like glycosaminoglycans (Figure 3.2) (Evans et al., 1992; Olson et 
al., 1992). When the mutants were incubated with antithrombin, GDFXa and FXa 
derivatives were inactivated with similar order association rate constants (k2). However in 
the presence of antithrombin and heparin, mutant FXa inactivation was impaired to varying 
degrees compared to GDFXa. This effect was minimal for R93A and R125A, whilst a 
significant decrease in k2 values was observed with all other mutants, ranging from a 4-fold 
decrease for K96A to a 25-fold decrease for R240A (Rezaie, 2000). These data suggests 
the order of importance of these FXa residues for binding heparin is Arg-240 > Lys-236 > 
Lys-169 > Arg-165 > Lys-96 > Arg-93 > Arg-125. 
FX FXa
Prothrombin Thrombin
Fibrinogen
FVa
Fibrin Clot
FXIIIa
Antithrombin
FIX
FXI FXIa
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FIXa
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Fibrin
 
Figure 3.2. Mechanism of action of heparin. 
Heparin produces its major anticoagulant effect by inactivating thrombin and FXa through 
an antithrombin-dependent mechanism. The heparin:antithrombin complex can 
inactivate FXIIa, FXIa, FIXa, FXa and thrombin, with the later two being most sensitive. 
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In contrast to FXa, FX exhibits a very weak affinity for heparin (Nogami et al., 2004). A 
study by Nogami et al., investigated the mechanism of interaction of FX and FXa with 
FVIIIa. FVIIIa bound to FXa via its heparin binding exosite (HBE), an interaction which 
was abolished in the presence of heparin (Nogami et al., 2004). However the effect of 
heparin on FX binding to FVIIIa was marginal. The affinities of FXa and FX for heparin 
were assessed using a heparin-sepharose column. In this study FXa was eluted at a NaCl 
concentration of 0.22 M, whilst FX failed to bind the column at 0.1 M and was instead 
detected in the column flow through fractions. This study suggests heparin binding to FXa 
is via the HBE, whilst this exosite is not as readily accessible in the zymogen (Nogami et 
al., 2004).  
In an attempt to investigate the role of the SP domain of FX in Ad5:FX binding to the cell 
surface, Waddington et al. employed the anticoagulants Ixolaris and nematode 
anticoagulant peptide 2 (NAPc2) to pharmacologically block the FX SP domain 
(Waddington et al., 2008). Ixolaris is isolated from the salivary gland of the tick Ixodes 
scapularis (Francischetti et al., 2002). It consists of 140 amino acids containing 10 
cysteines and 2 Kunitz-like domains and binds to FX or FXa, inhibiting tissue factor/FVIIa 
activation (Francischetti et al., 2002). NAPc2 is an 85 amino acid anticoagulant protein, 
isolated from the hematophagous hookworm Ancylostoma caninum (Cappello et al., 1995; 
Stassens et al., 1996). It is a potent inhibitor of FX activation mediated by tissue factor and 
FVIIa. SPR analysis revealed a high affinity interaction between human FX and NAPc2 
(dissociation rate constant (KD) = 7.28 x 10-11 M) or Ixolaris (KD = 1.30 x 10-9 M) 
(Waddington et al., 2008). This binding had no effect on Ad5 binding to FX (Waddington 
et al., 2008). Either anticoagulant alone was capable of decreasing the FX-mediated 
AdKO1 cell binding and transduction in HepG2 cells. Moreover, preinjection of FX in the 
presence of a three molar excess of either NAPc2 or Ixolaris, 30 min prior to 
administration of AdKO1 in warfarin-treated mice, significantly decreased hepatic gene 
transfer (Waddington et al., 2008).  
Ixolaris acts by binding to the HBE of FXa and mutagenesis studies indicate the order of 
importance of residues involved in this interaction is Arg-93 > Arg-165 > Lys-169 > Lys-
236 > Lys-96 > Arg-240 > Arg-125 (Monteiro et al., 2005). When the role of the amino 
acids in FX were analysed, the order of importance for Ixolaris complex formation was 
Arg-93 > Arg-165 > Lys-169 > Lys-236 > Arg-125 (Monteiro et al., 2008). Ixolaris 
binding to FX strongly decreases FX activation by the intrinsic FIXa/FVIIIa complex 
(Monteiro et al., 2008). This study suggests Ixolaris binds to residues within a heparin 
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binding proexosite (HBPE) in FX, a region which is not readily exposed to heparin or is in 
a distinct conformation in the zymogen form (Monteiro et al., 2008; Nogami et al., 2004). 
NAPc2 can bind with high affinity (KD ~1 nM) to both FX and FXa (Buddai et al., 2002). 
This reaction occurs independently of calcium and does not require zymogen activation or 
a fully functional active site (Buddai et al., 2002). A weaker interaction between NAPc2 
and bovine FX or FXa has been reported (Buddai et al., 2002). This may be due to 
sequence differences in the protease domains following residue 240, as in the presence of 
recombinant bovine FX, containing 25 residues from the COOH terminus of human FX, 
the high affinity interaction with NAPc2 was restored (Buddai et al., 2002; Murakami et 
al., 2007). The crystal structure of Gla domainless FXa and NAPc2, determined to 2.2 A, 
indicates binding to amino acid residues at positions 60-62, 88-93, 125, 178, 235-237, 240 
and 243 of FXa (Murakami et al., 2007). Table 3.1 and Figure 3.3 summarises the residues 
in FX or FXa to which Ixolaris and/or NAPc2 bind.  
Table 3.1. Amino acid residues of FX and FXa to which NAPc2 or Ixolaris bind.  
A list of the residues in the SP domain of FX or FXa to which Ixolaris or NAPc2 bind. 
FX/FXa amino acid Anticoagulant 
93R Ixolaris/NAPc2 
96K Ixolaris 
125R Ixolaris/NAPc2 
165R Ixolaris 
169K Ixolaris 
236K Ixolaris/NAPc2 
240R Ixolaris/NAPc2 
 
Although the study by Waddington et al. implicated a role for the FX SP domain in Ad5 
transduction (Waddington et al., 2008), the precise mechanism and amino acid residues 
responsible for FX-mediated Ad5 attachment to HSPGs have not been reported. 
Understanding the exact infectivity pathways of Ad5 is important to its optimisation and 
successful development as a gene therapy vector. Here, we investigate the role of the seven 
basic amino acid residues in the FX HBPE in Ad5:FX complex binding to HSPGs. 
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= residues interacting with Ixolaris only
= residues interacting with NAPc2 and Ixolaris
 
Figure 3.3. Residues to which NAPc2 and Ixolaris bind. 
Ribbon diagram of the human FX SP-EGF-2 domains (1HCG; Accelrys ViewerLite software 
(Padmanabhan et al., 1993)) highlighting amino acids residues to which Ixolaris alone 
(purple) or both Ixolaris and NAPc2 (yellow) bind. 
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3.2 Results 
3.2.1 Generation of FX plasmid constructs 
To assess the role of the SP domain of FX in Ad5:FX complex binding to HSPGs a FX 
plasmid construct was designed, in which the seven basic residues previously shown to 
constitute the HBPE were chosen for mutation (Monteiro et al., 2008; Nogami et al., 2004; 
Rezaie, 2000). The residues were Arg-93, Lys-96, Arg-125, Arg-165, Lys-169, Lys-236 
and Arg-240. First, human wild-type FX (WT FX) cDNA including the human 
prothrombin signal sequence and propeptide was cloned into the mammalian expression 
pCMV4 vector (human prothrombin signal sequence and propeptide followed by the 
sequence for the FX derivative - pCMV4-ss-pro-II-FX (Camire et al., 2000)). Efficient γ-
carboxylation is a critical post-translational modification of FX. FX is synthesised in its 
precursor form, which is translocated to the endoplasmic reticulum where glutamic acid 
residues in the Gla domain undergo γ-carboxylation. This depends on membrane bound γ-
carboxylase and vitamin K, as well as the propeptide acting as a substrate for the enzyme 
(Suttie et al., 1987). Previous studies have shown that exchanging the FX propeptide with 
one that binds γ-carboxylase with a reduced affinity, such as prothrombin, results in an 
increase in γ-carboxylase activity by allowing greater substrate turnover thus improving 
protein production by increasing the yields of the functional γ-carboxylated protein 
(Camire et al., 2000; Stanley et al., 1999). This WT FX plasmid was a kind gift from Prof. 
John McVey (Thrombosis Research Institute, London, UK). Seven codons encoding the 
basic amino acid residues R93, K96, R125, R165, K169, K236 and R240 in the WT FX 
cDNA sequence were substituted with alanine, as performed by GeneArt (Paisley, UK). 
This was called “SP mutant”. In addition, site-directed polymerase chain reaction 
mutagenesis to convert the basic residues arginine or lysine to alanine was used to create 
four FX mutant constructs in house; R93A_K96A, R125A, R165A_K169A and 
K236A_R240A. DNA sequencing analysis confirmed the mutations in the WT FX at the 
desired amino acid residues.  
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Figure 3.4. Amino acids residues for mutagenesis studies. 
(A) Amino acid sequence of human FX including the human prothrombin signal sequence 
and propeptide (obtained for the Swiss-Prot database and annotated using CLC Protein 
Workbench 5). Red arrows indicate the seven amino acid residues targeted for 
mutagenesis studies. (B) Ribbon diagram of the human FX SP-EGF-2 domains (1HCG; 
Accelrys ViewerLite software (Padmanabhan et al., 1993)), SP is in blue and EGF-2 is in 
red. The diagram highlights the amino acids residues (green) chosen for mutagenesis.  
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3.2.2 Cloning FX SP mutant into pcDNA3.1+zeocin  
The SP mutant cDNA was cloned into a pMK-RQ plasmid using Sfil cloning sites. pMK-
RQ was not a viable expression cassette for use in order to produce rFX protein via 
transfection into a mammalian cell line as this plasmid construct did not possess a suitable 
promoter. Therefore a cloning strategy was designed in which the SP mutant fragment was 
firstly inserted into a pSCb plasmid and then finally into a pcDNA3.1+zeocin plasmid 
(Figure 3.5). Primers were designed to amplify the FX SP mutant from the pMK-RQ 
plasmid, adding an AflII site at the 5’ end and amplifying through HindIII at the 3’ end. 
AflII-FX SP mutant-HindIII was amplified by PCR using two commercially synthesised 
primers and Herculase II proofreading polymerase (Table 3.2). The FX SP mutant PCR 
products were electrophoresed on a 1% agarose gel. Bands of 1.5 kb were isolated from the 
gel (Figure 3.5). Bands were gel extracted and the purified PCR product was ligated into 
the pSCb plasmid. pSCb_FX SP mutant was digested with EcoRI. At this point, 
pcDNA3.1+zeocin was dephosphorylated by digestion with EcoRI. The digests were 
electrophoresed on a 1% agarose gel. Bands of 1.5 kb for FX SP mutant and 5 kb for 
pcDNA3.1+zeocin were isolated from the gel (Figure 3.5). The FX SP mutant insert was 
ligated into the pcDNA3.1+zeocin plasmid according to the T4 ligase ligation protocol (3:1 
insert:vector ratio). After 1 h ligation at room temperature the ligation product was 
transformed into competent cells and spread on ampicillin resistant agar plates. The 
colonies were picked and small scale preparations of the DNA were performed. A 
diagnostic digest using BglII enzyme (two BglII sites present, one in the backbone and one 
in the SP mutant insert) was electrophoresed on a 1% agarose gel to ensure the insert was 
present. There were two fragments on the gel, a 5609 bp fragment for 
pcDNA3.1+zeocin_FX SP mutant backbone and a 978 bp fragment for the BgIII digestion 
product (Figure 3.5). The sequence was confirmed by DNA sequencing.  
Table 3.2. Primer design. 
FX SP mutant forward (containing AflII sequence highlighted in blue) and reverse primers 
were designed and commercially synthesised.  
Primer  Sequence  Tm 
FX SPmutant – forward 5’ GAATCTTAAAGGAAGGCCGTCA 3’ 60.6 
FX SPmutant – reverse 5’ GGCCCATGAGGCCCAGG 3’ 62 
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Figure 3.5. Cloning of the FX SP mutant sequence into pcDNA3.1+zeocin. 
Gel electrophoresis was preformed on (A) The FX SP mutant fragment which was 
amplified from the pMK-RQ construct, producing a band of 1.5 kb. (B) The 
pcDNA3.1+zeocin was digested, producing a band of 5 kb and the FX SP mutant fragment 
(band of 1.5 kb) was cut from the pSCb construct. (C) The pcDNA3.1+zeo_FX SP mutant 
vector was digested using BgIII enzyme producing a fragment of 978 bp and a band of 
5609 bp for the pcDNA3.1+zeo_FX SP mutant backbone. 
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3.2.3 Producing recombinant FX protein  
The WT and SP mutant FX constructs were transiently transfected into 293T cells in the 
presence of 5 µg/ml vitamin K. Recombinant FX (rFX) in the conditioned media was 
quantified by human FX ELISA and found to be at concentrations ranging from 0.1 µg/ml 
to 0.4 µg/ml after 5 days. To increase the yield of the protein produced, stable cell lines 
were generated based on zeocin resistance. Zeocin belongs to the family of antibiotics 
isolated from Streptomyces. It shows strong toxicity against mammalian cell lines and is 
commonly used as a selection tool. To generate a stable cell line that expresses a protein 
from an expression construct, the minimum concentration of zeocin required to kill the 
untransfected host cell line has to be determined. Therefore doses ranging from 100 µg/ml 
to 500 µg/ml of zeocin were tested on the ability to kill 293T cells after seven days. Cells 
sensitive to zeocin show morphological changes upon exposure to the antibiotic. The cells 
become an abnormal shape and long appendages appear as the plasma membrane breaks 
down (Figure 3.6). Eventually, the cells completely break down and only cellular debris 
remains in the media. A concentration of 200 µg/ml zeocin was chosen as the optimum 
dose for generating stable cell lines (Figure 3.6). 
Next stable cell lines to constitutively produce the WT and SP mutant rFX were generated. 
Firstly, 293T cells were transfected with the pcDNA3.1+zeocin_FX SP mutant plasmid, 
co-transfected with a plasmid encoding the WT FX and the pcDNA3.1+zeocin or co-
transfected with a control GFP plasmid and the pcDNA3.1+zeocin. Transfection efficiency 
was ~70% at 48 h post-transfection as assessed by GFP control cells under a fluorescent 
microscope (Figure 3.6). Media in the cell culture dishes was replaced with 10% complete 
media supplemented with 5 µg/ml vitamin K and 200 µg/ml zeocin. After 2-3 weeks mock 
transfected cells were dead and colonies had formed with cells transfected with 
pcDNA3.1+zeocin_FX SP mutant plasmid, co-transfected with WT FX and 
pcDNA3.1+zeocin or co-transfected with a control GFP and pcDNA3.1+zeocin (Figure 
3.6). Colonies were picked and grown until 90% confluent. Conditioned media was 
collected from individual wells and a FX ELISA was preformed to identify the highest 
producing cells. These cells were then grown up in larger culture flasks. 
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Figure 3.6. Generating stable cell lines. 
Determining optimal concentration of zeocin (100-500 µg/ml) required to kill mock 
transfected 293T cells after seven days incubation. (B) Cells 15 days post-transfection (i) 
GFP transfected cells. (ii) Bright-field view of GFP transfected cells in the presence of 200 
μg/ml zeocin. (iii) Mock transfected cells in the absence of zeocin. (iv) Mock transfected 
cells, (v) SP mutant FX transfected cells and (vi) WT FX transfected cells in the presence of 
200 μg/ml zeocin. Images captured at 40x magnification and scale bar = 100 μm, 
applicable to all panels.   
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3.2.4 Purification and validation of rFX protein  
Conditioned media from cells cultured in serum free media supplemented with 5 µg/ml 
vitamin K was collected, dialysed and immunoaffinity purified using the calcium-
dependent 4G3 mouse monoclonal antibody coupled to a sepharose column. The 
conditioned media was applied to the monoclonal human FX immunoaffinity column and 
any FX in the media bound to the column. Bound proteins were eluted with the addition of 
EDTA (Figure 3.7). Fractions eluted from the column where analysed by SPR to assess 
binding to the 4G3 mouse monoclonal antibody. The 4G3 antibody was covalently 
immobilised on a biosensor chip and the individual fractions eluted from the column were 
injected over the chip at a flow rate of 30 µl/min. Eluted fractions 1, 2, 3 and 4 from the 
media from WT rFX cells and eluted fractions 2, 3 and 4 from the media from SP mutant 
rFX cells bound to the chip (Figure 3.7), indicating the presence of FX. These results 
correlate to the elution profiles obtained whilst passing the media through the 4G3 
sepharose column. In order to further confirm this, the load (the media prior to passing 
through the column), the flow through and the purified rFX was subjected to SDS-PAGE. 
Coomassie staining showed a number of different bands for the load and the flow through, 
however for each of the eluted fractions a single band was observed of 59 kDa, similar to 
the positive control purified plasma derived (pd) FX (HTI Technologies Ltd) (Figure 3.8). 
Furthermore, each rFX protein migrated as a single band with an apparent molecular mass 
of 59 kDa similar to the positive control FX as assessed by Western blot analysis using a 
primary monoclonal human anti-FX clone HX1 antibody (Figure 3.8). The purified rFX 
was quantified by both microBCA and ELISA for human FX. The WT rFX was ~57 µg/ml 
and the SP mutant rFX was ~9 µg/ml. 
3.2.5 Assessment of the biological activity of rFX 
The biological activity of the purified rFX was assessed. A chromogenic assay was used to 
monitor the conversion of FX to its active state (FXa), measured in the presence of tissue 
factor and FVIIa. Positive control FX, WT and SP mutant rFX proteins were converted to 
their active forms (FXa) in the presence of tissue factor and FVIIa, thus confirming their 
biological activity (Figure 3.9). This data demonstrates the mutations within the HBPE of 
the SP domain of FX did not affect the catalytic activity of FX or hinder activation by 
tissue factor and FVIIa complexes. 
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Figure 3.7. Purification and validation of rFX. 
(A) Immunoaffinity elution profiles of (i) WT and (ii) SP mutant rFX. Elution is monitored 
by absorbance at 280 nm. WT rFX and SP mutant rFX are recovered as single peaks when 
eluted from the calcium-dependent anti-FX 4G3 antibody affinity column with the 
addition of EDTA. (B) SPR analysis of (i) WT and (ii) SP mutant rFX fractions eluted from 
the 4G3 antibody affinity column binding to the 4G3 antibody immobilised on a biacore 
sensor chip. 
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Figure 3.8. Validation of purified rFX. 
(A) Coomassie staining of SDS-PAGE for (i) WT and (ii) SP mutant rFX. Lanes (L) represent 
load prior to passing through the column, (FT) represents unbound material that flowed 
through the column, (1, 2, 3) represents fractions eluted from the column, (CON) 
represents plasma derived human FX positive control. (B) Western blot analysis of rFX 
was performed. rFX was probed with a primary monoclonal human anti-FX clone HX1 
antibody (1:1,000 dilution) and a goat anti-mouse infrared dye (800CW)-labelled 
secondary antibody (LI-COR). (i) Lanes A, B, C, represent WT rFX purified by 4G3 column; 
lane CON represents plasma derived human FX positive control (ii) lanes A, B, C, represent 
SP mutant rFX purified by 4G3 column. 
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Figure 3.9. Activation of rFX. 
Activation of positive control FX, WT rFX and SP mutant rFX. The amidolytic activity of FXa 
was measured using 1 mM chromogenic substrate S-2765 (Quadratech, Surrey, UK) in the 
presence of 100 nM tissue factor, 100 nM factor VIIa and 6 mM CaCl2. All measurements 
were determined kinetically at 405 nm. *p<0.05 as compared to the corresponding 
positive control FX, WT or SP mutant conditions, as determined by one-way ANOVA and 
Dunnett’s multiple comparison post-test. Error bars represent SEM (n = 3/group).  
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3.2.6 Mutating residues in the FX HBPE has no effect on FX binding to Ad5 
hexon  
To ensure the mutations in the FX SP domain had no effect on FX binding to Ad5 both 
WT and SP mutant rFX binding to Ad5 hexon was analysed using SPR (performed by 
Prof. John McVey (Thrombosis Research Institute, London, UK)). Ad5 hexon was 
covalently immobilised on a biosensor chip and running buffer, positive control FX, WT or 
SP mutant rFX was injected over the chip at a flow rate of 30 µl/min. Directly after 
injection of running buffer, positive control FX, WT or SP mutant rFX, either the FX 
monoclonal antibody HX-1 or the monoclonal antibody 4G3, were passed over the chip at 
a flow rate of 30 µl/min. Protein binding to the Ad5 hexon and binding of the antibodies to 
the material bound to the chip was detected as a change in response units. Data was 
analysed using Biacore T100 Evaluation software.  
SPR analysis indicated that the positive control FX, conditioned media of cells transfected 
with either WT or SP mutant FX bound to hexon. The positive control FX or rFX 
dissociated from the chip upon the addition of EDTA indicating that the reaction occurs in 
a calcium-dependent manner (Figure 3.10). There was no significant difference in response 
units for binding to hexon for the WT and SP mutant rFX (Figure 3.10). The conditioned 
media of cells transfected with either WT or SP mutant FX bound to the chip was 
subsequently confirmed to be FX by binding of the two monoclonal antibodies against 
human FX (HX-1 and 4G3) (Figure 3.11). Therefore the seven mutated residues in the 
HBPE of FX have no effect on FX binding to Ad5 hexon. 
3.2.7 FX dose response  
Previous studies have shown FX at concentrations below physiological levels (< 8-10 
µg/ml) to be effective in increasing Ad5 gene transfer (Parker et al., 2006; Zaiss et al., 
2011). Here, the effects of lower concentrations of FX than previously described were 
assessed for their ability to increase Ad5 transduction. SKOV3 cells were incubated with 
Ad5 in the absence or presence of 10 ng/ml, 100 ng/ml, 1 µg/ml or 10 µg/ml pd FX for 3 h 
at 37°C. Cells were washed once, complete media added and incubated at 37°C for a 
further 45 h when transgene expression was analysed. All four doses of FX tested caused a 
significant increase in Ad5 gene transfer as shown by β-galactosidase transgene expression 
(Figure 3.12). The ability of FX to be effective at concentrations as low as 10 ng/ml 
highlights the high affinity interaction between Ad5 hexon and FX. 
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Figure 3.10. HBPE mutations have no effect on rFX binding to Ad5 hexon.  
(A) Representative subtracted sensorgrams of positive control FX, WT rFX and SP mutant 
rFX binding hexon, injected at time 0 for 60 sec at a flow rate of 30 μl/min (B) 
Quantification of relative binding of running buffer, WT rFX or SP mutant rFX to hexon at 
the end of the injection as indicated by the arrow. *p<0.05 as compared to WT rFX 
conditions as determined by one-way ANOVA and Dunnett’s multiple comparison post-
test. NS = non-significant, p>0.05. Error bars represent SEM (n = 5/group).  
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Figure 3.11. Anti-FX antibody binding to rFX bound to Ad5 hexon.  
Representative subtracted sensorgrams of binding of anti-FX antibodies 4G3 or HX-1 to 
the chip following injection of running buffer, positive control FX (green and yellow lines), 
WT (blue and grey lines) or SP mutant rFX (pink and purple lines), injected at time 0 for 60  
sec at a flow rate of 30 μl/min. 
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Figure 3.12. Ad5 transduction in the presence of increasing concentrations of FX. 
SKOV3 cell were infected with 1000 vp/cell of Ad5 in the absence or presence of 
increasing concentrations (10 ng/ml, 100 ng/ml, 1 μg/ml or 10 μg/ml) of positive control 
pd FX. Ad5 transgene expression was measured 48 h post-infection. *p<0.05 as compared 
to non-FX conditions as determined by one-way ANOVA and Dunnett’s multiple 
comparison post-test. Error bars represent SEM (n = 4/group). 
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3.2.8 Effect of the FX SP domain mutations on Ad5:FX binding to HSPGs  
As cell surface binding of Ad5:FX complexes is mediated by HSPGs (Bradshaw et al., 
2010), confocal microscopy was used to evaluate the interaction of fluorescently-labelled 
Ad5 with cell surface HSPGs when complexed with WT or the SP mutant rFX. This was 
assessed by infection of SKOV3 cells (which have low levels of CAR expression, therefore 
allows us to look more specifically at Ad5 binding and transduction mediated by FX) with 
Alexa Fluor-488 fluorescently-labelled Ad5 in the presence of WT or SP mutant rFX for 1 
h at 4˚C. Incubation with Ad5 at 4˚C allows binding to the cell surface but not 
internalisation, which is energy dependent and hence occurs at 37˚C. After washing with 
PBS to remove unbound virus, the cells were fixed in 4% PFA. Immunocytochemistry was 
carried out using the pan-heparan sulphate antibody (clone 10E4) to stain for cellular 
HSPGs. Following pretreatment with WT rFX, Ad5 complexes were clearly visible on the 
cell surface and colocalised with HSPGs as shown by confocal microscopy (Figure 3.13). 
In contrast, in the absence of FX or when Ad5 was pretreated with equivalent 
concentrations of SP mutant rFX there were few virus particles bound to the cell surface 
and no observed colocalisation with HSPGs (Figure 3.13). This qualitative data indicates 
that the FX HBPE is required for efficient binding of Ad5:FX to HSPGs on the cell 
surface. 
3.2.9 The FX SP domain mutations decrease FX-mediated Ad5 cell binding  
To quantitatively assess the effects of the HBPE mutations on Ad5:FX-mediated cell 
binding, SKOV3 and HepG2 cells were used as they can be readily transduced via the FX 
pathway (Bradshaw et al., 2010). For experiments involving SKOV3 cells, a CARlow cell 
line (Kim et al., 2002), a β-galactosidase expressing Ad5 was utilised and for experiments 
involving HepG2 cells which have higher CAR expression Ad5KO1 was utilised. Vectors 
were incubated with SKOV3 or HepG2 cells in the absence or presence of positive control 
FX, WT or the SP mutant rFX for 1 h at 4˚C. After washing with PBS to remove unbound 
virus, cells were collected, total DNA was isolated and qPCR for Ad5 hexon was 
performed. Quantification of Ad5 cell surface binding by qPCR revealed that positive 
control FX and WT rFX caused a significant increase in binding of Ad5 to SKOV3 cells 
and Ad5KO1 to HepG2 cells compared to cells not treated with FX (Figure 3.14). WT rFX 
caused a significant ~14 fold increase compared to cells not treated with FX, whereas no 
significant increase was observed when SP mutant rFX was used at an equivalent 
concentration to WT rFX (Figure 3.14) Therefore, these results demonstrate that the 
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residues within the FX HBPE are required for FX-mediated Ad5 binding to the cell 
surface.
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Figure 3.13. Role of the HBPE in the FX SP domain in Ad5 binding to HSPGs.  
10,000 vp/cell of Alexa Fluor-488 fluorescently-labelled Ad5 (green) were allowed to bind 
SKOV3 cells for 1 h at 4˚C in the absence or presence of WT rFX or SP mutant rFX. Cells 
were then stained with a pan-heparan sulphate antibody (clone 10E4) (red). Nuclei were 
counterstained using DAPI. Images were captured on a confocal microscope using a 63x 
objective, scale bar = 20 μm, applicable to all panels.   
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Figure 3.14. Role of the FX SP domain in Ad5 cell binding.  
(A) Binding of 1000 vp/cell Ad5 to SKOV3 or (B) 1000 vp/cell Ad5KO1 to HepG2 cells for 1 
h at 4˚C in the absence or presence of positive control FX, WT rFX or SP mutant rFX was 
analysed. Vector genomes were detected by quantitative SYBR green PCR. *p<0.05 as 
compared to non-FX conditions as determined by one-way ANOVA and Dunnett’s 
multiple comparison post-test. Error bars represent SEM (n = 4/group). 
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3.2.10 The FX SP domain mutations inhibit FX-mediated Ad5 cell binding, 
internalisation and cytosolic transport  
To analyse the effects of FX mutagenesis on Ad5 cell binding, internalisation and cytosolic 
transport, cell trafficking assays using Alexa Fluor-488 fluorescently-labelled Ad5 were 
performed in SKOV3 cells. Cells were exposed to Ad5 in the absence or presence of 
positive control FX, WT or SP mutant rFX for 1 h at 4˚C to allow binding to occur. The 
cells were then either immediately washed in PBS and fixed in 4% PFA or fixed after 1 h 
at 37˚C to allow Ad5 internalisation and trafficking. Immunocytochemistry was carried out 
using a pericentrin antibody to stain the MTOC. Cells were counterstained using DAPI 
nuclear stain. Images were captured using a confocal microscope. 
In the presence of positive control FX or WT rFX, Ad5 bound the cell surface after 1 h at 
4˚C and after 1 h incubation at 37˚C efficiently trafficked toward the nucleus where it 
colocalised with the MTOC (Figure 3.15). However, when the same experiment was 
performed using the SP mutant rFX, Ad5 cell surface binding and trafficking to the 
perinuclear region was significantly decreased (Figure 3.15). Colocalisation of Ad5 with 
the MTOC was quantified visually by assessing the percentage of cells with Alexa Fluor-
488 fluorescently-labelled Ad5 and pericentrin co-staining. The percentage of cells with 
Ad5:MTOC colocalisation in the presence of SP mutant rFX conditions was significantly 
reduced compared to positive control FX and WT rFX. Ad5:MTOC colocalisation under 
SP mutant conditions closely resembled conditions in the absence of FX. These data 
demonstrate that mutating the seven amino acids in the FX SP domain inhibits FX-
mediated Ad5 cell binding, subsequent internalisation and cytosolic transport.  
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Figure 3.15. Role of the FX HBPE in Ad5 cellular trafficking.  
10,000 vp/cell of Alexa Fluor-488 fluorescently-labelled Ad5 (green) were allowed to bind 
SKOV3 cells for 1 h at 4˚C in the absence or presence of positive control FX, WT rFX or SP 
mutant rFX. Cells were then incubated at 37˚C for 0 or 60 min prior to fixation and 
staining for the MTOC marker pericentrin (red). Nuclei were counterstained using DAPI. 
Upper panel - colocalisation of fluorescently-labelled Ad5 particles with pericentrin is 
indicated by the yellow arrow. Images were captured on a confocal microscope using a 
63x objective, scale bar = 20 μm, applicable to all panels.   
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Figure 3.16. Role of the FX HBPE in Ad5 accumulation at the MTOC. 
Percentage of cells with colocalisation of fluorescently-labelled Ad5 with the MTOC 
marker pericentrin was calculated by analysing at least 5 separate 40x microscope fields 
per experimental condition. *p<0.05 as compared to non-FX conditions as determined by 
one-way ANOVA and Dunnett’s multiple comparison post-test. Error bars represent SEM 
(n = 5/group). 
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3.2.11 The FX SP domain mutations decrease FX-mediated Ad5 transduction 
compared to WT rFX 
The mutations in the FX HBPE inhibit FX-mediated Ad5 cell binding to HSPGs, 
subsequent internalisation and cytosolic transport to the nucleus. These data were further 
confirmed by analysing expression of the β-galactosidase transgene following transduction 
of β-galactosidase-expressing Ad5 in SKOV3 cells or Ad5KO1 in HepG2 cells, either in 
the absence and presence of heparin. Cells were incubated with the vector in the absence or 
presence of positive control FX, WT, SP mutant rFX and 100 µg/ml soluble heparin for 3 h 
at 37°C. Cells were then washed once, complete media added and incubated at 37°C for a 
further 45 h when transgene expression was analysed. Both WT rFX and positive control 
FX mediated a significant increase in Ad transgene expression in the absence of heparin in 
both cell types, whereas the SP mutant rFX resulted in no significant change in transgene 
expression compared to non-FX conditions in SKOV3 or HepG2 cells (Figure 3.17). In the 
presence of heparin, positive control FX-mediated and WT rFX-mediated Ad5 
transduction was ablated, thereby confirming the requirement for HSPGs in this infectivity 
pathway. There was also a significant decrease in Ad5 transduction under non-FX and SP 
mutant conditions in the presence of heparin compared to in its absence, in both cell types 
(Figure 3.17). These data indicates the critical importance of the HBPE in FX-mediated 
Ad5 gene transfer, an effect mediated via HSPGs. 
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Figure 3.17. Role of the FX HBPE in Ad5 gene transfer. 
(A) SKOV3 were infected with 1000 vp/cell of Ad5 and (B) HepG2 cell were infected with 
1000 vp/cell of Ad5KO1 in the absence or presence of positive control FX, WT rFX or SP 
mutant rFX with or without 100 μg/ml soluble heparin. Ad5 transgene expression was 
measured 48 h post-infection. *p<0.05 as compared to non-FX conditions, #p<0.05 as 
compared to matched treatments (-FX, +FX, WT or SP mutant rFX) in the absence of 
heparin, as determined by one-way ANOVA and Dunnett’s multiple comparison post-test. 
Error bars represent SEM (n = 4/group). 
  Chapter 3 | Results 
115 
3.2.12 Effects of single and double amino acid mutations in the SP domain 
on FX-mediated Ad5 gene transfer 
The importance of individual basic residues in the FX SP domain was dissected by 
generating single and double mutations in the HBPE. The double mutations were chosen 
based on their proximity to one another in the SP domain (Figure 3.18). 
Lys96
Arg93
Arg125 Lys236
Arg240
Lys169
Arg165
 
Figure 3.18. Ribbon diagram of the FX SP and EGF-2 domain.  
Ribbon diagram of the FX SP domain (blue) and EGF-2 domain (red) highlighting the single 
and double amino acids chosen for mutagenesis studies (1HCG; Accelrys ViewerLite 
software (Padmanabhan et al., 1993)). 
The single (R125A) and double mutant (R93A_K96A, R165A_K169A and 
K236A_R240A) FX plasmids were transiently transfected into 293T cells in the presence 
of 5 µg/ml vitamin K. rFX was expressed into serum free media supplemented with 5 
µg/ml vitamin K and conditioned media was concentrated using centricon centrifugal filter 
devices. The yield of rFX protein gained from the transient transfection of the single and 
double mutant FX encoding cDNAs was lower than the rFX protein purified from the WT 
or SP mutant stable cell lines (Table 3.3). Therefore experiments involving single and 
double FX mutants were carried out at a concentration of 10 ng/ml. Ad5 gene transfer in 
the absence or presence of 10 ng/ml positive control FX, WT rFX, SP mutant rFX, or rFX 
with mutations R93A_K96A, R125A, R165A_K169A, K236A_R240A in SKOV3 cells 
was assessed. β-galactosidase transgene expression was quantified 48 h post-infection. WT 
rFX mediated a significant increase in Ad5 gene expression in SKOV3 cells compared to 
Ad5 in the absence of FX (data normalised to non-FX conditions) (Figure 3.19). In contrast 
the SP mutant rFX resulted in no significant change in β-galactosidase expression 
compared to non-FX conditions. Analysis of Ad5 gene transfer in the presence of single or 
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double FX point mutants revealed that mutations at R93A_K96A, R125A, K236A_R240A 
but not R165A_K169A caused a significant reduction in Ad5 transduction compared to 
WT rFX (Figure 3.19). These results suggest that amino acids residues within the HBPE 
exhibit different levels of contribution in Ad5:FX complex binding to HSPGs.  
Table 3.3. Concentration of rFX protein. 
The average concentrations of rFX containing single and double point mutations 
produced by transient transfection in 293T cells. 
FX mutant μg/ml 
R93A_K96A 0.25 
R125A 0.18 
K236A_R240A 0.39 
R165A_K169A 0.27 
 
3.2.13 Role of HBPE on FX-mediated cell binding ex vivo 
To confirm the importance of the HBPE we characterised the effect of the SP mutations ex 
vivo by examining fluorescently-labelled Ad5 attachment to mouse liver sections. 4 µm 
liver sections from MF-1 mice were incubated with Alexa Fluor-488 fluorescently-labelled 
Ad5 in the absence or presence of WT or SP mutant rFX for 1 h on ice followed by 1 h at 
37°C. Sections were washed to remove unbound virus, fixed and the nuclei stained using 
DAPI. Sections were imaged using an Olympus Cell M imaging system. To quantify 
adherent Alexa Fluor-488 fluorescently-labelled Ad5 particles, 40x magnification images 
were captured and processed using ImageJ counting software. In the presence of WT rFX 
there is a significant increase in the number of Ad5 virus particles associated with the 
mouse liver slices (Figure 3.20). However, under SP mutant rFX conditions there was ~5-
fold less adherent Ad5 particles compared to WT rFX conditions (Figure 3.21). Ad5 
binding to liver sections in the absence of FX closely resembled the levels of binding in the 
presence of SP mutant rFX. These results indicate that the residues in the HBPE of FX are 
responsible for FX-mediated Ad5 binding to liver sections ex vivo. 
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Figure 3.19. Effect of single and double point HBPE mutations on Ad5 gene transfer. 
SKOV3 cell were exposed to Ad5 alone or in the presence of 10 ng/ml WT rFX, SP mutant 
rFX, rFX with mutations at R93A_K96A, R125A, R165A_K169A, or K236A_R240A for 3 h 
and transgene expression was measured 48 h post-infection. *p<0.05 as compared to WT 
rFX as determined by one-way ANOVA and Dunnett’s multiple comparison post-test. 
Error bars represent SEM (n = 4/group). 
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Figure 3.20. Effect of mutations on Ad5 binding to liver sections ex vivo. 
Liver slices from MF-1 mice were incubated with PBS (negative control) or 2 × 10
9
 vp of 
Alexa Fluor-488 fluorescently-labelled Ad5 in the absence or presence of WT or SP mutant 
rFX. Images captured at 40x magnification, scale bar = 50 μm, applicable to all panels.  
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Figure 3.21. Quantification of Ad5 binding to liver sections ex vivo 
Attachment of Ad5 particles to liver slices were quantified using ImageJ counting 
software. Data represents the average number of particles by analysing at least six 
separate 40x microscope fields per experimental condition. *p<0.05 as compared to non-
FX conditions as determined by one-way ANOVA and Dunnett’s multiple comparison 
post-test. Error bars represent SEM (n = 6/group). 
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3.3 Discussion 
This study investigated the precise mechanism by which the Ad5:FX complex interacts 
with HSPGs by identifying the critical receptor interacting residues in the FX SP domain. 
Site-directed mutagenesis of residues Arg-93, Lys-96, Arg-125, Arg-165, Lys-169, Lys-
236 and Arg-240 was carried out in order to assess the contribution of these residues in 
Ad5:FX binding to the cell surface. Previous studies have employed similar mutagenesis 
techniques to investigate the involvement of these seven basic residues of FX for binding 
specific ligands (Monteiro et al., 2008; Monteiro et al., 2005; Rezaie, 2000). It was 
determined that unlike FXa in which the same residues are readily accessible by heparin, 
these amino acids in FX consist of a HBPE (Monteiro et al., 2008; Monteiro et al., 2005; 
Nogami et al., 2004). To note, this is similar to that reported for the heparin binding site 
(also known as thrombin-anion binding exosite 2) in thrombin and the partially exposed 
thrombin-anion binding exosite 1 in prothrombin, again suggesting a precursor state in the 
zymogen (Liu et al., 1991; Sheehan et al., 1994). 
In order to test the effects of the mutated HBPE, firstly the recombinant protein was 
produced by WT or SP mutant FX plasmid transfection into HEK 293T cells. Prior to 
purification the rFX protein was at concentrations ranging from 0.1 µg/ml to 0.4 µg/ml 
after 4-5 days. These yields are relatively low compared to other studies in which 
concentrations of up to 5 µg/ml after 24 h were achieved (Camire et al., 2000; Rudolph et 
al., 1997). The biosynthesis of FX is a complex process, involving extensive co- and post-
translational modifications including glycosylation, γ-carboxylation and β-hydroxylation. 
These involve the removal of the signal sequence, the propeptide and the internal tripeptide 
and the addition of N- and O- linked oligosaccharides to the heavy chain. The 11 glutamic 
acid residues in the Gla domain undergo γ-carboxylation by the vitamin-K dependent γ-
glutamyl carboxylase located in the endoplasmic reticulum, a process directed by the 
propeptide. In addition, the EGF-1 domain contains an aspartic acid (Asp63) which is post-
translationally modified to β-hydroxyaspartic acid (McMullen et al., 1983).  
Next, the rFX protein was purified and validated. The protein was immunoaffinity purified 
using the calcium-dependent 4G3 mouse monoclonal antibody coupled to a sepharose 
column. SPR, Coomassie gel and western blot analysis confirmed the generation of 
purified rFX protein of the correct molecular weight (59 kDa), similar to the FX positive 
control (Furie et al., 1988). Production of FX in HEK cells and purification using a 
calcium-dependent monoclonal antibody has previously been shown to have functional 
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properties almost indistinguishable to plasma purified FX (Rudolph et al., 1997). 
Therefore, this expression system is useful for producing FX variants to correlate structure 
and function. In order to test the functionality of the rFX, amidolytic activity assays were 
carried out. There was no difference in the amidolytic activity of the SP mutant relative to 
WT rFX. This suggests the mutagenesis of the HBPE residues did not alter tissue factor 
and FVIIa activation and therefore did not effect the catalytic pocket of FXa, as is in 
concordance with previous studies (Rezaie, 2000). In relation to this, Parker et al. 
demonstrated that zymogen activation to FXa is not required for the FX-mediated increase 
in Ad5 gene transfer (Parker et al., 2006). 
It was necessary to ascertain whether the mutations in the FX SP domain caused any effect 
on the FX Gla domain binding to the Ad5 hexon. SPR analysis indicated that the WT or SP 
mutant rFX bound to hexon in a calcium-dependent manner, suggesting the mutations did 
not hinder the direct interaction with the virus. Human FX has previously been reported to 
bind to Ad5 in the presence of calcium and readily dissociate upon the addition of EDTA 
(Parker et al., 2006; Waddington et al., 2008). As both WT and SP mutant rFX bound to 
the hexon and there was no significant difference in the binding response units, these data 
also indirectly suggest the glutamic acid residues of the Gla domain were efficiently γ-
carboxylated, a process necessary for calcium-dependent binding. 
In recent years the Ad5:FX pathway has been the focus of several studies, accumulating 
data on the effects of FX on Ad5 binding and gene transfer (Kalyuzhniy et al., 2008; 
Parker et al., 2006; Waddington et al., 2008). It has been well documented that Ad5:FX 
complex binding to the cell surface of hepatocytes is mediated by HSPGs (Bradshaw et al., 
2010; Parker et al., 2006; Waddington et al., 2008). In addition, several other pathogens 
also exploit HSPGs as primary attachment receptors for infection in vivo, including human 
papilloma virus (Johnson et al., 2009), herpes simplex virus (Shukla et al., 1999), human 
immunodeficiency virus-1 (Endress et al., 2008) and adeno-associated virus (Summerford 
et al., 1998). Moreover, FIX but not FX has been demonstrated to efficiently mediate 
binding of Ad18 and Ad31, to HSPGs (Jonsson et al., 2009; Lenman et al., 2011). FIX 
binds to the hexon protein of species A Ad18 and Ad31 but not Ad12 to enhance cell 
surface binding and gene transfer (Lenman et al., 2011). Therefore, using confocal 
microscopy the interaction of fluorescently-labelled Ad5 with HSPGs when complexed 
with WT or the SP mutant rFX was assessed. As expected in the presence of WT rFX there 
were an abundance of viral particles at the cell surface which colocalised with HSPGs 
(Bradshaw et al., 2010; Parker et al., 2006), whilst in the presence of SP mutant rFX there 
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was no colocalisation, closely resembling conditions in the absence of FX. This qualitative 
report was further confirmed by qPCR, showing a significant decrease in Ad5 cellular 
binding in the presence of SP mutant compared to WT rFX. These data support the 
previously demonstrated function of HSPGs in Ad infection, and indicates the inability of 
SP mutant rFX to mediate binding to these cellular receptors, thereby supporting a role for 
the HBPE in bridging the Ad5:FX interaction to the cell surface.  
Subsequently, the effects of FX mutagenesis on Ad5 cell binding, internalisation and 
cytosolic transport in cell trafficking assays were analysed. In the presence of human FX, 
Ad5 has been shown to bind to the cell surface, internalise and efficiently traffic toward the 
nucleus, reaching the MTOC by as early as 15 min and by 1 h approximately 90% of cells 
had viral particles colocalised with the MTOC (Bradshaw et al., 2010). In this study, 
fluorescently-labelled Ad5 in the presence of positive control FX or WT rFX efficiently 
trafficked toward the nucleus, with > 80% Ad5:MTOC colocalisation by 1 h, whereas in 
the absence of FX or the presence of the SP mutant rFX surface binding and cytosolic 
trafficking was abolished.  
Several studies have employed heparin to demonstrate the role of HSPGs as primary 
attachment receptors, which is structurally very similar to heparin sulphate (HS) side 
chains but displays higher general sulfation and therefore acts as a competitive inhibitor 
(Bradshaw et al., 2010; Lenman et al., 2011). In addition, heparinase which cleaves HS 
side chains has been used to inhibit HS-mediated viral attachment (Boyle et al., 2006; 
Bradshaw et al., 2010; Lenman et al., 2011; O'Donnell et al., 2009). In the present study 
the ability of the rFX proteins to enhance Ad5 gene transfer in the absence and presence of 
soluble heparin was investigated. In agreement with previous data, Ad5 transduction was 
enhanced in the presence of control FX in SKOV3 and HepG2 cells (Alba et al., 2009; 
Parker et al., 2006; Waddington et al., 2008). In contrast, the SP mutant rFX caused no 
significant increase in gene transfer compared to conditions in the absence of FX. FX-
mediated Ad5 gene transfer was ablated in the presence of soluble heparin, as in agreement 
with previous work (Bradshaw et al., 2010). There was also a significant decrease in gene 
transfer under non-FX and SP mutant conditions, in the presence of heparin versus in its 
absence. Earlier work by Dechecchi et al. has demonstrated a role for HSPGs for Ad5 and 
Ad2 in non-FX-mediated cellular binding (Dechecchi et al., 2001; Dechecchi et al., 2000). 
This was initially thought to be due to an interaction with a 91KKTK94 motif in the Ad fiber 
shaft, but later found that mutation of this motif instead hinders efficient intracellular 
trafficking (Kritz et al., 2007).  
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It should be pointed out that whilst previous studies have demonstrated a very low affinity 
for FX to interact with heparin due to the precursor state of heparin binding residues, 
heparin efficiently blocked Ad5:FX mediated transduction (Bradshaw et al., 2010; Nogami 
et al., 2004). This may simply be due to the inaccessibility of the HSPGs in the presence of 
heparin. However, heparin possesses a very similar structure to HSPGs, the attachment 
receptors for Ad5:FX complexes, thus perhaps indicating a conformational change in the 
catalytic domain of FX upon binding to Ad5 which exposes the HBPE. Currently this is 
solely a hypothesis but may warrant additional investigation. 
In order to further dissect the interaction, the effects of single and double point mutations 
in the FX HBPE on Ad5 transduction in vitro were assessed. The double point mutations 
R93A_K96A, R125A, R165A_K169A and K236A_R240A were chosen due to their 
relative positions in the FX construct and orientation in the 3D model of the human FX SP 
domain. As mentioned previously rFX yields were low following plasmid transfections. 
Due to time restraints, stable cell lines producing these rFX derivatives were not generated. 
The ability of FX to enhance Ad5 gene transfer at concentrations below physiological 
levels was shown in this study as well as others (Parker et al., 2006; Zaiss et al., 2011). 
Therefore, we tested the effects of the four rFX mutants R93A_K96A, R125A, 
R165A_K169A and K236A_R240A at a concentration of 10 ng/ml for effects on Ad5 gene 
transfer in SKOV3 cells. As before, the SP mutant rFX showed significantly lowered 
levels of Ad5 gene transfer compared to WT rFX. rFX with mutations at positions 93 and 
93 as well as positions 125, 236 and 240 showed a significant decrease in Ad5 transduction 
compared to WT rFX. This indicates that the residues Arg-93, Lys-96, Arg-125, Lys-236 
and Arg-240 but not Arg-165 and Lys-169 play a fundamental role in Ad5:FX binding to 
the cell surface. Of interest, four of these residues Arg-93, Arg-125, Lys-236 and Arg-240 
were bound by both NAPc2 and Ixolaris, which effectively blocked Ad5 binding and 
transduction in vitro and in vivo (Monteiro et al., 2008; Monteiro et al., 2005; Murakami et 
al., 2007; Waddington et al., 2008). In addition future studies investigating the roles of 
Arg-93, Lys-96, Arg-125, Lys-236 and Arg-240 using individually mutated FX constructs 
could further evaluate the contribution of each of these amino acid residues in this 
interaction.  
To investigate whether the role of the HBPE in FX-mediated Ad5 infection translates to a 
more physiological setting, a previously established ex vivo liver model was used 
(Bradshaw et al., 2010). Attachment of fluorescently-labelled Ad5 particles to mouse liver 
sections was significantly increased in the presence of WT rFX. This result is in agreement 
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with previously published data (Bradshaw et al., 2010). However in the presence of SP 
mutant rFX, Ad5 binding to mouse livers was not enhanced, thereby indicating that 
residues in this HBPE have a critical role in FX-mediated Ad5 cellular binding ex vivo. 
Due to time constraints and the low yields of FX produced, in vivo analysis of the 
involvement of the FX HBPE in Ad5 hepatic gene transfer was not performed. Ideally, if 
sufficient quantities were available, 10 µg/ml of the WT or mutated rFX proteins would be 
injected into warfarin-treated mice 30 min prior to the injection of Ad5. At 48 h post-
administration the levels of Ad5 gene transfer would be assessed to investigate if the 
HBPE mutations in FX abrogated FX-mediated liver transduction in vivo. 
A number of studies suggesting methods to improve rFX production involve cotransfection 
of certain intracellular processing enzymes required for efficient biosynthesis (Camire et 
al., 2000; Drews et al., 1995; Preininger et al., 1999). FX requires efficient post-
translational endoproteolytic processing for production of the mature FX protein. One such 
approach aimed at achieving full propeptide cleavage from recombinant vWF involves co-
expression of the endoprotease furin with vWF in Chinese hamster ovarian cells (Drews et 
al., 1995; Plaimauer et al., 2001; Preininger et al., 1999). This may be another viable 
approach to enhancing rFX protein production. 
Previous studies have shown the ability of physiological concentrations of FIX, FVII and 
protein C to enhance Ad5 transduction in vitro, however only FX was demonstrated to 
fully restore Ad hepatic gene transfer in warfarin-treated mice (Parker et al., 2006; 
Waddington et al., 2008). Sequence comparisons revealed that the seven residues within 
the HBPE of FX were not conserved across the other vitamin K-dependent coagulation 
factors (Figure 3.22). When FX is compared to FVII, FIX or protein C six of the seven 
residues in the serine proteases differ. This may imply differences in binding to HSPGs in 
vivo could be due to the lack of a conserved HBPE. In addition, human FX demonstrated a 
greater ability to mediate Ad5 hepatic gene transfer in mice compared to murine FX (Zaiss 
et al., 2011). The sequence alignment of human and murine FX demonstrates the four 
residues in the HBPE, R165, K169, K236 and R240, are conserved (Figure 3.23). The 
remaining three residues are charge conserved (i.e. Arg-Lys or Lys-Arg) thus maintaining 
positive charge. Analysis of heparin-sepharose binding of Ad5 suggested that human FX 
complexed with Ad5 has a greater affinity for HSPGs than Ad5:murine FX, which may 
contribute in differences in their ability to enhance Ad5 transduction both in vitro and in 
vivo (Zaiss et al., 2011).  
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Understanding the precise infectivity pathways of Ad5 is important to its successful 
development and optimisation as a clinical gene therapy vector. This study has 
concentrated on gaining a greater knowledge of the mechanism of Ad5:FX complex 
engagement with the cell surface. In this study, FX HBPE mutant constructs were 
generated and functional rFX produced in order to study the importance of the seven 
proexosite residues for Ad5:FX binding to HSPGs. SPR analysis of recombinant protein 
demonstrated that the SP mutations had no effect on FX-specific binding to the Ad5 hexon, 
however FX-mediated binding and transduction was ablated both in vitro and ex vivo. 
Taken together, this study uncovers the HBPE to have a fundamental involvement in FX-
mediated Ad5 complex engagement with HSPGs at the surface of target cells and broadens 
the knowledge of a key in vivo tropism determining pathway. 
 
Figure 3.22. Sequence alignments of human FX, FVII, FIX and protein C.  
Sequences for the SP domains of human FX, FVII, FIX and protein C were obtained for the 
Swiss-Prot database. Arrows point to the residues within the HBPE of human FX.  
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Figure 3.23. Sequence alignments of human FX and murine FX. 
Human and murine FX sequences were obtained for the Swiss-Prot database and 
annotated using CLC Protein Workbench 5. Arrows point to the amino acid residues 
within the HBPE of human FX.  
 
     
 
 
 
 
 
Chapter 4 
Assessing the effects of a panel of small 
molecule inhibitors of cellular kinases on 
FX-mediated Ad5 transduction 
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4.1 Introduction 
A great deal of research has been devoted to investigating the early stages of Ad5 cell entry 
and infection, the majority of which is based around the uptake of Ad5 via the classical in 
vitro pathway, initiated by the virus docking to CAR (Bergelson et al., 1997). The 
activation of surface receptors initiates multiple virus-induced cell signaling pathways, 
host cell responses to incoming virus particles and viral uncoating events (Burckhardt et 
al., 2011; Farmer et al., 2009; Greber et al., 1993; Li et al., 1998a; Nakano et al., 2000). 
Whilst CAR-mediated Ad5 infectivity has been extensively studied, the post-binding 
events governing FX-mediated Ad5 intracellular transport and gene expression have not 
been fully characterised.  
In vitro, following engagement of the Ad5 fiber knob with CAR, the cytoplasmic domain 
of CAR activates p44/42 MAPK, which in turn promotes CAR clustering at the plasma 
membrane (Farmer et al., 2009). When cells were preincubated with a MEK 1/2 inhibitor, 
integrin activation and CAR-induced cell adhesion to αvβ3 ligands were prevented, 
indicating a secondary role for p44/42 MAPK in integrin localisation (Farmer et al., 2009). 
Binding of the pentameric penton base to integrin receptors also promotes integrin 
clustering which in turn initiates signalling cascades involving kinases such as PI3K and 
protein kinase A (PKA) (Li et al., 1998b; Suomalainen et al., 2001). Pharmacological 
inhibition of PI3K, using the compounds wortmannin or LY293002 inhibit Ad5 
internalisation and gene transfer, indicating its requirement for efficient Ad5 infection (Li 
et al., 1998b). Recent work also demonstrates the ability of CAR to mediate clustering of 
JAML and recruit PI3K (Verdino et al., 2010). A further study utilised pharmacological 
agents to inhibit PKA activity or the p38MAPK inhibitor SB203580, which disrupted 
cytoplasmic motility and prevented effective nuclear targeting of incoming Ad5 
(Suomalainen et al., 2001). Inhibition of protein kinase C has also been shown to affect 
membrane trafficking of Ad5 by preventing viral escape from endosomes (Nakano et al., 
2000). It is clear that intracellular signalling molecules play an important role in virus 
internalisation, actin cytoskeleton polymerisation and microtubule-dependent motility 
during Ad5 infectivity and thereby act as important regulators of early virus-host 
interactions (Li et al., 1998b; Nakano et al., 2000; Suomalainen et al., 2001). 
Initial engagement of Ad5 particles to cellular receptors elicits viral motion along the 
plasma membrane, three types of which exist; diffusive motions, drifting motions, and 
confinement (Burckhardt et al., 2011). Studies by Wodrich et al. and Burckhardt et al. 
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demonstrated that viral uncoating is initiated at the cell surface, caused by the drifting 
motions mediated by CAR combined with the immobile integrins confining such 
movement (Burckhardt et al., 2011; Wodrich et al., 2010). This dual action results in the 
shedding of viral fibers as well as exposing protein VI, an internal Ad capsid protein that 
possesses membrane lytic activity (Burckhardt et al., 2011). A study by Bradshaw et al. 
demonstrated a requirement for an intact penton base RGD motif for optimal post-
attachment cell entry via the FX pathway, thus indicating the interaction with cellular 
integrins as co-receptors for internalisation is retained (Bradshaw et al., 2010). However, 
the involvement of integrins in Ad capsid disassembly and signalling in the FX pathway 
requires further investigation.  
Following CAR and integrin receptor engagement and the initial stages of viral uncoating, 
virus endocytosis takes place, primarily via the formation of clathrin coated vesicles 
regulated by adaptor protein complex 2 and the GTPase dynamin (Figure 4.1) (Boucrot et 
al., 2010; Varga et al., 1991; Wang et al., 1998). Subsequently, the low pH of the 
endosomes acts as a trigger for further viral disassembly and membrane penetration 
(Greber et al., 1993), contributed to by the activation of PKC and the viral protease 
(Medina-Kauwe, 2003). In the endosomes the lytic factor, protein VI, remains partially 
associated with the viral capsid as Ad travels towards the nucleus (Wodrich et al., 2010). 
Rab5 is a regulator of clathrin-mediated endocytosis of Ad5 and vesicle fusion with early 
endosomes (Rauma et al., 1999). Bradshaw et al. demonstrated colocalisation of Ad5 
particles with the early endosomal markers Rab5 and the Rab5 effector protein early 
endosome antigen 1 (EEA1) 15 min post-infection following incubation with FX in 
SKOV3 cells (Bradshaw et al., 2010), indicative of a correlation between the CAR and 
FX-mediated intracellular pathways. Lysis of the endosomes leads to viral escape and the 
cytosolic Ad5 is then engaged in bidirectional microtubule-based transport (Suomalainen 
et al., 1999). The minus ends of microtubules are located in the perinuclear area, while 
plus ends extend toward the cell periphery. Ad5 is transported along the microtubule 
cytoskeleton in a minus-ended directed movement towards the MTOC, as a result of Ad5 
hexon directly binding to dynein intermediate and light chains (Bremner et al., 2009; 
Kelkar et al., 2004; Suomalainen et al., 1999). FX-mediated Ad5 cell transport also 
appears to follow a similar pattern of trafficking, with accumulation of viral particles at the 
MTOC by 60 min post-infection (Bradshaw et al., 2010). When the virus dissembles from 
the microtubules it reaches the nuclear pore complex (NPC) (Greber et al., 1997). At this 
point the Ad genome disengages from the capsid, through attachment to nuclear histone 1 
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binds to the CAN/Nup214 receptor, and the viral DNA is imported into the nucleus 
(Trotman et al., 2001) (Figure 4.1). 
Understanding the precise mechanism of viral MTOC release and transport to the nuclear 
pores has been at the centre of several investigations. It has been suggested that this 
process may occur due to a switch in motor proteins, from dynein- to kinesin-mediated 
transport (Henaff et al., 2011). A recent study by Strunze et al. demonstrated that kinesin-
1, which directs viral particles towards the plus end of microtubules disrupted Ad capsids 
bound to the NPC and the NPC itself, thereby releasing capsid fragments in the cytoplasm 
and increasing nuclear envelope permeability, thus facilitating nuclear import of viral DNA 
(Strunze et al., 2011). Other studies have implicated a critical role for protein VI in 
efficient nuclear targeting. Protein VI encodes a proline rich PPxY motif (where x can be 
any amino acid) which recruits ubiquitin ligases, Nedd4.1 and Nedd4.2, and mutation of 
this motif does not affect capsid morphology, membrane penetration and endosomal escape 
but the virus particles are defective in microtubule-dependent trafficking and genome 
delivery to the nucleus (Wodrich et al., 2010). As with several steps of early Ad infection 
these processes may not be mutually exclusive but act in cohort to result in efficient gene 
transfer. 
It is evident that over the years an abundance of data has accumulated based on CAR-
mediated Ad5 cell entry, signalling and intracellular transport. Whilst recent studies have 
shown similarities in intracellular trafficking following engagement of Ad5:FX to cellular 
HSPGs, whether there is general overlap between Ad5 capsid uncoating, intracellular 
transport and signalling via both pathways requires further elucidation. Thus, gaining a 
greater understanding of the early stages of Ad5 infection via FX bridging the virus to 
HSPGs is an important step in improving the knowledge of this pathway. The present 
study employs a series of pharmacological interventions in vitro to investigate cellular and 
signalling events occurring during FX-mediated Ad5 infection. 
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Figure 4.1. Ad5 infectivity pathway.  
In vitro Ad5 uses CAR as its primary attachment receptor, this promotes binding of the 
penton base RGD motif to αvβ integrins. This then triggers clathrin-mediated endocytosis 
and partial virus disassembly. Ad5 enters the low pH endosomes, pVI is released and the 
endosomes are lysed. Cytosolic Ad5 binds dynein and is transported along microtubles 
towards the MTOC. The virus docks to the nuclear pore complex receptor CAN/Nup214 
and the viral DNA is imported into the nucleus for subsequent transcription and 
replication. 
  Chapter 4 | Results 
132 
4.2 Results 
4.2.1 Role for PKA, PI3K and p38MAPK in FX-mediated Ad5 intracellular 
transport 
The effect of kinase inhibitors that have previously been reported to affect cell entry and 
intracellular transport of Ad via the CAR pathway were analysed for effects on FX-
mediated Ad5 cellular trafficking (Li et al., 1998b; Suomalainen et al., 2001). Human 
adenocarcinomic alveolar basal epithelial A549 cells were preincubated with the PKA 
inhibitor H89 dihydrochloride (40 µM), the PI3K inhibitor LY 294002 hydrochloride (100 
µM) or the p38 MAPK inhibitor SB 203580 (10 µM). Cells were then were exposed to 
Ad5 in the presence of FX and the kinase inhibitors for 1 h at 4˚C to allow for cellular 
binding, followed by 3 h at 37˚C, providing sufficient time for virus internalisation and 
transport to the MTOC. Using confocal microscopy the effects of each of the kinase 
inhibitors on FX-mediated Ad5 cytosolic transport was visually assessed. By 180 min Ad5 
trafficking to the MTOC was disrupted in the presence of all inhibitors. Unlike the control 
conditions, in the presence of the compounds the virus did not colocalise in a punctuate 
spot at the MTOC, but instead formed a diffuse pattern around the perinuclear region. 
When colocalisation of Ad5 with the MTOC was quantified it was found to be 
significantly reduced in the presence of FX by coincubation with PKA, PI3K or p38 
MAPK inhibitors (Figure 4.2). This suggests a requirement for these kinases for efficient 
Ad5 intracellular trafficking via FX-mediated Ad5 infection.  
4.2.2 Screening a library of kinase inhibitors for effects on FX-mediated 
Ad5 gene transfer  
A collection of 80 different kinase inhibitors were investigated for their affects on FX-
mediated Ad5 transduction in SKOV3 cells (Table 4.1). The Tocris Kinase Inhibitor 
Toolbox library was a kind gift from Dr. Jo Mountford (University of Glasgow) who 
obtained the set from Tocris Bioscience. The library was designed to selectively target a 
diverse range of cellular kinases. SKOV3 cells express very low levels of CAR (Kim et al., 
2002) and therefore allow for a more specific investigation of the Ad5:FX pathway. All 
kinase inhibitors were screened at the same dose of 20 µM for the first 3 h, followed by 10 
µM for the remainder of the assay. This shift in concentrations was primarily to 
accommodate experimental design. Of the 80 kinase inhibitors tested, 23 caused a 
significant reduction in FX-mediated Ad5 transduction and exhibited no significant 
difference compared to levels of Ad5 transduction in non-FX control conditions, as 
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assessed by β-galactosidase expression at 48 h post-infection and subsequent statistical 
analysis (Figure 4.3). These consisted of a wide range of divergent kinase inhibitors 
including; IkB kinases, protein kinase C, TGF-β type I receptor activin receptor-like 
kinases, epidermal growth factor receptor, rho-kinase, spleen tyrosine kinase, checkpoint 
kinases, cyclin-dependent kinases, met kinase, mitogen activated protein kinase, Akt 
kinase, glycogen synthase kinase 3 and c-Jun N-terminal kinases. However, as the same 
dose of each inhibitor was applied to the cells, many of the described inhibitors were found 
to cause substantial cytotoxicity as visually assessed, therefore were excluded from 
additional analysis. ER-27319 is an inhibitor of spleen tyrosine kinase (Syk) (Moriya et al., 
1997). This compound significantly reduced FX-mediated Ad5 transduction (Figure 4.3). 
When quantified, this inhibitor caused approximately 35% decrease in cell viability 
compared to untreated control conditions after coincubation with cells for 48 h (Figure 
4.4). Syk has not previously been described in relation to Ad5 infection, therefore this 
inhibitor was chosen for further studies as it blocked Ad5:FX gene transfer with a 
minimally toxic effect. 
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Figure 4.2. Ad5 transport in the presence of PKA, PI3K and p38MAPK inhibitors. 
(A) A549 cells were incubated with PKA, P13K or p38MAPK inhibitors for 30 min at 37°C 
then 10,000 vp/cell of Alexa Fluor-488-labelled Ad5 (green) in the presence of FX and the 
different kinase inhibitors were allowed to bind cells for 1 h at 4°C, followed by 
incubation at 37°C for 3 h prior to fixation and staining for pericentrin (red). Examples of 
colocalisation of Ad5 with pericentrin are indicated by the yellow arrows. Scale bar = 20 
μm, applicable to all images. (B) % cells with colocalisation of Ad5 with the MTOC marker 
pericentrin was calculated by analysing at least 5 separate 40x microscope fields per 
condition. *p<0.05 as compared to control conditions as determined by one-way ANOVA 
and Dunnett’s multiple comparison post-test. Error bars represent SEM (n = 5/group).
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Figure 4.3. Effect of kinase inhibitors on FX-mediated Ad5 gene transfer. 
SKOV3 cells were incubated with 20 µM of each kinase inhibitor for 30 min at 37°C, washed, then incubated with 100 µl serum free media with 1000 
vp/cell Ad5 in the absence or presence of FX and 20 µM kinase inhibitor for 3 h at 37°C, followed by the addition of 100 µl media containing 20% serum 
and further incubation at 37°C. Ad5 transgene expression was quantified 48 h post-infection. Kinase inhibitors are listed in Table 4.1 *p<0.05 as 
compared to plus FX conditions and not significantly greater than minus FX conditions, as determined by one-way ANOVA and Bonferroni’s multiple 
comparison post-test. Error bars represent SEM (n = 4/group). 
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Table 4.1. Kinase inhibitor library. 
List of the 80 kinase inhibitors from the Tocriscreen
TM
 Kinase Inhibitor Toolbox’. 
No. Compound Name Main target 
1 AG 490 EGFR 
2 ML 9 hydrochloride MLCK 
3 AG 213 EGFR and PDGFR 
4 Fasudil hydrochloride CDK and ROCK 
5 GF 109203X PKC 
6 Genistein EGFR 
7 LY 294002 hydrochloride PI3K 
8 U0126 MEK 
9 PD 98059 MEK 
10 Y-27632 dihydrochloride p160ROCK 
11 SB 202190 p38 MAPK 
12 Olomoucine CDK 
13 LFM-A13 BTK 
14 ZM 336372 c-Raf 
15 ZM 449829 JAK3 
16 ZM 39923 hydrochloride JAK3 
17 GW 5074 c-Raf1  
18 PP 1 Src  
19 SB 203580 hydrochloride p38MAPK 
20 (-)- Terreic acid BTK 
21 PP 2 Src  
22 SU 4312 VEGFR  
23 SP 600125 JNK 
24 Purvalanol A CDK 
25 Purvalanol B CDK 
26 Rottlerin PKC 
27 SB 431542 TGF-βRI ALK5 
28 SB 216763 GSK-3 
29 SB 415286 GSK-3 
30 Arctigenin IκBα 
31 NSC 693868 CDK, GSK-3 
32 SB 239063 p38 MAPK 
33 SL 327 MEK1 and MEK2 
34 Ro 31-8220 mesylate Broad spectrum 
35 Aminopurvalanol A CDK 
36 API-2 Akt 
37 GW 441756 NGF receptor tyrosine kinase A 
(TrkA) 
38 GW 583340 dihydrochloride EGFR  
39 Ro 08-2750 NGF 
40 TBB CK2 
41 1,2,3,4,5,6-Hexabromocyclohexane JAK2  
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42 HA 1100 hydrochloride ROCK 
43 BIBX 1382 dihydrochloride EGFR 
44 CGP 53353 PKC 
45 Arcyriaflavin A CDK4/cyclin D1 
46 ZM 447439 Aurora B  
47 ER-27319  Syk  
48 ZM 323881 hydrochloride VEGFR-2/KDR 
49 ZM 306416 hydrochloride VEGFR 
50 IKK 16 IKK 
51 Ki 8751 VEGFR 
52 10-DEBC hydrochloride Akt/PKB 
53 TPCA-1 IKK 
54 SB 218078 ChK1 
55 TCS 359 FLT3R  
56 PD 198306 MEK 
57 Ryuvidine CDK 4 
58 IMD 0354 IKK  
59 CGK 733 ATR, ATM  
60 PHA 665752 cMET 
61 PD 407824 ChK1, Wee1 
62 LY 364947 TGF-βRI 
63 CGP 57380 MAPK 
64 PQ 401 IGF1R 
65 PI 828 PI3K 
66 NU 7026 DNA-PK 
67 D 4476 CK1 and TGF-βRI ALK5 
68 EO 1428 p38MAPK 
69 H 89 dihydrochloride PKA  
70 FPA 124 Akt  
71 GW 843682X PLK 
72 Iressa EGFR  
73 SU 5416 VEGFR 
74 1-Naphthyl PP1 Src  
75 Dorsomorphin dihydrochloride AMPK 
76 BIO GSK-3 
77 SD 208 TGF-βRI 
78 Compound 401 DNA-PK 
79 BI 78D3 cJNK 
80 SC 514 IKK 
 
Abbreviations: epidermal growth factor receptor (EGFR), myosin light chain kinase 
(MLCK), platelet-derived growth factor receptor (PDGFR), cyclic nucleotide-dependent 
protein kinase (CDK), rho-associated protein kinase (ROCK), protein kinase C (PKC), 
mitogen-activated protein kinase kinase (MAPK), mitogen-activated protein 
kinase/extracellular signal-regulated kinase kinase (MEK), rho-associated kinase 
(ROCK), Bruton's tyrosine kinase (BTK), Janus tyrosine kinase 3 (JAK3), c-Jun N-
terminal kinase (JNK), transforming growth factor-β type I receptor (TGFβR1) activin 
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receptor-like kinase (ALK), glycogen synthase kinase-3 (GSK-3), nerve growth factor 
(NGF), casein kinase-2 (CK2), IκB kinase (IKK), checkpoint kinase 1 (ChK1), polo-like 
kinase (PLK), vascular endothelial growth factor (VEGF), FMS-like tyrosine kinase 3 
receptor (FLT3), insulin-like growth factor receptor (IGF1R), DNA-dependent protein 
kinase (DNA-PK). 
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Figure 4.4. Effect of ER-27319 on cell viability after 48 h. 
SKOV3 cells were infected with 1000 vp/cell of Ad5 in the presence of FX and 20 µM 
ER-27319 for 3 h, followed by 10 µM ER-27319 for a further 45 h, when a MTT assay 
was performed. *p<0.05 as compared to Ad5+FX treated cells as determined by one-
way ANOVA and Dunnett’s multiple comparison post-test. Error bars represent SEM (n 
= 4/group). 
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4.2.3 Effect of ER-27319 on FX-mediated Ad5 cell attachment and 
intracellular transport 
The effect of ER-27319 on FX-mediated Ad5 cell attachment and intracellular 
trafficking was investigated. Firstly, Ad5 binding to SKOV3 cells was assessed. The 
compound resulted in no significant difference in cellular binding compared to control 
conditions in the absence or presence of FX indicating it acts at a post-entry level 
(Figure 4.5). Next, A549 and SKOV3 cells were incubated with 20, 50 or 100 µM ER-
27319 and fluorescently labelled-Ad5 in the presence of FX for 1 h at 4˚C and then 
fixed after 15 min, 60 min or 180 min at 37˚C. In both A549 and SKOV3 cells, virus 
binding to the cell surface and subsequent internalisation were not decreased in the 
presence of ER-27319, as assessed visually (Figure 4.6 and Figure 4.7). In the presence 
of FX control conditions, Ad5 trafficked efficiently toward the nucleus. By 60 min Ad5 
was found to be colocalised with the MTOC, as stained for using the pericentrin 
marker. This is in contrast to cells incubated with ER-27319, in which Ad5 trafficking 
was observed to be substantially disrupted (Figure 4.6 and Figure 4.7). This was 
evident at all doses of ER-27319 but the effect was made more prominent as the dose 
was increased. In the presence of the kinase inhibitor the virus did travel toward the 
nucleus, however it accumulated within the perinuclear region and did not form 
punctuate colocalised spots with the MTOC staining but more diffusely around the 
nucleus. At 180 min, the pattern of Ad5 in the presence of ER-27319 remained 
dissimilar to control conditions, with the virus inhibited from fully colocalising with the 
MTOC and preventing efficient trafficking. The percentage of cells where complete 
MTOC:virus colocalisation did occur were quantified and the number of cells was 
found to be significantly decreased in the presence of ER-27319 demonstrating the 
ability of this compound to disrupt Ad5 intracellular transport compared to controls 
(Figure 4.8). Coincubation of cells with ER-27319 resulted in no displacement or 
abnormal staining of the MTOC as shown by immunocytochemistry experiments 
staining with an antibody against pericentrin. Concentrations of up to 100 µM ER-
27319 have been used in vitro in previous publications (Moriya et al., 1997). However, 
to ensure the effects on intracellular transport observed in this assay were not as a result 
of ER-27319 induced toxicity, we assessed the effects of such concentrations on cell 
viability at the 180 min time point. ER-27319 did have a negligible effect on cell 
viability at the higher concentration, however this did not reach statistical significance 
(Figure 4.9). 
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Figure 4.5. Effect of ER-27319 on Ad5 binding to SKOV3 cells. 
SKOV3 cells were preincubated with 20 μM ER-27319 for 30 min prior to the addition 
of 5000 vp/cell of Alexa488-labelled Ad5 in the absence or presence of FX. 
Fluorescently labelled Ad5 binding to cells was quantified by FACS analysis. NS = non 
significant, p>0.05 as compared to matched control conditions as determined by one-
way ANOVA and Dunnett’s multiple comparison post-test. Error bars represent SEM (n 
= 4). 
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Figure 4.6. Effect of ER-27319 on FX-mediated Ad5 trafficking in A549 cells. 
Cells were incubated with ER-27319 for 30 min at 37°C then 10,000 vp/cell of Alexa488-labelled Ad5 (green) in the presence of FX and ER-27319 were 
added for 1 h at 4°C, followed by incubation at 37°C for 1 h or 3 h prior to staining for pericentrin (red). Examples of fluorescently-labelled Ad5 
colocalisation with pericentrin are indicated by yellow arrows. 63x magnification, scale bar = 20 μm, applicable to all images. 
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Figure 4.7. Effect of ER-27319 on FX-mediated Ad5 trafficking in SKOV3 cells. 
Cells were incubated with ER-27319 for 30 min at 37°C then 10,000 vp/cell of Alexa555-labelled Ad5 (green) in the presence of FX and ER-27319 were 
added for 1 h at 4°C, followed by incubation at 37°C for 1 h or 3 h prior to staining for pericentrin (red). 63x magnification, scale bar = 20 μm, applicable 
to all images. 
  Chapter 4 | Results 
143 
0
10
20
30
40
50
60
70
80
90
100
60 mins 180 mins
%
 
Co
m
pl
et
e 
M
TO
C 
co
lo
ca
lis
at
io
n
CON
20 µM ER
50 µM ER
100 µM ER
* *
%
 
Co
m
pl
et
e 
M
TO
C 
co
lo
ca
lis
at
io
n
 
Figure 4.8. Effect of ER-27319 on Ad5 colocalisation with the MTOC. 
The percentage of SKOV3 cells with complete colocalisation of Ad5 with pericentrin 
was calculated by analysing at least 5 separate 40x microscope fields per experimental 
condition. *p<0.05 as compared to control conditions at the individual time points as 
determined by one-way ANOVA and Dunnett’s multiple comparison post-test. Error 
bars represent SEM (n = 5). 
 
0
20
40
60
80
100
120
Control 20 µM ER 50 µM ER 100 µM ER
%
 
Vi
ab
le
 
Ce
lls
A549 SKOV3
 
Figure 4.9. Effect of ER-27319 on cell viability after 4 h. 
Cells were incubated with 20 µM, 50 µM or 100 µM ER-27319 for 4 h and a cell 
viability MTT assay was performed. Error bars represent SEM (n = 4). 
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4.2.4 Effect of the Syk inhibitor BAY 61-3606 on FX-mediated Ad5 
infectivity  
To investigate whether the inhibition of Ad5:FX gene transfer caused by ER-27319 
was as a result of the compound blocking Syk activity, the effects of an alternative Syk 
inhibitor, BAY 61-3606 (2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-
ylamino]-nicotinamide dihydrochloride), on FX-mediated Ad5 infectivity were 
analysed. The mechanisms of action of both compounds differ (Moriya et al., 1997; 
Yamamoto et al., 2003). ER-27319 is reported to inhibit the tyrosine phosphorylation 
of Syk induced by the IgE receptor, Fcε receptor I (FcεRI) in mast cells but not in 
human peripheral B cells, whilst the more potent and highly selective inhibitor BAY 
61-3606 prevents Syk activity in an ATP competitive manner in mast cells and 
basophils and shows efficacy in monocytes and eosinophils (Moriya et al., 1997; 
Yamamoto et al., 2003). Therefore, fluorescently labelled-Ad5 binding and 
intracellular transport in the presence of FX and increasing doses of BAY 61-3606 
were assessed in SKOV3 cells using confocal microscopy. Ad5 cellular binding and 
trafficking to the nucleus in the presence of the inhibitor did not differ to Ad5 plus FX 
control conditions (Figure 4.10). Next, the effect of BAY 61-3606 on FX-mediated 
Ad5 transduction in SKOV3 cells was analysed. There was no significant difference in 
Ad5 gene transfer in the absence or presence of the kinase inhibitor, hence BAY 61-
3606 did not affect FX-mediated Ad5 infectivity (Figure 4.11). 
4.2.5 Syk gene and protein expression 
Syk expression at the gene and protein level was next analysed in SKOV3 and A549 
cells. In these experiments human colorectal adenocarcinoma SW620 cells were 
employed as a positive control as previous studies have shown them to have high levels 
of Syk (Leroy et al., 2009). First, relative expression of Syk was investigated by qRT-
PCR performed on cDNA derived from the three cell types. qRT-PCR demonstrated 
high levels of Syk expression in positive control SW620 cells, whereas the presence of 
Syk in SKOV3 and A549 was undetectable (Figure 4.12). Western blot analysis was 
performed to assess the expression of the Syk protein in SW620, SKOV3 and A549 cell 
lysates. In concordance with the qRT-PCR results Syk was detected in SW620 cells, 
whilst both SKOV3 and A549 cell lysates were negative for Syk protein expression 
(Figure 4.12). 
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Figure 4.10. Effect of BAY 61-3606 on FX-mediated Ad5 intracellular transport. 
SKOV3 cells were incubated with BAY 61-3606 for 30 min at 37°C, washed, then 
10,000 vp/cell of Alexa488-labelled Ad5 (green) in the presence of FX with BAY 61-
3606 were allowed to bind cells for 1 h at 4°C, followed by incubation at 37°C for 0, 60 
or 180 min prior to fixation. 63x magnification, scale bar = 20 μm, applicable to all 
images. 
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Figure 4.11. Effect of BAY 61-3606 on FX-mediated Ad5 transduction. 
SKOV3 cells were incubated BAY 61-3606 for 30 min at 37°C, washed, then incubated 
with 1000 vp/cell Ad5 -/+ FX and BAY 61-3606 for 3 h at 37⁰C. Ad5 transgene 
expression was quantified 48 h post-infection. Error bars represent SEM (n = 4). 
*p<0.05 as compared to plus FX conditions, as determined by one-way ANOVA and 
Dunnett’s multiple comparison post-test. NS = non significant, p>0.05. 
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Figure 4.12. Syk kinase expression in SW620, A549 and SKOV3 cells. 
(A) RNA was extracted from SW620, A549 and SKOV3 cells and converted to cDNA. 
qRT-PCR was performed on the samples to detect Syk. Error bars represent SEM (n = 
4). (B) SW620, A549 and SKOV3 cell lysates were subjected to western 
immunoblotting and detection with an anti-Syk antibody. 70 µg of each protein 
sample was loaded onto a 10% gel and Syk was probed with 2 µg/ml of the primary 
mouse monoclonal anti-Syk antibody and a rabbit anti-mouse HRP secondary antibody 
(1:1000 dilution).  
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4.2.6 Mechanism of action of ER-27319 
Through personal correspondence with Dr. Juan Rivera (National Institute of Health, 
Bethesda, Maryland, USA) additional information on the mechanism of action of ER-
27319 was obtained. Dr. Juan Rivera was an author of the paper entitled “ER-27319, an 
acridone-related compound, inhibits release of antigen-induced allergic mediators from 
mast cells by selective inhibition of Fcε receptor I-mediated activation of Syk”. From 
this communication it was noted that ER-27319 does not bind directly to Syk or 
interfere with the Syk ATP binding site. The compound selectively binds to the 
immunoreceptor tyrosine-based activation motif (ITAM) of the FcεRI gamma subunit 
in mast cells and does not directly interfere with Syk activity (Figure 4.13). This ITAM 
is encoded for by the consensus amino acid sequence (D/E)-x-x-Y-x-x-(L/I)-(xn=6-8)-Y-
x-x-(L/I) in which x can represent any amino acid. SKOV3 and A549 cells are reported 
to be negative for FcεRI expression, as documented on the NCI-60 database 
(http://dtp.nci.nih.gov/docs/misc/common_files/cell_list.html).  
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Figure 4.13. Mechanism of action of ER-27319 in mast cells. 
Antigen-induced receptor dimerisation of the Fc receptor leads to phosphorylation of 
the receptors' ITAMs by Src-family protein tyrosine kinases (for example, Lyn, Lck and 
Fyn). Phosphorylated ITAMs act as a membrane docking site for cytoplasmic Syk. ER-
27319 binds to the ITAMs of the FcεRI gamma subunit, thereby blocking the Syk 
binding site and preventing Syk from becoming activated.  
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4.2.7 ITAM-containing viral proteins 
It was postulated that ER-27319 may be binding to an alternative ITAM-containing 
protein present in these cells or on Ad5 itself and thereby disrupting viral intracellular 
transport. Previous studies have reported ITAMs expressed in several viral proteins 
including the mouse mammary tumour virus (MMTV) envelope protein (Env) (Katz et 
al., 2005), the Kaposi’s sarcoma-associated herpesvirus (KSHV) K1 protein (Lee et al., 
1998), the Epstein barr virus (EBV) latent membrane protein 2A (LMP2A) (Fruehling 
et al., 1997), the Simian Immunodeficiency Virus (SIV) negative regulatory factor 
protein (Dehghani et al., 2002), the Bovine leukemia virus (BLV) gp30 protein, 
Hantaan virus G1 (Mou et al., 2007) as well as several others. Therefore human Ad 
subgroup C protein sequences were analysed using the SwissProt database for the 
presence of conventional ITAM sequences and “ITAM-like” motifs with different 
numbers of residues (n) between the two Y-x-x-I/L modules. Sequence scanning of the 
Ad2 and Ad5 proteomes were preformed in search of amino acids encoding for 
potential ITAMs. Two ITAM-like sequences were found on the hexon protein (Figure 
4.14 and Table 4.3). Although previous work has described flexibility in the ITAM 
encoding sequence, neither of the potential Ad5 ITAMs strictly followed that reported 
for FceRI gamma subunit, instead of the of the conventional 7 amino acid residues 
between the two Y-x-x-I/L modules as in FceRI gamma, the hexon ITAM-like 
sequences expressed 17 or 22 amino acids (Table 4.3 and Figure 4.14). 
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Table 4.2. ITAM containing viral proteins. 
Viral proteins encoding ITAM sequences. The canonical ITAM residues are highlighted 
in red.  
Virus protein Amino acid sequence Reference 
MMTV Env  
 
AYDYAAIIVKRPPYVLL 
 
(Katz et al., 2005) 
EBV LMP2A 
 
HSDYQPLGTQDQSLYLGL 
 
(Fruehling et al., 1997) 
BLV gp30 
 
DSDYQALLPSAPEIYSHLSPTKPDYINL 
 
(Reichert et al., 2001) 
SIV Nef 
 
GDLYERLLRARGETYGRL 
 
(Dehghani et al., 2002) 
Hantavirus-G1 
(NY1) 
 
GCYRTLGVFRYKSRCYVGL 
 
(Humphrey et al., 2005) 
Rhadinovirus R1 
 
HNEYNHLNELNMIEQYDWL 
 
(Damania et al., 1999) 
 
 
 
 
 
Table 4.3. Searching the Ad proteome for ITAMs. 
The Ad5 proteome was scanned using the SwissProt database for the presence of 
ITAM sequences (Yxx(L/I)xnYxx(L/I). The canonical ITAM residues are highlighted in 
blue.  
Ad capsid protein Amino acid sequence x(n length) 
Hexon QWSYMHISGQDASEYLSPGLVQFARATETYFSL 
 
22 
Hexon ASTYFDIRGVLDRGPTFKPYSGTAYNAL 
 
17 
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(A)
(B)
Y11-x-x- I14
Y37-x-x- L40
Y99-x-x- I102
Y120-x-x- L123
 
Figure 4.14. Ad5 hexon ITAMs. 
(A) Ribbon diagram of an individual Ad5 hexon monomer (green) highlighting the 
positions of the four Yxx(L/I) amino acids motifs (blue and red). (B) Ribbon diagram of 
the Ad5 hexon trimer (monomers in green, cyan and pink) highlighting the relative 
positions of the ITAM-like motifs (blue and red). These images were generated using 
POLYVIEW-3D (http://polyview.cchmc.org/polyview3d.html) (Porollo et al., 2007).  
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4.2.8 ITAM containing cellular proteins 
By performing literature searches the presence of ITAM amino acid sequences in 
cellular proteins were investigated. These are described in Table 4.4. The NCI-60 
database was employed to investigate the possible expression of these ITAM-
containing cellular proteins in SKOV3 and A549 cells, as these cell types were used to 
define the original phenotypic effects. The proteins ezrin, radixin and moesin (ERM) 
were highlighted as the most likely ITAM-containing protein candidates to be present 
in SKOV3 and A549 cells, thus this ERM family of proteins were investigated further.  
Table 4.4. ITAM-containing cellular proteins. 
Proteins encoding ITAM sequences. Canonical ITAM residues are highlighted in red.  
Protein Amino acid sequence Reference 
CD3γ 
 
DQLYQPLKDREDDQYSHL 
 
(Haks et al., 2002) 
CD3δ 
 
DQVYQPLRDRDDAQYSHL 
 
(Dave et al., 1997) 
CD3ε 
 
NPDYEPIRKGQRDLYSGL 
 
(Sommers et al., 2000) 
CD3ζ-1 
 
NQLYNELNLGRREEYDVL 
 
(Yudushkin et al., 2010) 
CD3ζ-2 
 
EGLYNELQKDKMAEAYSEI 
 
(Lysechko et al., 2005) 
CD3ζ-3 
 
DGLYQGLSTATKDTYDAL 
 
(Gil et al., 2001) 
FcεRIβ 
 
DRVYEELNIYSATYSEL 
 
(Furumoto et al., 2004) 
FcεRIγ 
 
DGVYTGLSTRNQETYETL 
 
(Sakurai et al., 2004) 
DAP12 
 
ESPYQELQGQRSDVYSDL 
 
(Lanier et al., 2000) 
Igα 
 
ENLYEGLNLDDCSMYEDI 
 
(Kraus et al., 2001) 
Igβ 
 
DHTYEGLDIDQTATYEDI 
 
(Gazumyan et al., 2006) 
Merlin 
 
EMEYLKIAQDLEMYGVNYFAI 
 
(Barrow et al., 2006) 
Ezrin 
 
MLEYLKIAQDLEMYGINYFEI 
 
(Rozsnyay et al., 1996) 
Radixin 
 
MMEYLKIAQDLEMYGVNYFEI 
 
(Urzainqui et al., 2002) 
Moesin 
 
VLEYLKIAQDLEMYGVNYFSI 
 
(Urzainqui et al., 2002) 
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4.2.9 Ezrin, radixin and moesin gene expression 
ERM proteins are important regulators of the cell cortex, capable of interacting with 
both the plasma membrane and filamentous actin (Figure 4.15). Furthermore, these 
proteins can control signalling pathways through their ability to bind transmembrane 
receptors and link them to downstream signalling components (Dransfield et al., 1997; 
Ruppelt et al., 2007; Tang et al., 2007). Ezrin, radixin and moesin gene expression in 
SKOV3 and A549 cells was therefore assessed. Expression was investigated by qRT-
PCR performed on cDNA, derived from the both cell types. All three members of the 
ERM family were present in both SKOV3 and A549 cells (Figure 4.16). Moesin 
showed the highest levels of expression, in particular in SKOV3 cells. Ezrin was found 
to be more highly expressed in SKOV3 cells than A549s, whilst radixin was expressed 
in lower quantities in both cell types. Next ERM protein expression was assessed by 
western blot analysis. ERM proteins were expressed at the protein level in both SKOV3 
and A549 cells (Figure 4.17).  
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Figure 4.15. Schematic of ERM activation. 
In the active conformation, the N-terminal domain of ERM proteins (red) binds to the 
C-terminal actin-binding domain (green). The α-helical domain is in orange. 
Phosphatidylinositol 4,5 bis-phosphate (PIP2) binding to the N-terminal and 
phosphorylation of the C-terminal induces and stabilises the unfolded active 
conformation, allowing the N-terminal domain to bind transmembrane receptors and 
the actin-binding domain to interact with actin filaments. This figure was adapted 
from Ivetic et al. (Ivetic et al., 2004). 
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4.2.10 Effects of ER-27319 on ERM protein expression 
The effects of ER-27319 on viral intracellular trafficking and the expression of ezrin, 
radixin and moesin were investigated. SKOV3 cells were incubated with ER-27319 and 
fluorescently labelled-Ad5 in the presence of FX for 1 h at 4˚C and then fixed after 0 
min or 180 min at 37˚C and stained using antibodies against ezrin, radixin or moesin. 
IgG controls for all antibodies were negative for unspecific staining. At the 0 min time 
point there was no specific colocalisation of Ad5 with the ERM proteins (Figure 4.18). 
As previously shown, the compound severely disrupted Ad5 intracellular trafficking by 
180 min. The compound did not cause any obvious differences in the expression or 
localisation of the ERM proteins compared to control conditions (Figure 4.18). 
However the staining of all three proteins was variable with differences in their 
expression even within the untreated control conditions at the different time points, 
making it difficult to draw a clear conclusion, however under these conditions no gross 
difference was observed. 
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Figure 4.16. ERM gene expression in A549 and SKOV3 cells. 
RNA was extracted from A549 and SKOV3 cells and converted to cDNA. qRT-PCR was 
performed on the samples to detect ezrin, radixin and moesin expression. Error bars 
represent SEM (n = 4). 
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Figure 4.17. Ezrin, radixin and moesin protein expression in SKOV3 cells. 
SKOV3 cell lysates were subjected to western immunoblotting and detection with an 
anti-ezrin, anti-radixin or anti-moesin antibody. Lanes represent replicate SKOV3 cell 
lysate samples. 50 µg of each protein sample was loaded onto a 10% gel and probed 
with either the primary rabbit polyclonal antibody anti-ezrin (1:750 dilution), the 
rabbit monoclonal anti-radixin (1:1000 dilution) or the rabbit monoclonal anti-moesin 
(1:2500 dilution) and a swine anti-rabbit HRP secondary antibody (1:1000 dilution). 
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Figure 4.18. Effect of ER-27319 on ERM proteins expression and FX-mediated Ad5 
cellular trafficking. 
SKOV3 cells were incubated with media alone, 20 µM or 100 µM ER-27319 for 30 min at 
37°C then 10,000 vp/cell of Alexa Fluor-555-labelled Ad5 (red) in the presence of FX with 
20 µM or 100 µm ER-27319 were allowed to bind cells for 1 h at 4°C, followed by 
incubation at 37°C for 3 h prior to fixation. Cells were stained using (A) 1:200 dilution of a 
polyclonal rabbit anti-ezrin antibody (green), (B) 1:200 dilution of a monoclonal rabbit 
anti-radixin antibody (green) or (C) 1:200 dilution of a monoclonal anti-moesin (green) 
antibody. Nuclei were counterstained using DAPI.  
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4.3 Discussion 
Among the first consequences of viral binding to cellular receptors is the activation of key 
intracellular signalling pathways. This study was aimed at investigating the involvement of 
a broad range of kinases and cellular proteins following Ad5:FX engagement with HSPGs, 
by employing small molecule inhibitors to decipher dependencies on individual signalling 
molecules. The study was also designed to develop Ad5 infectivity screening technologies 
prior to the initiation of Chapter 5. 
Initially compound inhibitors of PKA, PI3K and p38MAPK were tested for their effects on 
Ad5 intracellular transport in the presence of FX. These kinases have previously been 
reported to have a critical role in Ad5 trafficking and nuclear targeting via the CAR 
pathway (Li et al., 1998b; Suomalainen et al., 2001). In previous experiments, cells were 
preincubated with the kinase inhibitors at 37˚C for 30 min and drugs were kept present 
throughout virus binding, internalisation and gene delivery (Li et al., 1998b; Suomalainen 
et al., 2001), therefore this experiment was designed in a similar manner using the same 
concentrations i.e. 40 µM of the PKA inhibitor H89 dihydrochloride, 100 µM of the PI3K 
inhibitor LY 294002 hydrochloride or 10 µM of the p38MAPK inhibitor SB 203580. 
Coincubation of cells with the compounds in the presence of Ad5 and FX disrupted 
efficient viral intracellular transport as demonstrated by the decreased levels of MTOC 
colocalisation by 3 h post-infection compared to control conditions. In the presence of the 
PI3K or p38MAPK inhibitors MTOC colocalisation was reduced by greater than 40%, 
whilst in the presence of the PKA inhibitor by almost 70%, indicating a critical role for 
these kinases in efficient Ad5 nuclear targeting via the FX pathway (Suomalainen et al., 
2001). In addition to the study by Bradshaw et al., reporting a important role for the penton 
base RGD motif for optimal cell entry in the presence of FX, these data suggest overlap 
with classical in vitro CAR-mediated infection mechanisms (Bradshaw et al., 2010).  
Next, a broad library of kinase inhibitors (n = 80) were screened to evaluate any having an 
affect on Ad5 gene transfer in the presence of FX in SKOV3 cells. Similarly to the 
previous experiment, cells were preincubated with the inhibitors for 30 min prior to the 
addition of virus. However in this case, as the number of compounds to be tested was quite 
large, all compounds were used at the same dose. An average concentration of ~10 µM 
was recommended by the manufacturer for several of the compounds, therefore cells were 
first incubated with Ad5 in the presence of FX and 20 µM compound in 100 µl serum free 
media for 3 h, followed by the addition of 100 µl media containing 20% serum, thus giving 
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a final concentration of 10 µM compound in 10% serum for the remainder of the assay. At 
these concentrations several compounds previously described as important for Ad5 
infection were not highlighted as having a role in FX-mediated Ad5 gene transfer 
including inhibitors of MEK (e.g. U0126) (Farmer et al., 2009), PI3K (e.g. LY 294002 
hydrochloride or PD98059) (Li et al., 1998b) and p38MAPK (e.g.SB 203580 
hydrochloride) (Suomalainen et al., 2001). This could be due to differences in 
experimental design, for instance other studies have used higher concentrations of 
compound (> 20 µM), investigated earlier stages of Ad5 infection and more subtle effects 
of kinase inhibition using confocal or electron microscopy (Farmer et al., 2009; 
Suomalainen et al., 2001). This was highlighted by the fact that in this study at higher 
concentrations H89 dihydrochloride and LY 294002 hydrochloride resulted in inefficient 
viral trafficking toward the nucleus by 3 h, however at lower concentrations did not 
significantly decrease Ad5 gene transfer at 48 h post infection. However, it cannot be ruled 
out that kinases known to be activated following Ad5 binding to CAR are not the same as 
those involved in Ad5:FX engagement with HSPGs, or perhaps there are subtle differences 
between the pathways. On the other hand, some of the inhibitors used in this screen were 
employed at concentrations above their previously reported IC50 values and in turn may 
have resulted in non-specific effects and caused substantial cytotoxicity thereby making 
full interpretation of their effects on FX-mediated Ad5 gene transfer difficult. For example 
the highly potent MEK inhibitor PD 198306 has an IC50 value of 8 nM, whilst at 
concentrations above 1 µM can decrease ERK, c-Src, cdks and PI3K activity (Ciruela et 
al., 2003). The cdk4 inhibitor Ryuvidine, has on IC50 value of 6 µM for cdk4 in a range of 
cancer cell lines but has also been reported to have cytotoxic potential (Ryu et al., 2000). 
Therefore, the inhibitor chosen for further study was the synthetic compound ER-27319 as 
this resulted in > 90% decrease in FX-mediated Ad5 gene transfer, whilst causing minimal 
toxicity.  
ER-27319 was previously reported to selectively inhibit Syk activity (Moriya et al., 1997). 
Syk is a 72 kDa, non-receptor tyrosine kinase that acts as a key mediator of 
immunoreceptor signalling. This cytoplasmic protein is expressed prevalently in 
haematopoietic cells but is also found in a wide range of non-haematopoietic cells 
including fibroblasts (Yamada et al., 2001), oesteoclasts (Mócsai et al., 2004), hepatocytes 
(Tsuchida et al., 2000), endothelial (Yanagi et al., 2001), neuron-like cells (Tsujimura et 
al., 2001) and epithelial cells (Ulanova et al., 2005) suggesting Syk has a broad range of 
functions in multiple biologic processes beyond the immune system. Syk is classically 
activated via ITAMs, present either in the cytoplasmic tail of the receptor itself or on 
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receptor-associated transmembrane adaptors (Figure 4.19). In addition, Syk has been 
reported to be activated through G-protein-coupled receptors (Wan et al., 1996) and by 
integrins which do not contain conventional ITAMs but instead employ ITAM-containing 
adaptor proteins such as DAP12 or FcRγ (Mocsai et al., 2006). Previously an involvement 
of Syk kinase in relation to Ad5 infectivity has not been described. Therefore, it was 
decided that investigation into a role for Syk would be of interest and ER-27319 was 
chosen for additional experimentation. 
(A) 
N-
SH2 SH2 Kinase
Catalytic     
Region
Inter-
domain B
Inter-
domain A
Docking     
Region
ITAM 
binding    
Region
-C
 
(B) 
 
Figure 4.19. Spleen tyrosine kinase. 
(A) Syk domain structure (B) Schematic of the Syk signalling pathway. Figure taken from 
Mocsai et al. 2010 (Mócsai et al., 2010).  
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In the kinase screen experiment, ER-27319 was tested at a concentration of 20 µM for the 
first three and a half hours, followed by 10 µM for the remainder of the assay. These doses 
were similar to those used in a previous in vitro study in which ER-27319 was reported to 
have an IC50 value of 10 µM for inhibition of Syk in human and rat mast cells (Moriya et 
al., 1997). Although 48 h coincubation with this compound did result in a decrease in cell 
viability, this was not thought to be the primary reason for the significant reduction in FX-
mediated Ad5 transduction in SKOV3 cells. Consequently, in order to analyse the effects 
of the compound after shorter incubations and the effects on the early stages to Ad5 
infection, intracellular transport of fluorescently-labelled Ad5 in the presence of FX was 
investigated. When cells were incubated with increasing doses of ER-27319 in the 
presence of Ad5 and FX, intracellular trafficking was substantially disrupted. The 
compound prevented efficient colocalisation with the MTOC by 180 min as assessed 
visually and quantitatively, therefore in contrast to Ad5 plus FX control conditions. For 
Ad5 to reach the nucleus a series to sequential steps are required including endocytosis, 
partial capsid disassembly, endosomal escape, microtubule based transport to the MTOC 
and nuclear import. This inhibitor appeared to cause a post-entry block in viral infectivity 
and had an effect at the later stages of trafficking, hindering MTOC accumulation. It 
appeared as though the virus was trapped in an alternative cellular compartment in a 
perinuclear region and at 180 min in SKOV3 cells this is particularly evident. This data 
demonstrates the ability of the ER-27319 to prevent efficient Ad5 intracellular transport 
and infection in the presence of FX. 
In order to investigate the effects of ER-27319 on Ad5 infectivity it was important to 
understand the compounds mode of action. In a previous study ER-27319 is reported to 
selectively inhibit the tyrosine phosphorylation and activation of Syk induced by the FcεRI 
receptor in mast cells (Moriya et al., 1997). Syk is characterised by a C-terminal kinase 
domain, two N-terminal Src homology (SH2) domains and two intervening domains, A 
and B (Figure 4.19). The tandem SH2 domains bind to diphosphorylated ITAMs (D/E)-x-
x-Y-x-x-(L/I)-(xn=6-8)-Y-x-x-(L/I) of the cytoplasmic region of receptors. The tyrosines 
embedded within this motif are necessary and sufficient for ITAM signalling. This triggers 
Syk activation and initiates downstream signalling. In the study by Moriya et al. the 
compound prevented the phosphorylation of Syk induced by the phosphorylated ITAM of 
the FcεRI γ subunit (Moriya et al., 1997). ER-27319 was described as specific for Syk and 
at concentrations up to 100 µM it had no effect ZAP-70, another member of the Syk family 
or the downstream target PLC-γ1 in Jurkat T cells (Law et al., 1996; Moriya et al., 1997). 
The compound did not affect the activity of Lyn kinase, a Src family member, which is 
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responsible for the phosphorylation of FcεRI receptor β and γ subunits leading to Syk 
binding, indicating it was not preventing receptor phosphorylation (Moriya et al., 1997).  
In order to further analyse the effects of using a Syk inhibitor on Ad5 intracellular 
transport and gene transfer, an alternative kinase inhibitor BAY 61-3606 was utilised. 
BAY 61-3606 is reported to be a potent and specific inhibitor of Syk acting in an ATP-
competitive manner (Yamamoto et al., 2003). It has an IC50 value of 10 nM in mast cells 
and demonstrated greater than 626-fold selectivity over other tyrosine kinases such as Lyn 
and Src (Yamamoto et al., 2003). It also has been shown to be effective in inhibiting the 
release of various inflammatory mediators in basophils, B cells and monocytes (Yamamoto 
et al., 2003). Therefore although both inhibitors are reported to decrease Syk activity it is 
evident the mechanism by which BAY 61-3606 acts differs from that of ER-27319. This 
compound was employed to investigate whether it would affect FX-mediated Ad5 
infectivity. In this study, the coincubation of SKOV3 cells with increasing doses of BAY 
61-3606 did not affect Ad5 intracellular trafficking or FX-mediated Ad5 gene transfer at 
48 h post-infection. This data suggests that ER-27319 may not be disrupting FX-mediated 
infectivity via an effect directly related to Syk activity. 
To investigate this, the expression levels of Syk in our cells were investigated by qRT-PCR 
and western blot analysis. Syk has previously been shown to be present on a range of non-
haematopoietic cell lineages including human mammary epithelial cells (Ruschel et al., 
2004) and several types of airway epithelial cells (Ulanova et al., 2005). However, qRT-
PCR and western blotting of SKOV3 and A549 cells revealed no detectable Syk gene or 
protein expression. This is in agreement with previous studies (Ulanova et al., 2005). 
Therefore it was confirmed that ER-27319 was not causing its effects via Syk inhibition. 
In order to find out additional information on the precise mechanism of action of ER-
27319 the authors of the PNAS publication entitled “ER-27319, an acridone-related 
compound, inhibits release of antigen-induced allergic mediators from mast cells by 
selective inhibition of Fcε receptor I-mediated activation of Syk” were contacted. The 
compound does not bind directly to Syk but instead binds to the ITAM of the FcεRI 
gamma subunit, thereby preventing the interaction between the Syk SH2 domains and the 
doubly phosphorylated ITAMs. In the study by Moriya et al. the compound did not prevent 
activation of Syk via binding to phosphorylated Igβ ITAMs, therefore implying a 
specificity in the interaction between ER-27319 and the ITAM of the FcεRI gamma 
subunit. However, Syk possesses high structural flexibility and can recognise a variety of 
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phosphorylated ITAMs that vary both in sequence and in the length of the intervening 
amino acids between the SH2 binding motifs (Table 4.4) (Kumaran et al., 2003). In a study 
by de Mol et al., the seven amino acids between the phosphorylated SH2 binding motifs 
YETL and YTGL of the FcεRI gamma chain ITAM were replaced by a non-peptidic 
flexible and a rigid propynylbenzoy linker of similar length (de Mol et al., 2005). Both 
ligands exhibited comparable affinities for Syk thereby indicating that the spacer region 
between the two phosphotyrosines do not contribute to binding. Therefore it was 
hypothesised that ER-27319 may also bind to additional ITAM-containing proteins other 
than that of the FcεRI gamma subunit. This hypothesis was developed into our model 
system. 
Several viral ITAM signalling domains have been previously described. These are, in 
general, thought to enhance viral pathogenesis by interfering with normal antigen receptor 
signalling. A study reported the presence of an ITAM signalling domain encoded within 
the β-retrovirus MMTV env gene which can associate with Syk and participates in virus-
induced mammary tumours (Katz et al., 2005; Ross et al., 2006). Mutation of this ITAM 
prevented the induction of tumours and altered patterns of oncogenic activation (Katz et 
al., 2005; Ross et al., 2006). In addition, the K1 protein of KSHV contains an ITAM 
sequence capable of binding to SH2 domain containing proteins (Lee et al., 1998). The 
EBV LMP2A also possesses an ITAM to which Syk can bind (Fruehling et al., 1997) and 
regulates downstream PI3K/Akt pathway signalling (Swart et al., 2000). Several other 
viruses including rhadinovirus, bovine leukaemia virus, Hantaan virus and African horse 
sickness virus contain ITAM domains. Therefore, due to the variety of viruses which 
express functional ITAMs, the possible presence of a conventional ITAM sequence or the 
“less stringent” ITAM-like sequence, Y-X-X-(L/I)-(Xn)-Y-X-X-(L/I), on the Ad5 capsid 
proteome was investigated. Two ITAM-like sequences were identified on the hexon 
protein. However, neither QWSYMHISGQDASEYLSPGLVQFARATETYFSL or 
ASTYFDIRGVLDRGPTFKPYSGTAYNAL conformed to the canonical ITAM sequence, 
having variation in the spacing between the Y-X-X-(L/I) motifs. However, the possibility 
of a direct interaction between ER-27319 and the Ad5 capsid could be further investigated 
using SPR. This could be performed by coating a biacore sensor chip with Ad5 and passing 
20 µM ER-27319 over the chip to assess potential binding. 
Rather than ER-27319 binding to a virus ITAM it was postulated that it could be binding to 
a cellular ITAM-containing protein and thereby disrupting efficient FX-mediated Ad5 
trafficking. The previously reported cellular proteins possessing an ITAM domain are 
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listed in Table 4.4. The majority of these are immunoreceptors and transmembrane adaptor 
molecules but several more ubiquitously expressed intracellular proteins are also included. 
Employing the NCI-60 database 
(http://dtp.nci.nih.gov/docs/misc/common_files/cell_list.html) as a tool to scan for the 
presence of ITAM-containing proteins in SKOV3 and A549 cells, it was found that the 
ezrin, radixin and moesin were the most likely candidates to be expressed in both cell 
types. The ERM family of proteins act as regulated “cross-linkers” between the plasma 
membrane and the cortical actin cytoskeleton. They arose from gene duplication in 
vertebrates and their structures are closely related, featuring a N-terminal membrane 
binding domain of approximately 300 amino acids known as FERM (Four point one Ezrin, 
Radixin, Moesin) and a C-terminal domain containing a major F-actin binding site 
(Funayama et al., 1991; Gary et al., 1995; Gould et al., 1989; Lankes et al., 1991). ERMs 
have widely distributed expression patterns. In vivo, ezrin is most highly enriched on the 
apical side of polarised epithelial cells, whilst radixin is abundant in the liver and moesin is 
predominantly found in endothelial cells but is also present in a subset of epithelial cells 
(Amieva et al., 1994; Berryman et al., 1993). Of note, ezrin and moesin can bind to 
heparin and the ezrin N-terminal domain can link syndecan-2, a HSPG, to the actin 
cytoskeleton (Granés et al., 2003; Lankes et al., 1988; Lankes et al., 1991). Previous work 
has demonstrated the expression of all three ERM proteins in a range of cultured epithelial 
and fibroblastic cells (Hayashi et al., 1999; Maeda et al., 1999). In this study qRT-PCR 
and western blot analysis confirmed the presence of ezrin, radixin and moesin in both 
SKOV3 and A549 cells. Both moesin and ezrin have been reported to directly interact with 
Syk in an ITAM dependent manner and mediate signalling by the leukocyte adhesion 
receptor P-selectin glycoprotein ligand 1 (Urzainqui et al., 2002). Therefore this family of 
ITAM-containing proteins were investigated as potential targets for ER-27319 induced 
effects on Ad5 infectivity. 
It is of interest that in the recent publication by Farmer et al. the authors speculate that 
p44/42 MAPK does not exert its effects on the subcellular localisation of integrins through 
a direct interaction but perhaps instead via an intracellular integrin activation protein such 
as talin, a protein which mediates integrin inside-out signalling by direct binding of its 
FERM domain to the cytoplasmic tail of integrins (Calderwood et al., 2002; Farmer et al., 
2009). However, currently this is only a hypothesis and requires additional study. Radixin 
also demonstrates integrin activation activity, being capable of binding to integrin αMβ2, 
thereby enhancing its adhesive activity (Tang et al., 2007). 
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We investigated whether ER-271319 in the absence or presence of Ad5 plus FX could alter 
the cellular distribution of ERM expression. In cultured epithelial cells ERMs are reported 
to be expressed both in the cytoplasm and at the plasma membrane where they are 
localised to actin rich regions such as microvilli, ruffling membranes, cell-cell borders and 
cleavage furrows (Hayashi et al., 1999). ERMs can exist in an inactive or active 
conformation (Gary et al., 1995). Binding to the membrane lipid phosphatidylinositol 4,5-
biphosphate (PIP2) results in the phosphorylation of a conserved threonine in the actin 
binding site and localisation of ERMs to actin-rich membrane extensions (Barret et al., 
2000; Hayashi et al., 1999). This also involves the small GTP-binding protein Rho (Matsui 
et al., 1998). In addition, ERM proteins are reported to be phosphorylated on tyrosine 
residues in vivo (Thuillier et al., 1994). Conversely, dephosphorlyation leads to their 
translocation to the cytoplasm (Fievet et al., 2004). It was hypothesised that as ERMs play 
a role in the regulation of the plasma membrane, cytoskeleton and signalling cascades, they 
may have a role in the early stages of Ad5 infection. Furthermore, it was postulated that 
ER-27319 could interfere with the efficient activation of ERMs, disrupting their function 
in virus infected cells. Unfortunately, from immunocytochemistry results analysing the 
distribution of ezrin, radixin and moesin in SKOV3 cells it was difficult to draw a clear 
conclusion as to whether ERM expression is altered in the presence of Ad5 or ER-27319 
compared to untreated control conditions. There is substantial variation in the expression 
of all three proteins in untreated cells at the different time points. For example with regards 
to ezrin staining at 0 min in control cells, the expression is evenly distributed throughout 
the cytoplasm, whereas at 180 min it is more concentrated around the nuclei. These 
disparities made it almost impossible to dissect any subtle changes which may be 
occurring.  
For immunocytochemisty and confocal experiments, cells were fixed in 4% PFA for 15 
min and permebilised in 0.1% Tween20 for 10 min prior to staining for the ERM markers. 
Ideally this would immobilise the antigens, whilst still retaining authentic cellular and 
subcellular architecture and permitting the antibody unhindered access. However it may be 
that these conditions were too severe. Alternative fixation methods were investigated. In a 
study by Hayahi et al. several fixatives were assessed for there ability to inactivate 
enzymes such as phosphatases without strong chemical modification and the effects on the 
distribution of C-terminally phosphorylated ERMs were analysed (Hayashi et al., 1999). 
The fixatives included 1% or 4% PFA, ethanol/acetone, methanol and trichloroacetic acid 
(TCA). The antibody used specifically recognised C-terminally phosphorylated ERMs but 
not non-phosphorylated ERM proteins. This antibody did not produce any 
  Chapter 4 | Results 
167 
immunofluorescence signals in PFA-treated cells and only gave rise to signals in TCA 
fixed cells indicating a sensitivity of these proteins to fixation methods (Hayashi et al., 
1999). It would be of interest in future work to employ this TCA method of fixation and 
analyse ERM distribution in SKOV3 and A549 cells. In addition, to specifically look at the 
role of ERM protein function in Ad5 infectivity, siRNA silencing or chemical inhibiton of 
these proteins would be attractive options.  
Finally, taking a different approach to investigating the mechanism of action of ER-27319 
the compounds structure was assessed. This is a synthethic, acridone-related compound 
(Moriya et al., 1997). Acridone (10H-acridin-9-one) is a tricyclic ring, having nitrogen at 
10th position and ketone group at 9th position (Figure 4.20). It’s derivatives have previously 
been reported to possess antiviral activity against both RNA and DNA viruses including 
Semliki forest, coxsackie B, Western equine encephalitis, herpes simplex, Epstein barr, 
pseudorabies, dengue viruses and cytomegalovirus (Akanitapichat et al., 2000; Itoigawa et 
al., 2003; Kramer et al., 1976; Lowden et al., 2003). Several different targets and 
metabolic points have been suggested as potential mediators of these effects. Acridone-
related compounds are reported as acting on nucleotides by intercalating viral DNA and 
RNA strands (Stankiewicz-Drogoń et al., 2010; Stankiewicz-Drogon et al., 2008), as DNA 
topoisomerase II inhibitors (Goodell et al., 2006) and as inducers of interferon (Storch et 
al., 1986). Moreover, a study by Zarubaev et al. demonstrated a direct antiviral effect of 
10-carboxymethyl-9-acridanone (cycloferon) against Ad6 in HepG2 cells (Zarubaev et al., 
2003). Treatment with the drug significantly reduced the yield of infectious virus in vitro 
and affected the structure of intranuclear virus-specific inclusions. The authors suggest the 
ability of the drug to suppress the late stages of the adenoviral cycle, late DNA replication 
and/or packaging into virions during viral assembly (Zarubaev et al., 2003). Many of the 
potential modes of action for these compounds appear to involve post-nuclear entry, 
transcription and replication stages of viral infection. In the current study it appears as 
though ER-27319 is causing effect prior to nuclear import, however due to its structural 
similarity to other acridone derivatives previously described, a similar nuclear target can 
not be ruled out and is of certain interest. 
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Acridone ER-27319
 
Figure 4.20. Compound structure. 
Chemical structure of acridone and its derivative ER-27319. 
The dynamics of intracellular transport depend on virus binding and extracellular signals 
transmitted via plasma membrane receptors being relayed by the corresponding signalling 
cascades and cellular proteins. In this study, several kinases including PKA, PI3K and 
p38MAPK were identified as critical to efficient FX-mediated Ad5 intracellular transport. 
These are no doubt part of extensive signalling pathways along with the reorganisation of 
cellular proteins required for effective viral infection. The identification of the compound 
ER-27319 as an inhibitor of Ad5 nuclear targeting and gene transfer was a novel finding, 
however a major challenge within this project was to identify the substrates of ER-27319, 
in order to obtain a comprehensive understanding of how this inhibitor was causing effect. 
Unfortunately within the time frame of this project it was not possible to conclude the 
precise mechanism of action of ER27319 and determine how it was causing such dramatic 
effects on Ad5 intracellular trafficking and nuclear targeting. Several aspects of this 
investigation warrant further study, such as the role of ERM proteins in Ad5 infection, as 
selective targeting of such cellular components or signalling pathways could have potential 
as antiviral therapies. Understanding the intricacies of Ad5 infection is a difficult process 
but will ultimately aid in the prediction and manipulation of the host response. 
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5.1 Introduction 
A large body of recent work has focused on precluding FX-mediated Ad5 transduction, by 
investigating strategies to block the direct interaction of the Ad hexon with the coagulation 
factor. Methods such as genetic manipulation of the virus capsid or polymer conjugated Ad 
complexes have been studied, as discussed earlier in this thesis (Alba et al., 2009; Short et 
al., 2010; Subr et al., 2009). The use of pharmacological agents including heparin, 
warfarin and X-bp in animal studies have highlighted the efficacy of a drug intervention 
approach, however such drugs are not ideal therapies in a gene therapy clinical setting due 
to anticoagulation properties and toxicity profiles (Atoda et al., 1998; Bradshaw et al., 
2010; Waddington et al., 2008). Less attention has been placed on investigating novel 
therapeutically viable pharmacological approaches to block Ad transduction in the 
presence of FX but this area may hold great promise. Therefore, this study was aimed at 
identifying an inhibitor of FX-mediated Ad5 transgene expression, with ultimately the in 
vivo utility of this approach. 
During the past two decades a fundamental change has occurred in the drug discovery 
process, with a growing trend toward the use of high throughput screens (HTS). HTS of 
large compound libraries in search of lead candidates is a phenomenon which has invaded 
a diverse range of fields, both in the pharmaceutical and academic sectors (Andersson et 
al., 2010; Inglese et al., 2007; Johnston et al., 2002). The aim being to test a great number 
of compounds against target molecules in a short period of time, by combining automation 
with translation of well defined traditional bench top assays into miniaturized 96-, 384- or 
1,536-microwell plate formats and large scale data analysis. HTS is a multilevel process, 
comprising several key stages; target validation, assay development, primary and 
secondary screening, data analysis, absorption, distribution, metabolism and excretion 
(ADME) investigation, toxicology assessments and generation of lead compounds 
(Johnston et al., 2002). The primary screen is therefore just the initial step of an integrated 
process (Figure 5.1). Here, a HTS strategy was devised in order to assay > 10,000 
compounds in search of those which prevented Ad5 transduction via the FX pathway.  
The well documented Ad5:FX interaction resulting in Ad5 binding to hepatocytes in vivo 
indicates that several steps of this pathway may serve as potential targets for intervention 
(Bradshaw et al., 2010; Kalyuzhniy et al., 2008; Vigant et al., 2008; Waddington et al., 
2008). The drugability of a given target is critical to the success of any HTS and the ability 
of X-bp to bind to the FX Gla domain and decrease Ad5 liver gene transfer in mice for 
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example, highlights the feasibility of the Ad5:FX pathway to be effectively modulated by a 
ligand (Liu et al., 2009; Waddington et al., 2008). Having a well defined target, this study 
commenced at the assay development stage in the HTS process. 
 
Assay development
Chemistry
Compounds Actives Hits Leads
Targets
SARs
Structural 
verificationSynthesis
HTS Follow-up Validation
Automation
 
Figure 5.1. Steps of the HTS process. 
Graphical summary of the integrated steps involved in the HTS process. 
A suitable starting library is of critical importance (Bleicher et al., 2003; McGovern et al., 
2002). Previously the generation of compounds was directed by chemical structures and 
selectivities rather than on pharmacological properties. In this regard, in vitro affinities 
were optimised at the expense of solubility, metabolic stability and permeability properties 
and often compounds which appear to be promising lead candidates are not always suitable 
for further medicinal chemistry exploration, which precludes their progression (Bleicher et 
al., 2003). In addition, seemingly attractive hits can fail to exhibit obedient structure-
activity relationships (SAR) which can lead to the termination of such compounds, as 
without a well defined target, SAR is the only available means of compound optimisation. 
Hits develop into lead compounds through comprehensive assessment of their chemical 
integrity, biological actions, synthethic assessibility, SAR and ADME properties 
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(Hodgson, 2001). Screening libraries of compounds with drug-like properties is preferable, 
possessing improved ADME and toxicity properties they are likely to reduce the number of 
false positives or nuisance compounds (cytotoxic, detergents or positively charged 
compounds) identified in the primary screen and the rate of attrition at the later stages. The 
library chosen for this screen was the Pharmacological Diversity Drug-like Set from 
Enamine (additional information describing this library, including chemical structures can 
be obtained from http://www.enamine.net). Design of this set was based on 
pharmacological properties rather than on the chemical structure of compounds. For each 
compound a profile of 3081 predicted pharmacological properties was generated by 
Enamine and any compounds possessing toxic signatures were removed, then 
pharmacological profiles were clustered for the rest of the structures, thereby generating a 
varied assortment of 10,240 low molecular weight (majority < 500 Da) drug-like 
compounds.  
Today, robust cell-based screening approaches are commonly used to identify biologically 
active compounds in viral screens (Andersson et al., 2010; Baldick et al., 2010; Basu et al., 
2011). Despite often being more labour intensive (production of large quantities of cells 
and virus, the inherent variability of assay performance due to differences in cell passage 
number and handling etc.) they have the benefit of more realistic screening parameters 
compared to virtual screening technologies, without a preconceived idea of the compounds 
mechanism of action or safety profile. Configuring assays to function within the 
constraints imposed by HTS (simple protocol with few steps, low volumes, microtitre plate 
format, short assay time, easily measured readout) can be difficult and only a subset of 
biological assays are amenable (Inglese et al., 2007). In this study the FX-mediated Ad5 
transduction pathway and routinely used cell-based infectivity protocols were exploited to 
design a robust Ad5 fluorescence reporter gene based HTS using SKOV3 cells (CARlow) in 
the presence of FX. 
Identification of a novel small molecule inhibitor of FX-mediated Ad5 transduction could 
have several benefits over alternative methods of liver detargeting. An attractive incentive 
for using a pharmacological approach to prevent Ad5 hepatic gene transfer, is that there is 
no requirement for genetic manipulation of Ad5 capsid proteins, which can often be very 
time consuming and interfere with large scale virus production (Alba et al., 2009). As for 
regulatory issues regarding the use of such viruses in the clinic, capsid modified Ad5 
vectors would require additional toxicology and safety studies to be performed. Regarding 
polymer conjugated Ad complexes, this process involves coating the entire capsid in a 
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synthetic shield, which may result in decreased affinity of the virus not only to FX but 
alternative native receptors. The use of alternative Ad serotypes devoid of FX binding is 
also a viable option, however a vast array of safety and clinical data has been obtained 
using Ad5, for which novel and less commonly used vectors lack. Identification of a safe 
compound which specifically blocks Ad5 binding to FX or FX-mediated Ad5 gene transfer 
may hold great promise for preventing unwanted liver transduction and decreasing Ad5 
related hepatoxicity in the clinical setting. 
As the screen is designed to identify inhibitors of FX-mediated Ad5 transduction, any hits 
may also have potential value as a treatment against naturally occurring disseminated Ad 
infection. In healthy individuals Ad infection is mostly self-limiting, however in immune 
comprised individuals (e.g. suffers of hereditary immunodeficiencies, AIDS patients or 
haematopoietic stem cell transplant recipients undergoing immunosuppressive treatment) 
Ads exploit the impaired immunological response and can cause more prolonged, severe 
and even life threatening disease. Infections can manifest in diverse clinical syndromes, 
ranging from upper and lower respiratory tract disease, (kerato)conjunctivitis or 
gastroenteritis to more serious complications including hemorrhagic cystitis, hepatitis, 
myocarditis, coagulopathy, encephalopathy, nephritis or multi-organ failure (Abzug et al., 
1991; Chuang et al., 2003; Echavarría, 2008; Straussberg et al., 2001). Disseminated Ad 
infections are often fatal, reaching a mortality rate of 50%, whilst pediatric transplantation 
patients are yet more prone to the disseminated disease, with mortality rates up to 83% in 
immunodeficient children (Chakrabarti et al., 2002; Munoz et al., 1998). Despite this, Ad 
can be detected in peripheral blood 3 weeks prior to the onset of clinical symptoms, 
thereby leaving a wide therapeutic window by which to treat the potentially life threatening 
disseminated infection (Lion et al., 2003). 
There are currently no formally approved antiviral agents available that specifically treat 
Ad infection. In some clinical cases cidofovir ((S)-1-(3-hydroxy-2-
phosphonylmethoxypropyl)cytosine) and ribavirin (1-β-d-ribofuranosyl-1,2,4-triazole-3-
carboxamide) have been employed and have demonstrated some efficacy against Ad 
infection (Lenaerts et al., 2006; Neofytos et al., 2007). Ribavirin is a purine nucleoside 
analogue that shows efficacy against RNA and DNA viruses (Lenaerts et al., 2006; 
Pawlotsky et al., 2004). Cidofovir is an acyclic nucleoside phosphonate analogue that is 
used as a broad-spectrum antiviral agent (Baba et al., 1987; De Clercq, 2003). However 
the efficacy of these compounds is contentious as they have not been rigorously tested in 
randomised controlled clinical trials for their efficacy in treating Ad infection (reviewed by 
Chapter 5 | Results 
174 
Lenaerts et al. (Lenaerts et al., 2008)). This suggests a gap in the market for a selective 
anti-adenoviral compound, as such potential screen hits may warrant investigation in this 
regard.  
In recent years, several low molecular weight compounds identified from HTS assays have 
shown successes in modulating viral functions (Baldick et al., 2010; Basu et al., 2011; 
Hoffmann et al., 2011; Larson et al., 2008; Micheva-Viteva et al., 2011; Mueller et al., 
2008; Thompson et al., 2010). One such study developed a fluorescence-based assay using 
hepatitis C virus (HCV) with a firefly reporter to screen 1 million small molecules for 
blockers of HCV entry and identified a potent and selective HCV inhibitor from the HTS 
process (Baldick et al., 2010). Another study employed 200,000 compounds and tested the 
library in a cell-based system to identify small molecule antagonists of HIV-1 latency 
(Micheva-Viteva et al., 2011). These reported successes highlight the feasibility of using a 
HTS to find an inhibitor of FX-mediated Ad5 transduction. 
Advancements in the understanding of the mechanisms underlying Ad5 liver transduction 
has created several targets for drug discovery. The aim of this study was to screen a 
pharmacologically diverse library of drug-like compounds to identify a safe inhibitor of 
FX-mediated Ad5 transduction. To efficiently ascertain whether compounds exert such 
biological activity, a robust fluorescence-based HTS was developed using SKOV3 cells 
(CARlow) seeded in a 384-well microplate format to analyse FX-mediated Ad5GFP 
infection. 
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5.2 Results 
5.2.1 Design and optimisation of an assay compatible with HTS 
It has been previously described in this thesis and several publications that co-incubation 
of Ad5 with 10 µg/ml FX causes a substantial increase in Ad5 transduction in vitro and in 
vivo compared to Ad5 alone (Bradshaw et al., 2010; Waddington et al., 2008). In this 
study, initial optimisation and validation experiments were performed to convert this 
frequently employed assay into a high throughput SKOV3 cell-based screen in order to test 
10,240 compounds for their ability to inhibit FX-mediated Ad5 gene transfer. 
5.2.2 Plates – 384-well assay format to increase assay robustness 
Several different types of well plates were tested for their suitability in the HTS assay set-
up. These included both 96- and 384-well formats; CellBIND 96-well flat clear bottom 
black, low volume 384-well flat clear bottom black, CellBIND® 384-well flat clear bottom 
black, 384-well optical imaging flat clear bottom black and Greiner Bio One 384 µ-clear 
flat bottom black cell culture microplates. 384 µ-clear flat bottom black cell culture 
microplates (catalogue number 781091, Greiner Bio One) were chosen for the HTS. The 
SKOV3 cells adhered to these plates and they allowed for high quality fluorescence 
imaging using the IN Cell Analyser 2000. Furthermore the 384-well set up increased the 
robustness of the assay, decreasing amounts of reagents required (cells, number of plates, 
volumes of media, compound, virus, FX and storage space etc.) and this format was time 
and cost effective. 
5.2.3 Cells – optimal seeding densities 
To examine the effects of cell density, SKOV3 cells were seeded at densities ranging from 
750 cell/well to 5000 cell/well in 384-well plates. At a density of 1500 cell/well the cells 
adhered to the plates, were not washed off during liquid dispensing and aspirating steps 
and were not over confluent at 72 h after seeding, thus allowing for clear image acquisition 
using the IN Cell Analyser 2000 and accurate segmentation of cells with the IN Cell 
Developer Toolbox V1.6 analysis software. Therefore a density of 1500 cell/well in 50 µl 
media was chosen for the HTS assay. Prior to starting the assay the cells were tested for 
mycoplasma infection and found to be negative.  
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5.2.4 Control-based method of normalisation 
In vitro FX has been reported to cause up to log-fold increases in Ad5 transduction 
compared to conditions in the absence of FX (Bradshaw et al., 2010; Parker et al., 2006; 
Waddington et al., 2008). When tested in this study in SKOV3 cells, 1000 vp/cell of Ad5 
in the presence of 10 µg/ml FX resulted in high levels of GFP expression, whilst in the 
absence of FX the levels were low (~41-fold difference) (Figure 5.2). GFP expression was 
treated as the primary readout, with clear positive and negative controls and a large signal 
window in which to investigate compounds inhibiting FX-mediated Ad5 gene expression. 
Therefore, this assay was very accommodating to the control-based method of 
normalisation and this method was chosen as standard approach for dealing with sources of 
HTS variability; fixed positive and negative controls on each plate, allowing for the 
normalisation of the test data to the controls and representation of data as percentage 
inhibition of FX-mediated Ad5GFP expression. 
5.2.5 Designing robotic liquid handling protocols 
As the compounds were dissolved in 100% DMSO it was important to investigate the 
levels of this organic solvent tolerable to the cells and the activity of the assay in order to 
minimise the number of dilution plates required and to facilitate assay automation. The 
impact of DMSO concentrations was examined prior to designing liquid handling 
protocols and the production of replicate mother plates. This was performed by manually 
infecting cells with 1000 vp/cell of Ad5 in the absence or presence of FX and increasing 
concentrations of DMSO (0.2 – 1%). A concentration of 1% DMSO was well tolerated by 
the cells as assessed by MTT assay and did not effect FX-mediated Ad5GFP expression 
after 48 h (Figure 5.2). Therefore, a final DMSO concentration of 1% was compatible with 
this assay.  
A major focus of the experiment was to design the robotic liquid handling protocols in the 
minimum number of steps possible, whilst still maintaining assay integrity in order to 
decrease random variability (e.g. errors which arise due to technical or instrumental issues) 
and systemic variability (e.g. errors which arise due to differences between reagent lots, 
buffer preparations or incubation times) that contribute to ‘noise’ associated with 
experimental data. Furthermore, this was a key factor in order to keep costs down, an 
important consideration when performing a HTS. Consequently, 32 mother plates were 
produced, in which compounds were at 100 µM in 100% DMSO, leaving the outer 
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columns 1, 2, 23 and 24 empty to later allow for easy incorporation of assay plate controls. 
In order to facilitate assay automation, daughter plates were produced, in which Ad5 was 
incubated with the compound or DMSO, whilst in the assay plate FX or serum free media 
alone was preincubated on the cells. The contents of the daughter plates were added to the 
relevant wells of the assay plates, followed by the control additions. This gave a final 
concentration of 1000 vp/cell of Ad5 in the absence or presence of 10 µg/ml FX plus 10 
µM compound. An important quality control feature of a HTS is good plate design. All 
assay plates contained an equal number of positive (16 wells of Ad5) and negative (16 
wells of Ad5+FX+DMSO) controls, the locations of which in columns 2 were reversed in 
column 23 in an attempt to reduce the influence of potential intra-plate positional and row 
effects (Figure 5.3). No positive or negative control or test wells were located on the outer 
most columns (1 and 24) to decrease intra-plate edge related variability. In an effort to 
monitor and reduce the influence of inter-plate variability and the incidence of false 
positives, three replicates of each plate containing the controls and test compounds were 
produced providing an n = 3 for each compound.  
In an additional attempt to aid assay automation, instead of washing cells and re-adding the 
compounds after 3 h incubation at 37˚C, an equal volume of media containing 20% serum 
was added to the cells, resulting in a final compound concentration of 5 µM in 10% serum 
containing media on the cells. At no point during the assay did the concentration of DMSO 
exceed 1% and for the majority of the time (~45 h) remained at 0.5%. Following 48 h 
incubation at 37˚C, the media was removed, the cells were washed in PBS and fixed in 4% 
PFA prior to staining with 10 µg/ml Hoechst 33342 and 10 µg/ml propidium iodide. 
Throughout the liquid handling steps the cells remained adherent to the plates and the 
fixation and staining provided good conditions for imaging.  
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Figure 5.2. Effect of DMSO on SKOV3 cell viability and assay activity. 
(A) SKOV3 cells were incubated with increasing concentrations of DMSO for 48 h and then 
a MTT assay was performed. (B) Cells were infected with 1000 vp/cell of Ad5 in the 
absence or presence of FX plus DMSO. Ad5 transgene expression was measured 48 h 
post-infection. *p<0.05 as compared to non-FX conditions as determined by one-way 
ANOVA and Dunnett’s multiple comparison post-test. Error bars represent SEM (n = 
3/group). 
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Figure 5.3. Assay plate layout. 
Schematic of the 384-well assay plate, highlighting the position of the positive and 
negative controls. Yellow = untreated controls, green = compounds, purple = negative 
controls and grey = positive controls. 
5.2.6 Design of imaging analysis conditions 
5.2.6.1 Acquiring 
The image acquisition settings on the IN Cell Analyser 2000 were developed and 
optimised to produce a robust assay delivering high quality fluorescence images. A single 
10x image of the centre of each well of the 384-well plate was captured of Hoechst 33342 
nuclear staining (40 ms exposure time), GFP expression (60 ms exposure time) and 
propidium iodide non-viable nuclear staining (45 ms exposure time). The conditions were 
optimised in order to capture both the MIN and MAX GFP control wells without saturation 
or under-exposure, whilst maximising the signal window. Fast hardware autofocus options 
were chosen, which optimise the quality of the images, and along with the short exposure 
times contributed to the speed of acquisition. An individual 384-well plate took 
approximately 15 min to image using the optimised automated conditions. Each acquisition 
captured thousands of cells (average > 3,500 cells per field of view), thus providing a 
reasonable size database by which to calculate results. 
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5.2.6.2 Analysis 
Images were analysed using IN Cell Developer Toolbox V1.6 software, a high content 
cellular analysis package that utilises a vast array of user-definable parameters, 
calculations, measures and output formats to allow for individualised assay analysis. The 
primary output measure of this assay was chosen as GFP intensity normalised to viable cell 
count per field of view. Therefore in order to obtain an accurate measure, precise 
segmentation of the cells and GFP was critical. Nuclear staining with Hoechst 33342 and 
non-viable nuclear staining with propidium iodide enabled per cell data to be obtained. As 
nuclei were more uniform in shape and more easily separated from one another than the 
heterogeneous SKOV3 cell population, the stained nuclei were first segmented based on 
size and shape, and then the segmented nuclei were used to seed the segmentation of 
individual cells (Figure 5.4). During the optimisation steps, the bright-field images of cells 
were also used as an approximate outline of cell shape. Cells were classed as viable or non-
viable depending on propidium iodide staining. GFP expression was segmented based on 
the signal intensity (Figure 5.4). Intensity-based measurements can fluctuate or decrease 
for a given set of plates depending on whether or not the plates were assayed on the same 
day, therefore it was important to perform preliminary checks of GFP intensity prior to 
starting the analysis on any given day. Several measures/classifications were defined and 
results were calculated. In order to prevent skewing of results due to compound toxicity 
non-viable cells were discarded from the analysis and a measure of GFP intensity per 
viable cell per field of view was calculated (Figure 5.5). Under optimised conditions each 
384-well plate took approximately 25 min to analyse with the IN Cell Developer Toolbox 
software. Sufficient viable cell counts and the positive and negative controls widely 
separated from each other allowed for a reproducible signal window (Figure 5.6). The 
signal was normalised to controls on each plate and the final readout reported as 
percentage inhibition of FX-mediated Ad5GFP expression. Low levels of GFP expression 
in the absence of FX in this CARlow cell line compared to in the presence of FX and the 
analysis design enabled consistently high signal-to-background ratios (calculated by the 
equation averageMAX/averageMIN control), a commonly used parameter employed to 
estimate the separation or range of an assay signal window (Sittampalam et al., 1997).  
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Figure 5.4. Design of image analysis conditions – signal window. 
SKOV3 cells were infected with 1000 vp/cell of Ad5GFP in the absence or presence of FX. 
At 48 h post-infection cells were fixed and stained with Hoechst 33342. Cells were imaged 
using the IN Cell Analyser 2000 and images were analysed using the IN Cell Developer 
Toolbox. Nuclei (blue), cells (pink) and GFP expression (green) were segmented based on 
their staining, size, shape and intensity. 10x magnification, scale bars = 50 μm. 
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Figure 5.5. Design of image analysis conditions – defining non viable cells. 
SKOV3 cells were infected with 1000 vp/cell of Ad5 in the absence or presence of 40 µM 
T0501-7827 (Enamine, Ukraine), a cytotoxic compound. After 48 h cells were fixed and 
stained with Hoechst 33342 and propidium iodide. Cells were imaged using the IN Cell 
Analyser 2000 and images were analysed using the IN Cell Developer Toolbox. Nuclei 
were segmented based on Hoechst 33342 staining and non-viable cells were segmented 
based on propidium iodide staining. Once parameters were defined, the IN Cell Developer 
Toolbox was used to calculate the number of viable cells. 10x magnification, scale bars = 
50 μm. 
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Figure 5.6. Testing screening control conditions. 
SKOV3 cells were infected with 1000 vp/cell of Ad5GFP in the absence or presence of FX. 
At 48 h post-infection cells were fixed and stained with Hoechst 33342, imaged using the 
IN Cell Analyser 2000 and analysed using Developer Toolbox. (A) Trellis heat map of the 
assay plate highlighting the plus and minus FX control conditions. (B) Quantification of 
GFP intensity normalised to the number of viable cells per field of view for the positive 
and negative control wells. *p<0.05 as compared to non-FX conditions. Error bars 
represent SEM (n = 16). 
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Table 5.1. Traditional screening assay versus the HTS format. 
 
Parameters Traditional  
screening assay 
High throughput  
screening assay 
Plate Up to 96 well, clear  384 well, black, clear bottom 
Cells 2x10
4
 1.5x10
3 
Virus 1000 – 10000 vp/cell 1000 vp/cell 
Well volume 200 μl 50 μl 
FX  10 μg/ml 10 μg/ml 
Liquid handling Manual 
Assay components added 
singly 
Robotic 
Assay components added 
simultaneously 
Compound stock Dry powder, individual tubes  Dissolved in DMSO, preplated 
Controls Row B Column 2 and 23 
Incubation times 3 h, 45 h 3 h, 45 h 
Reporter gene β-gal, GFP, luciferase GFP 
Data normalisation To protein content -
measured by BCA assay 
To % viable cells - imaging 
Hoescht 33342 and propidum 
iodide staining 
Detection method Victor Wallac2 IN Cell Analyser 2000, 
Developer Toolbox software 
Readout RLU/mg of protein GFP intensity/no. viable cells 
Toxicity analysed No  Yes 
No. screened 20-80 compounds/week  1000-3000 compounds/week 
 
5.2.7 Assay validation 
Using the assay conditions outlined above, the optimised HTS protocol was tested using a 
small subset of compounds selected from the Pharmacological Diversity Drug-like Set 
compound library in order to validate the assay format. Principle component analysis 
(PCA) plots were generated by Dr. Murray Robertson (University of Strathclyde, 
Glasgow), describing the diversity in chemical space of the 10,240 compounds from the 
library (Figure 5.7). Chemicals can be characterised by a wide range of ‘descriptors’. Here 
‘chemical space’, a term often used in place of ‘multi-dimensional descriptor space’, is a 
region defined by a particular choice of descriptors and the limits placed on them (Dobson, 
2004). In this instance these parameters included the molecular mass, lipophilicity and 
topological features of each compound. From this 80 compounds were initially chosen to 
assay based on the spread of compound chemical space within the library (compound I.Ds 
supplied in the appendices to this thesis). When the 80 compounds were plotted within a 
worldwide database for >80,000 various marketed and developmental drugs, the so called 
World Drug Index (WDI) (Derwent WDI, Derwent Information Ltd., 14 Great Queen 
Street, London, WC2B 5DF, U.K), compounds were in a relatively small area of chemical 
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space compared to the substantially larger dataset. As the compounds from this library are 
designed as ‘drug-like’ small molecules this was as expected. 
The 80 compounds were assayed on the same day across four 384-well plates to compare 
the variability of the assay format and reproducibility of inter and intra-plate controls 
(Figure 5.8). The positive and negative controls were positioned in columns 2 and 23 (as 
described in section 5.2.5) and 20 compounds were tested in triplicate across the plates. 
The assay provided a robust and reproducible assay signal window; in the presence of FX 
there was an approximate 16-fold increase in GFP intensity/no. of viable cells compared to 
conditions in the absence of FX. The Z’ factor is the most widely used method to assess 
HTS quality, being reflective of both the assay signal dynamic range and the data variation 
associated with the signal measurements (Zhang et al., 1999). The Z’ factor is calculated 
by the equation: 
Z’ = 1 – (3 X SD MAX CONTROL + 3 X SD MIN CONTROL) / (Average MAX CONTROL – Average MIN 
CONTROL)   
(SD = standard deviation) 
The individual Z’ factors from each of the four plates were 0.48, 0.6, 0.63 and 0.58 
(average = 0.57). The combination of a high signal-to-background ratio and an average 
Z’factor > 0.5 indicates the control-based method of data processing and hit identification 
strategy would be suitable for the HTS and the assay is robust and reliable. Whilst several 
of the 80 compounds in this screen caused a significant decrease in GFP intensity/no. of 
viable cells compared to plus FX conditions, only compound numbers 48 and 64 reached 
the 75% inhibition of FX-mediated Ad5 transduction cut-off, and as expected the majority 
of compounds were inactive in this assay (Figure 5.8). These data validate the HTS 
protocol and the activity of the Pharmacological Diversity Drug-like Set compound library. 
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Figure 5.7. Priniciple component analysis of the compound library. 
PCA plots of (A) the chemical spread of the 10,240 compounds in the library (blue), (B) 80 
of the most diverse compounds from within the set (red) and (C) the 80 diverse 
compounds (red) plotted against the WDI (green).     
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Figure 5.8. 80 compound screen in SKOV3 cells to validate the HTS method. 
A collection of 80 diverse compounds from the Pharmacological Diversity Drug-like Set compound library were tested on SKOV3 cells for their ability 
to inhibit FX-mediated Ad5 transduction using the HTS assay protocol. *p<0.05 compared to plus FX conditions as determined by one-way ANOVA 
and Bonferroni’s post-test. Error bars represent SEM (n = 3). 
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5.2.8 HTS to identify inhibitors of FX-mediated Ad5 gene transfer 
Based on the preliminary data and assay optimisation studies, 10,240 compounds from the 
Pharmacological Diversity Drug-like Set library were screened in the HTS at a single 
concentration of 10 µM in triplicate wells. Over 96 384-well assay plates were run 
throughout the screen over a period of several weeks. Employing a 75% inhibition of FX-
mediated Ad5GFP expression as the criterion for further evaluation, 288 compounds were 
identified as hits (Figure 5.9 and Figure 5.10). The vast majority of compounds screened in 
this assay were considered inactive, as defined by the assay parameters i.e. caused no 
inhibition (Figure 5.10). In total the number of compounds causing ≤ 0% inhibition of FX-
mediated Ad5GFP expression was 7,603, whilst 2,349 compounds appeared to cause some 
inhibition (> 0% < 75%) but did not reach the stringent 75% cut-off for selection for 
further screening (Figure 5.10).  
The 288 compounds resulting in over 75% inhibition equated to a ~2.8% hit rate for the 
HTS. In the presence of the 288 compounds FX-mediated Ad5GFP expression was 
significantly decreased compared to plus FX control conditions as determined by Student t-
tests (Figure 5.10B). However this 2.8% hit rate was higher than was expected (< 1% 
(Koresawa et al., 2004; Sills et al., 2002; Yarrow et al., 2003)), suggesting cytotoxic 
compounds or false positives from assay variation were included. Nonetheless, in an 
attempt to avoid missing potential hits the 288 compounds were selected for further 
analysis and their effects were re-evaluated in a secondary assay using a similar screening 
format.  
5.2.9 Enhancers of FX-mediated Ad5 gene transfer 
A number of the compounds screened in this assay caused a substantial increase in FX-
mediated Ad5GFP expression, with compounds enhancing Ad5 gene transfer by up to 10-
fold (Table 5.2 and Figure 5.11). Further study and statistical analysis of compounds which 
enhance Ad5 gene transfer was outside the scope of this study.   
Table 5.2. Summary of compounds enhancing FX-mediated Ad5 gene transfer. 
Fold 
increase 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 
8 
 
9 
 
10 
No. of 
compounds 
 
4370 
 
1945 
 
762 
 
273 
 
122 
 
67 
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Figure 5.9. HTS of the Pharmacological Diversity Drug-like Set. 
SKOV3 cells were infected with 1000 vp/cell of Ad5GFP in the absence or presence of FX plus 10 μM compound. At 48 h the cells from the 10,240 
compounds tested were fixed and stained with Hoechst 33342 and propidium iodide, then screened for their ability to inhibit FX-mediated Ad5GFP 
expression using the IN Cell Analyser 2000 and Developer Toolbox analysis software. Compounds causing > 75% inhibition, as indicated by the red 
line, are highlighted in blue. 
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Figure 5.10. HTS inhibitors of FX-mediated Ad5 gene transfer. 
(A) Graphical summary of HTS data, highlighting compounds causing > 75% inhibition in 
blue, those causing between 0 and 75% inhibition in light blue and those causing no 
inhibition in grey (B) The 288 compounds causing > 75% inhibition. Error bars represent 
SEM (n = 3/compound). 
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Figure 5.11. HTS enhancers of FX-mediated Ad5 gene transfer. 
Graphical summary of the HTS data showing the large number of compounds from the 
Pharmacological Diversity Drug-like Set which caused an increase in FX-mediated Ad5GFP 
expression. 
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5.2.10 HTS quality control 
Minimal assay signal variation and high signal-to-background ratios are important factors 
in HTS. There was a high signal-to-background ratio for each of the 32 sets of plates 
assayed, the minimum being 7.5:1 and in most cases were several fold higher with the 
average being 29.82 ± 3.93-fold (Table 5.3). The magnitude of the signal window and its 
reproducibility further confirms the suitability of this assay to the control-based method of 
data normalisation.  
A plot of the percent inhibition from the 32 sets of assay plates classified by plate row and 
the plate row median data value indicates that the assay was well behaved and the majority 
of compounds were inactive and exhibited activity levels similar to the plus FX control 
conditions (i.e. ≤ 0% inhibition of FX-mediated Ad5 gene transfer) (Figure 5.12). There 
was a minimal trend toward positional bias depending of the plate row, with every second 
row (rows B, D, F, H, J, L, N and P) having a increased median activity value compared to 
the next (rows A, C, E, G, I, K, M and O) (Figure 5.12). Systemic positional bias such as 
row, column or edge effects can result in false positives or negatives in such large datasets. 
Therefore all 288 compounds identified as hits from the HTS were selected for further 
analysis to minimise the risk of bypassing potential true hits.  
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Table 5.3. HTS data quality control review.  
A summary of the signal-to-background ratios for each of the 32 sets of 384-well plates 
assayed. 
Plate I.D. Signal-to-background ratio 
 
1 13.26 
2 15.93 
3 50.25 
4 20.03 
5 25.22 
6 40.05 
7 30.00 
8 21.89 
9 52.30 
10 7.54 
11 20.53 
12 32.32 
13 9.81 
14 8.73 
15 10.02 
16 17.55 
17 15.46 
18 15.04 
19 12.69 
20 38.65 
21 35.43 
22 35.93 
23 97.81 
24 13.57 
25 10.21 
26 36.48 
27 9.68 
28 37.69 
29 38.57 
30 27.96 
31 61.401 
32 92.14 
 
Average 
 
 
29.81771 ± 3.93 
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Figure 5.12. Plate positional effects. 
(A) Graphical summary of the HTS data categorised by plate row A to P. Each row is 
separated by colour. (B) Plot of plate row median percentage inhibition of FX-mediated 
Ad5GFP expression with the median trendline. 
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5.2.11 Secondary screening of compounds 
In the secondary assay the 288 most active compounds from the initial screen were retested 
at the same concentration of 10 µM in triplicate wells using the same assay format. The 
secondary screen was repeated twice on separate occasions. On completion of these assays 
the majority of compounds described as hits from the primary screen were disqualified as 
false positives; either not causing any inhibition (103 of the 288 compounds – 36%) or as 
causing less than 75% inhibition of FX-mediated Ad5 gene transfer (167 of the 288 
compounds – 58%) (Figure 5.13). Several marginal hits from the primary screen did not 
reach the cut-off of 75% inhibition when retested, with 28 of the 288 compounds causing 
50-75% inhibition (Figure 5.13). A total of 17 compounds were identified as reproducibly 
causing greater than 75% inhibition in this assay and causing a significant decrease 
compared to plus FX conditions as determined by one-way ANOVA and Dunnett’s 
multiple comparison post-test. Therefore these preliminary hits were selected for further 
analysis (Figure 5.14). 
5.2.12 Effects of preliminary hits on cell viability 
The 17 compounds identified as preliminary hits from the HTS assays, were assessed for 
effects on cell viability by propidium iodide nuclear staining and MTT assay. Two of the 
compounds were found to be toxic to cells (making a total of 3 of the 288 compounds in 
the secondary screen causing cytotoxicity - ~1%) (Figure 5.15). Therefore, a further two 
compounds were disqualified from the preliminary hit list and the remaining 15 
compounds were selected for further analysis and manual testing. 
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Figure 5.13. Secondary screen. 
(A) The 288 active compounds from the HTS were rescreened in a secondary assay using 
the same format as before. Compounds causing > 75% inhibition are highlighted in blue. 
(B) Inhibitors of FX-mediated Ad5GFP expression categorised by the percentage inhibition 
and separated by colour. 
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Figure 5.14. Preliminary hits. 
The 17 compounds which caused > 75% inhibition in the secondary screen. Error bars 
represent SEM (n = 3/compound). 
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Figure 5.15. Effects of preliminary hits on cell viability. 
SKOV3 cells were incubated with 10 μM compound for 3 h, followed by incubation with 5 
μM compound for a further 45 h when cell viability was assessed. (A) Cells were fixed in 
4% PFA and stained with Hoechst 33342 and propidium iodide. Cells were imaged using 
the IN Cell Analyser 2000 and total cell counts and viable cell counts were performed 
using the IN Cell Developer Toolbox software. (B) MTT assay was performed. *p<0.05 as 
compared to control conditions as determined by one-way ANOVA and Dunnett’s 
multiple comparison post-test. Error bars represent SEM (n = 3/compound). 
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5.2.13 Manual testing of preliminary HTS hits 
In order to confirm the activity of the 15 compound hits from the HTS it was important to 
test them in the standard 96-well manual assay format, without the use to assay automation 
such as robotic liquid handling equipment and high content cellular screening analysis 
equipment including the IN Cell Analyser and IN Cell Developer Toolbox software. This 
assay was repeated three times. This assay further narrowed down the preliminary hits to 
five compounds validated as causing > 75% inhibition of FX-mediated Ad5 gene transfer 
(Figure 5.16). The five inhibitors were identified as T5424837 (abbreviated to T’837), 
T5550585 (T’585), T5660138 (T’138), T0503-0831 (T’0831) and T5960817 (T’817) from 
the Pharmacological Diversity Drug-like Set library. The compounds had molecular 
weights ranging from 334 to 423 Da (Figure 5.16).  
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Figure 5.16. Manual testing of preliminary hits. 
SKOV3 cells seeded in 96-well plates were infected with 1000 vp/cell of Ad5GFP in the 
absence and presence of FX plus 10 μM compound in 100 μl serum free media. After 3 h 
100 μl media containing 20% serum was added to cells. After 48 h cells were washed in 
PBS and lysed. GFP expression from the cell lysates was analysed using the Victor Wallac2 
plate reader at 450 nm absorbance. Blue = compounds causing > 75% inhibition, grey = no 
inhibition and navy = < 75% inhibition. Error bars represent SEM (n = 4/compound). 
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Figure 5.17. Structures of the 5 candidate hit compounds. 
The chemical structures of the 5 compounds identified as consistently causing > 75% 
inhibition of FX-mediated Ad5 gene transfer. 
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5.2.14 IC50 determination of the candidate hit compounds 
In an attempt to rank the compounds by percentage inhibition and potency of the effect, 
eight serial 2-fold dilutions of each of the five compounds were prepared and assayed on 
SKOV3 cells with FX-mediated Ad5 transgene expression as the readout. Instead of using 
Ad5GFP, Ad5lacZ was employed in this assay and this did not hinder the compounds 
activity, as assessed by % inhibition of FX-mediated Ad5 transgene expression, indicating 
their effects are independent of the viral reporter gene. All compounds ablated FX-
mediated Ad5 transduction at the top concentrations of 10 and 20 µM, having IC50 values 
below 4.5 µM. Compound T’817 was the most potent with an IC50 value of 0.47. The other 
four compounds produced very similar dose response curves, with low levels of inhibition 
at the lowest concentration of 0.15 µM. 
5.2.15 Effect of candidate hit compounds on FX-mediated Ad5 intracellular 
transport 
In order to gain more information of the mechanism of action of the five hit compounds, 
their effects on fluorescently-labelled Ad5 trafficking in the presence of FX was assessed 
in SKOV3 cells. Compounds were tested at 10 µM and effects were analysed at 0, 15, 60 
and 180 min time points. Apart from compound T’817 none of the hits caused a substantial 
decrease in Ad5 binding to the cell surface as assessed visually. However, intracellular 
trafficking at all subsequent time points appeared to be disrupted by each of the inhibitors, 
with the most severe effects seen with T’817. Instead of forming a punctuate spot at the 
MTOC by 60 min, the virus was more diffusely situated in the perinuclear region in the 
presence of each of the compound compared to the plus FX conditions. When the 
percentage of cells with which the virus particles colocalised with the MTOC were 
quantified it was found that colocalisation was significantly reduced at 15, 60 and 180 min 
with all inhibitors. These data from visual assessments of viral trafficking assays indicate 
that the compound T’817 decreases cellular binding, whilst the other four compounds 
T’837, T’585, T’138 and T’0831 are causing their principle effect post-cell binding and 
disrupt intracellular trafficking to the nucleus.   
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(B) 
Name Compound I.D. IC50 
T’817 T5960817 0.47 
T’837 T5424837 2.47 
T’585 T5550585 2.78 
T’138 T5660138 2.02 
T’0831 T0503-0831 4.47 
 
Figure 5.18. IC50 determination of the candidate hit compounds. 
(A) Cells were infected with 1000 vp/cell of Ad5lacZ in the absence or presence of FX plus 
0.15, 0.3, 0.6, 1.25, 2.5, 5, 10 or 20 μM compound in 100 μl serum free media. After 3 h 
100 μl media containing 20% serum was added to cells. Transgene expression was 
measured 48 h post-infection. Data was normalised to minus and plus FX control 
conditions and represented at percentage inhibition. Error bars represent SEM (n = 
4/compound). (B) Table represents the IC50 values for each of the compounds. The IC50 
was calculated by fitting a 4-parametre logistic non-linear regression model equation 
using MasterPlex ReaderFit analysis software (Hitachi Solutions America, Ltd., MiraiBio 
Group). 
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Figure 5.19. Effects of candidate hits on FX-mediated Ad5 intracellular trafficking. 
Cells were incubated with 10,000 vp/cell of Alexa488-labelled Ad5 (green) in the presence 
of FX and 10 μM compound for 1 h at 4°C, followed by incubation at 37°C for 0, 60 or 180 
min prior to staining for pericentrin (red). Images were captured on a confocal 
microscope at 63x magnification, scale bar = 20 μm, applicable to all panels. White arrows 
highlight examples of Ad5 accumulation at the MTOC. 
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Figure 5.20. Effect of candidate hits on Ad5 colocalisation with the MTOC. 
The percentage of SKOV3 cells with complete colocalisation of Ad5 with pericentrin was 
calculated by analysing at least 5 separate 40x microscope fields per experimental 
condition. *p<0.05 as compared to control conditions at the individual time points as 
determined by one-way ANOVA and Dunnett’s multiple comparison post-test. Error bars 
represent SEM (n=5/condition). 
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5.2.16 Structural analysis and determination of hit compounds 
Structural analysis of the compounds and follow up library design was performed by 
Dmytro Kovalskyy (Enamine, Ukraine). Structural analysis of the five candidate hits 
revealed that compounds T’817 and T’0831 may have bias toward promiscuity (Baell et 
al., 2010; McGovern et al., 2002). T’0831 had several hydrophobic features in a very 
compact spatial shape, which can confer bias toward hydrophobic cavities on protein 
surfaces. This could be the source of the observed activity and therefore may be unlikely to 
produce highly specific and potent interactions. On reorder from Enamine, compound 
T’817 no longer showed any inhibition of FX-mediated Ad5 gene transfer. This may be a 
result of impurities within the initial batch, decomposition over time attributing to the 
activity or the promiscuous nature of the compound (Baell et al., 2010; McGovern et al., 
2002). On the other hand, upon batch reorder the effects of compounds T’585, T’138 and 
T’837 were reproducible and furthermore they display certain common structural features 
which increased their chances to be true positives and may indicate a common mode of 
action. Therefore, T’817 and T’0831 were no longer investigated in this study and 
additional work focused on validating T’585, T’138 and T’837. 
A pharmacophore model is one which represents the key physico-chemical interactions 
that mediate biological activity (Acharya et al., 2011). An initial pharmacophore model 
based on T’585, T’138 and T’837 was generated and a follow up library designed around 
each compound. The model was established in collaboration with Dmytro Kovalskyy 
(Enamine, Ukraine). Compounds T’585 and T’138 share a similar 3-phenyl-5-methlene-
1,2,4-oxadiazole moiety, whereas T’138 and T’837 have similar substituted condensed 
heterocyclic systems bridged to a 5-membered heterocyclic ring via two atom linkers 
(Figure 5.21). Hence, compound T’138 has features that overlap with both the other two 
hits. In an attempt to align all three molecules simultaneously, a pharmacophore hypothesis 
was suggested (Figure 5.21). The minimal core can be defined as two heterocyclic moieties 
bridged via 1-2 atom linker. The first moiety is a 5-membered electron ring heterocycle 
which may serve as a H-bond acceptor as well as a participant in Van der Waals contacts 
and the second moiety is larger by volume, lipophilic, condensed heterocycle that may 
serve as bulk Van der Waals contributor. The quinazoline (two fused six-membered 
aromatic rings; a benzene ring and a pyrimidine ring) and 1,3-benzodiaxane of T’138 and 
T’837, respectively, are examples of this. The 4-nitro-3,5-dimethyl-1,2-pyrazole of T’585 
is a bulky group that also obeys this model. An additional enforcement is provided by 
substitutions on both sides of the minimalist core. With T’585 additional interaction is 
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achieved by m-Cl-phenyl group attached to 5-position of oxazole. With T’837 2-phenyl 
and 5-Br groups of 1,3-benzodiaxane moiety can be a source of extensive van der Waals 
contacts. Finally, T’138 has substitutions on both heterocyclic moieties. Based on these 
considerations, additional compounds that resemble the minimalistic core with various 
substitutions on the periphery were identified in Enamines stock collection. 28 compounds 
were selected as a follow up library. 
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Figure 5.21. Structural alignments. 
(A) T’585 (green) with T’138 (blue) (B) T’138 (blue) and T’837 (red). Zones of high 
topological identity are highlighted. (C) Structural alignment of all three hits. Common 
minimal pharmacophore core is shown: 5-membered heterocycle with hydrogen bond 
acceptor and aromatic feature linked to a bulky lipophylic feature. Figure provided by 
Dmytro Kovalskyy (Enamine, Ukraine). 
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5.2.17 Assessing the activity of hit T5424837 analogues 
In an attempt to further validate the activity of T’837 and to perform some preliminary 
SAR analysis, T’837 and seven chemically related compounds were ordered from Enamine 
and tested for their ability to decrease Ad5 gene transfer in the presence of FX. As in 
previous experiments, T’837 decreased FX-mediated Ad5 transduction in SKOV3 cells 
(Figure 5.22). All of the analogues caused inhibition ranging from 35 to 85% (Figure 5.22). 
Three compounds T’5243639 (T’639), T’5306163 (T’163) and T’5677956 (T’956) 
resulted in levels of inhibition similar to the parent compound (Figure 5.22 and Figure 
5.23). These data validates the parent T’837 compound and suggests potential for more 
potent analogues.  
In an attempt to rank the compounds based on inhibition and potency, the IC50 of T’639, 
T’163 and T’956 were determined and compared to the parent compound. All inhibitors 
produced similar dose response curves, with values ranging from ~1 to 5 µM (Figure 
5.22A and B). The IC50 for T’837 (2.35 µM) was very similar to the previously tested batch 
of compound (2.47 µM). T’956 caused the greatest level of inhibition and had an IC50 of 3 
µM, therefore this analogue, in addition to T’837 was chosen for further studies. This 
compound is structurally very similar to the parent, with the addition of a benzyl ring 
(Figure 5.22B). 
 
Chapter 5 | Results 
210 
 
 
 
T5424837 Analogue Set
0
10
20
30
40
50
60
70
80
90
T'837 T'639 T'261 T'982 T'163 T'421 T'571 T'956%
 
In
hi
bi
tio
n
 
o
f F
X-
m
ed
ia
te
d 
Ad
5 
tr
an
sd
u
ct
io
n
*
*
*
*
%
 
In
hi
bi
tio
n
 
o
f F
X-
m
ed
ia
te
d 
Ad
5 
tr
an
sd
u
ct
io
n
 
Figure 5.22. Assessing the activity of T’837 analogues. 
Cells were infected with 1000 vp/cell of Ad5lacZ in the absence or presence of FX plus 10 
μM compound T’837 or 7 of its chemical analogues in 100 μl serum free media. After 3 h 
100 μl media containing 20% serum was added to cells. Transgene expression was 
measured 48 h post-infection. Data was normalised to minus and plus FX control 
conditions and represented as percentage inhibition. *p<0.05 as compared to the parent 
compound T’837 conditions as determined by one-way ANOVA and Dunnett’s multiple 
comparison post-test. Error bars represent SEM (n = 4/compound). 
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Figure 5.23. Chemical structures of T’837 analogues. 
The structures of T’837 and 7 chemically related compounds are shown. The analogues 
are categorised by their percentage inhibition of FX-mediated Ad5 transduction in SKOV3 
cells relative to the parent compound T’837. 
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Name Compound I.D. IC50 
T’837 T5424837 2.35 
T’163 T5306163 1.03 
T’956 T5677956 3.02 
T’639 T5243639 5.22 
 
(C) 
 
 
Figure 5.24. IC50 determination of compound T’837 and analogues.  
(A) Cells were infected with Ad5 in the absence or presence of FX plus 0.1, 0.5, 1, 5 or 10 
μM T’837 or chemically related compounds in 100 μl serum free media. After 3 h 100 μl 
media containing 20% serum was added to cells. Transgene expression was measured 
after 48 h. Data was normalised to minus and plus FX control conditions and represented 
as percentage inhibition. Error bars represent SEM (n = 4). (B) Table represents the IC50 
values for each of the compounds. The IC50 was calculated by fitting a 4-parametre logistic 
non-linear regression model equation using MasterPlex ReaderFit analysis software. (C) 
Structures of T’837 and T’956. 
T’837 T’956
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5.2.18 Assessing the activity of hit T5660138 analogues  
The ability of T’138 to inhibit Ad5 transduction in the presence of FX was compared to 
that of 10 chemically related compounds purchased from Enamine. All compounds 
possessed the same basic structure as the T’138 parent, in addition to having several extra 
peripheral groups. This allowed for further validation of T’138 whilst simultaneously 
investigating key functional groups within its structure. Several of the analogues (T’287, 
T’489, T’137 and T’432) caused no inhibition (Figure 5.25 and Figure 5.26). The three 
compounds T’494, T’136, and T’376 inhibited FX-mediated Ad5 transduction to similar 
levels as the parent compound (~95 to 100%) (Figure 5.25 and Figure 5.26). 
Next, serial dilutions (ranging from 10 to 0.1 µM) of the three most active analogues and 
T’138 were prepared and assayed in SKOV3 cells in an effort to grade the compounds in 
terms of percentage inhibition and potency of the effect. From this analysis, T’136 was 
found to be the most potent, having an IC50 value of 1 µM compared to 4.01 µM for the 
parent, 4.91 µM for T’376 and 5.33 µM for T’494. T’136, a m-Cl substituted analogue, 
showed 4-fold improved IC50 suggesting favourable hydrophobic contacts with the 
receptor and was the most effective compound in this assay, therefore it was selected for 
further investigation in conjunction to the parent T’138. 
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Figure 5.25. Assessing the activity of T’138 analogues. 
Cells were infected with 1000 vp/cell of Ad5lacZ in the absence or presence of FX plus 10 
μM compound T’138 or 10 of its chemical analogues in 100 μl serum free media. After 3 h 
100 μl media containing 20% serum was added to cells. Transgene expression was 
measured 48 h post-infection. Data was normalised to minus and plus FX control 
conditions and represented as percentage inhibition. *p<0.05 as compared to the parent 
compound T’138 conditions as determined by one-way ANOVA and Dunnett’s multiple 
comparison post-test. Error bars represent SEM (n = 4/compound).  
Chapter 5 | Results 
215 
T’494
T’138
T’287
T’197
T’489 T’137 T’432
T’136
T’477
T’376
Analogue inhibition ≥ T’138 inhibition
Analogue inhibition ≤ T’138 inhibition
Parent compound
T’043
 
Figure 5.26. Chemical structures of T’138 analogues. 
The structures of T’138 and 10 chemically related compounds are shown. The analogues 
are categorised by their percentage inhibition of FX-mediated Ad5 transduction in SKOV3 
cells relative to the parent compound T’138. 
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 (B) 
Name Compound I.D. IC50 
T’138 T5660138 4.01 
T’376 T6314376 4.91 
T’494 T7008494 5.33 
T’136 T5660136 1.00 
 
(C) 
 
Figure 5.27. IC50 determination of compound T’138 and analogues.  
(A) Cells were infected with Ad5 in the absence or presence of FX plus 0.1, 0.5, 1, 5 or 10 
μM T’138 or the most active analogues in 100 μl serum free media. After 3 h 100 μl media 
containing 20% serum was added to cells. Transgene expression was measured after 48 h. 
Data was normalised to minus and plus FX control conditions and represented as 
percentage inhibition. Error bars represent SEM (n = 4/compound). (B) Table represents 
the IC50 values for each of the compounds. (C) Structures of T’138 and T’136. 
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5.2.19 Assessing the activity of hit T5550585 analogues  
The third hit compound T’585 along with 11 additional chemical analogues were studied. 
As previously shown T’585 ablated FX-mediated Ad5 transduction (Figure 5.16 and 
Figure 5.28), as did another closely related compound T’402 (Figure 5.28 and Figure 5.29). 
Of the remaining 10 analogues, 5 compounds (T’006, T’327, T’011, T’009 and T’883) 
showed some inhibition of Ad5 gene transfer but to significantly lower levels than the 
parent, whilst 5 compounds (T’756, T’001, T’820, T’238 and T’036) resulted in no 
inhibition (Figure 5.28).  
Compounds T’402 and T’585 are structurally very similar with only a change in the 
positioning of a chlorine atom (Figure 5.29). In order to investigate whether this minor 
chemical alteration could affect the activity of the compound, dose response curves were 
generated comparing the two most active inhibitors in this series. Whilst the shape of the 
dose response curve was very similar for both compounds, T’402 was slightly more potent, 
producing an IC50 value of 4.43 µM versus 4.67 µM of T’585 (Figure 5.30). Due to the 
effect of this compound, T’402 along with T’585 was selected for additional 
experimentation. 
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Figure 5.28. Assessing the activity of T’585 analogues. 
Cells were infected with 1000 vp/cell of Ad5lacZ in the absence or presence of FX plus 10 
μM compound T’585 or 11 of its chemical analogues in 100 μl serum free media. After 3 h 
100 μl media containing 20% serum was added to cells. Transgene expression was 
measured 48 h post-infection. Data was normalised to minus and plus FX control 
conditions and represented as percentage inhibition. *p<0.05 as compared to the parent 
compound T’585 conditions as determined by one-way ANOVA and Dunnett’s multiple 
comparison post-test. Error bars represent SEM (n = 4/compound). 
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Figure 5.29. Chemical structures of T’585 analogues. 
The structures of T’585 and 11 chemically related compounds are shown. The analogues 
are categorised by their percentage inhibition of FX-mediated Ad5 transduction in SKOV3 
cells relative to the parent compound T’585. 
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 (B) 
Name Compound I.D. IC50 
T’585 T5550585 4.67 
T’402 T5572402 4.43 
 
(C) 
T’585 T’402
 
Figure 5.30. IC50 determination of compound T’585 and analogue.  
(A) Cells were infected with Ad5 in the absence or presence of FX plus 0.1, 0.5, 1, 5 or 10 
μM T’585 or its analogue T’402 in 100 μl serum free media. After 3 h 100 μl media 
containing 20% serum was added to cells. Transgene expression was measured after 48 h. 
Data was normalised to minus and plus FX control conditions and represented as 
percentage inhibition. Error bars represent SEM (n = 4/compound). (B) Table represents 
the IC50 values for each of the compounds. (C) Structures of T’585 and T’402.  
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5.2.20 Investigation of compound effect on Ad5:FX binding 
To investigate if the three hit compounds (T’837, T’138 and T’585) and their active related 
analogues (T’956, T’136 and T’402) were interfering with Ad5 binding to FX, SPR 
analysis was performed with the assistance of Dr. Sharon Kelly (University of Glasgow). 
FX was covalently immobilised on a biosensor chip and running buffer, 10 µM compound 
or an equivalent volume of DMSO was passed over the chip in order to assess if the 
compound was binding directly to FX (Figure 5.31). Directly after injection of each 
compound the chip was regenerated with EDTA and running buffer. There was a 
negligible increase in response units (average < 5 RU) after injection of each of the six 
compounds (Figure 5.31)  However this was thought likely to be the result of the injection 
process and not due to a true interaction between the compound and the FX bound to the 
chip. 
In order to investigate if the compound was interacting with the virus and thereby 
hindering Ad5 binding to FX, 10 µM compound or an equivalent volume of DMSO was 
preincubated with Ad5. Ad5 in the presence of each of the six compounds or DMSO was 
injected over the FX on the chip. Under Ad5 plus DMSO control conditions, there was a 
large increase in response units (up to ~60 RU), indicating virus binding to the FX 
immobilised on the chip (Figure 5.32). When Ad5 in the presence of each of the six 
compounds was passed over the chip, the increase in response units remained at similar 
levels (Figure 5.32).  These data suggest that incubation of Ad5 with the transduction 
inhibitors T’837, T’138, T’585 T’956, T’136 and T’402 does not interfere with Ad5 
binding directly to FX. 
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Figure 5.31. SPR analysis of compound binding to FX. 
Sensorgram of 10 μM T’837, T’138, T’585 T’956, T’136 and T’402 injected over FX 
immobilised to a biosensor chip for ~200 sec at a flow rate of 30 μl/min. Sensorgrams are 
subtracted for the control DMSO injection. 
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Figure 5.32. Effect of compounds on Ad5 binding to FX by SPR. 
Sensorgrams of Ad5 in the presence of 10 μM T’837, T’138, T’585 T’956, T’136 and T’402 
or DMSO injected over FX for ~200 sec at a flow rate of 30 μl/min. 
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5.2.21 Effect of hit compounds on FX-mediated Ad5 cellular binding 
To quantitatively assess if any of the six hit compounds, T’837, T’138, T’585 T’956, 
T’136 and T’402, caused their effect on Ad5 infectivity at the stage of Ad5:cellular 
binding, SKOV3 cells were incubated with 5000 vp/cell of fluorescently labelled Ad5 in 
the absence or presence of FX plus 10 µM compound for 1 h at 4˚C. Of the six compounds, 
T’138 and T’136 caused a significant decrease in FX-mediated Ad5 cell binding compared 
to plus FX conditions (Figure 5.33). This equated to ~25 % (T’138) and ~40% (T’136) 
inhibition of FX-mediated binding when normalised to minus and plus FX control 
conditions. The other compounds (T’837, T’956, T’585 and T’402) caused no significant 
difference compared to conditions in the presence of FX (Figure 5.33). 
5.2.22 Effect of compounds on CAR-mediated Ad5 transduction 
In order to assess if the compounds could block Ad5 transduction via the classical in vitro 
receptor CAR in addition to FX-mediated transduction, A549 cells were incubated with 
1000 vp/cell of Ad5 in the presence of 10 µM T’837, T’138, T’585 T’956, T’136 and 
T’402 with and without FX (Figure 5.33). Transgene expression was measured after 48 h. 
A549 cells express significant levels of CAR (Hidaka et al., 1999), therefore are a 
commonly used cell line to study CAR-mediated transduction, whilst also being positive 
for HSPGs and thus susceptible to FX-mediated Ad5 transduction (Bradshaw et al., 2010). 
Under control conditions, Ad5 transduction was significantly increased in the presence of 
FX (~6 fold) (Figure 5.33). All six compounds ablated Ad5 transduction in the absence and 
presence of FX. This data shows the ability of all six compounds to inhibit both CAR and 
FX-mediated Ad5 gene transfer. 
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Figure 5.33. Effect of compounds on FX-mediated Ad5 binding to SKOV3 cells and 
transduction in A549 cells. 
Binding of 5000 vp/cell of Ad5 to SKOV3 cells for 1 h at 4˚C in the absence or presence of 
FX plus 10 μM compound was analysed. (B) A549 cells were infected with Ad5 in the 
absence or presence of FX plus 10 μM compound in 100 μl serum free media. After 3 h 
100 μl media containing 20% serum was added to cells. Transgene expression was 
measured after 48 h. *p<0.05 as compared to plus FX or #p<0.05 as compared to minus 
FX conditions as determined by one-way ANOVA and Dunnett’s multiple comparison 
post-test. Error bars represent SEM (n = 4/condition). 
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5.2.23 Effect of compounds on Ad5 transduction in vivo 
To investigate whether the compounds were active in vivo and decreased Ad5 transduction 
and liver transduction, MF1 mice were injected intravenously with a high dose of 1 x 1011 
vp/mouse of Ad5 luciferase in the absence or presence of 10 µM T’138, T’136, T’585, 
T’402, T’837, T’956 or an equivalent volume of DMSO. Luciferase transgene expression 
was visualised by whole-body bioluminescence imaging and quantified 48 h after 
administration. Mice were injected on two separate days using an identical experimental 
procedure and the data pooled from both experiments. Group sizes: PBS n = 7, Ad5 n = 6, 
Ad5+DMSO n = 6, Ad5+T’138 n = 6, Ad5+T’136 n = 7, Ad5+T’837 n = 7, Ad5+T’956 n 
= 6, Ad5+T’585 n = 7 and Ad5+T’402 n = 6. As expected, Ad5 targeted the liver as 
evidenced by the high levels of luciferase expression visually and quantitatively assessed by 
whole-body bioluminescence imaging at 48 h post-injection (Figure 5.34 and Figure 5.35). 
There was no significant difference seen in the Ad5 plus DMSO control group, indicating 
that the vehicle did not cause an effect on Ad5 transduction in vivo (Figure 5.34 and Figure 
5.35). However in the presence of 10 µM T’138 and T’136 there were 6.7-fold and 4.6-fold 
decreases respectively in luciferase expression compared to Ad5 and Ad5 plus DMSO 
control conditions. This indicates that these two closely related compounds have activity 
and cause an effect in vivo on liver gene transfer of Ad5. The other four compounds T’585, 
T’402, T’837 or T’956 caused no significant decrease in Ad5 transduction compared to the 
animals in the Ad5 control groups under these conditions (Figure 5.34 and Figure 5.35). 
5.2.24 Effect of compounds on Ad5 liver accumulation in vivo 
To assess whether the compounds affected Ad5 liver accumulation, tissues were harvested 
48 h post-injection of Ad5 in the absence or presence of 10 µM T’138, T’136, T’585, 
T’402, T’837, T’956 or DMSO and homogenates produced. DNA was extracted from liver 
tissue homogenates and vector genomes were quantified by qPCR. QPCR was performed 
with Ad5 hexon specific primers, thus provided an accurate measure of Ad5 vector 
genome accumulation in the liver. DMSO caused no affect on the level of Ad5 genomes in 
the liver compared to the Ad5 alone group (Figure 5.35). In contrast, liver accumulation by 
Ad5 was significantly decreased following incubation with 10 µM T’138. Neither the 
T’138 analogue T’136 nor the other four compounds T’585, T’402, T’837 or T’956 
significantly reduced vector genomes present in the liver. 
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Figure 5.34. Effect of hit compounds on in vivo Ad5 transduction in MF1 mice. 
Luciferase expression visualised by whole-body bioluminescence imaging 48 h after 
intravascular administration of PBS, 1 x 10
11
 vp/mouse Ad5 alone or Ad5 in the presence 
of 10 μM T’138, T’136, T’585, T’402, T’837, T’956 or DMSO in MF1 mice. 
Chapter 5 | Results 
228 
*
0
2
4
6
8
10
12
14
PBS Ad5 DMSO T'138 T'136 T'837 T'956 T'585 T'402
A
ve
ra
ge
 
ra
di
a
n
ce
 
X1
07
 
(p
/s
/c
m
2 /s
r)
0
0.5
1
1.5
2
2.5
PBS Ad5 DMSO T'138 T'136 T'837 T'956 T'585 T'402
Ve
c
to
r 
ge
n
o
m
e
s 
X1
06
/1
00
n
g 
D
NA
(A)
(B)
*
*
A
ve
ra
ge
 
ra
di
a
n
ce
 
X1
07
 
(p
/s
/c
m
2 /s
r)
Ve
c
to
r 
ge
n
o
m
e
s 
X1
06
/1
00
n
g 
D
NA
 
 
Figure 5.35. Liver Ad5 accumulation and transduction at 48 h in vivo.  
(A) Luciferase expression as assessed by whole-body bioluminescence imaging was 
quantified at 48 h post-administration of PBS, Ad5 alone or Ad5 in the presence of 10 μM 
T’138, T’136, T’585, T’402, T’837, T’956 or DMSO. (B) Viral and total genomic DNA was 
extracted from liver samples taken 48 h post-injection. Vector genome accumulation was 
quantified by qPCR. *p<0.05 versus Ad5 as determined by Student’s t-test. Error bars 
represent SEM (n = 6/group).  
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5.3 Discussion 
Intravascular delivery of Ad5 is an attractive route for targeting the vasculature at defined 
sites, if not the only route suitable for targeting the multitude of micro-metastates required 
for many cancer gene therapy applications. Following contact with blood, Ad5 interacts 
with FX and mediates liver gene transfer (Kalyuzhniy et al., 2008; Waddington et al., 
2008). The initial aim of this study was to use a HTS to identify a small molecule which 
specifically blocked FX-mediated Ad5 gene transfer to prevent liver transduction. 
Furthermore, such an inhibitor may hold promise as an anti-adenoviral agent for the 
treatment of life threatening disseminated Ad5 infections in the bloodstream. While it 
remains unclear whether FX binding by the virus is used for Ad5 dissemination, blocking 
this pathway may have fundamental beneficial effects for disseminated Ad pathogenesis in 
addition to gene therapy applications. 
During the initial phase of this study the traditional methods of assessing Ad5 transduction 
in the presence of FX were adapted to generate an assay amenable to a HTS format. This 
set-up stage is one of the most crucial aspects of a HTS and warrants adequate time to be 
spent on optimisation (Sharlow et al., 2008; Shun et al., 2011). Here, an efficient, 
automated 384-well cell-based assay was developed and optimised using GFP as the output 
measure. Figure 5.36 highlights the different stages of assay development which were 
undertaken. Cell-based screen implementation presents several challenges, including the 
production of sufficient cells and virus for HTS, plating and adherence of cells for the 
assay, effects of compound exposure, cytotoxicity and capture of the assay signal 
(Johnston et al., 2002). Identifying systemic errors prior to the commencement of the 
screen is vital and efforts were made to control the variability of the assay in the context of 
several factors, including: DMSO tolerance, reagents and signal stability (Figure 5.36). 
Having an easily quantifiable readout simplifies and greatly aids in the efficiency of the 
screening process (Johnston et al., 2002; Trask et al., 2009). In the presence of FX 
Ad5GFP transgene expression was substantially increased compared to non-FX conditions, 
providing a robust and reproducible signal window (average of ~30 fold signal-background 
ratio) and therefore the control-based method of normalisation of data was chosen (Shun et 
al., 2011). Non-control-based methods of data normalisation such as the Z-score and B-
score (both plate-based statistical methods) are also frequently used HTS methods, which 
can reduce the impact of systemic row/column effects (Brideau et al., 2003; Zhijin Wu et 
al., 2008), but from preliminary testing this was not a major problem and control-based 
normalisation was most suited to this assay (Shun et al., 2011). 
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Figure 5.36. Cell-based assay development. 
Additional challenges to the development and implementation of cell-based screens 
beyond those associated with biochemical HTS formats. Figure adapted from Johnston et 
al. (Johnston et al., 2002). 
Many factors beyond biological activity can affect the data quality from HTS. The multiple 
automated steps involving the liquid handling robotics, with aspirations, dispersions and 
fluid transfers, the programmed high content cellular imaging and handling of large 
databases all contribute to systemic variation. The small scale screen of 80 compounds was 
performed in order to test and validate the HTS protocol. The reproducibility of controls, 
the high signal-to-background ratio and an average Z’factor of > 5 indicated that the assay 
was suited to a HTS format. 
From the primary screen, 288 of the 10,240 compounds tested resulted in > 75% inhibition 
of FX-mediated transduction and were identified as preliminary hits. An initial hit rate of 
~2.8% was higher than expected. Despite this, the main focus of the primary assay was to 
create a list of potential hits, in a cost and time effective manner, therefore in an attempt 
not to miss any such molecules all 288 were selected for two rounds of secondary 
screening. In order to distinguish assay variability from biological activity, the compounds 
showing potential were tested on multiple occasions, in secondary screens and manually 
using traditional routinely used methods. The false-positive rate (i.e. false-positive rate = 
[number of primary HTS actives – number of confirmed hits] x 100/number of primary 
HTS actives) was ~94%. From the 15 hits identified in the secondary screen as being non-
toxic and achieving > 75% inhibition, only five were demonstrated to be active when 
tested without the use of automated techniques, thus discarding a further two-thirds of the 
positive compounds. False positives from HTS are a common problem, the consequences 
of which depend on the time and resources spent on their identification and elimination in 
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the follow up hit characterisation stage (Brideau et al., 2003; Coan et al., 2009; Zhang et 
al., 1999). A graphical summary of the hit identification process is given in Figure 5.37. 
These data highlight the necessity of repeated testing of seemingly attractive compounds 
and the requirement for hit validation. However despite the high attrition rate, five repeat 
positive hits were identified from a screen of 10,240 molecules (0.048% hit rate). 
Upon further analysis, the compounds T’817, T’0831, T’138, T’585 and T’837 were 
identified as ablating Ad5 transduction in presence of FX, all of which had IC50 values < 
5.5 µM. The compounds T’138, T’585 and T’837 primarily interfered with a post-binding 
stage of the Ad infection pathway and all affected efficient virus trafficking to the MTOC, 
as demonstrated by confocal microscopy. From this early investigation of candidate hits, 
T’817 appeared to be the most effective, having the most potent effect on Ad5 transduction 
(IC50 = 0.47), intracellular trafficking and completely prevented Ad5 accumulation at the 
MTOC. However, an additional factor which can contribute to false positives is the 
presence of promiscuous compounds within the library itself (McGovern et al., 2002). 
Following post-screen structural analysis T’817 and T’0831 were eliminated due to the 
presence of sub-structural properties resembling those of ‘frequent false hitters’ from other 
screens (Baell et al., 2010; McGovern et al., 2002). Attempts to develop such peculiar or 
promiscuous compounds into viable leads are often futile, and a great amount of time and 
resources can be wasted on the characterisation of ‘fake’ hits (McGovern et al., 2002). 
Therefore, efforts were focused on validating the other three HTS hits, T’138, T’585 and 
T’837. Interestingly these three compounds share structural features and fit within the one 
pharmacophore model established by Enamine. This was seen as encouraging and 
improved the chances of them being true hits. Moreover, the fact that T’138 had similar 
features to both T’585 and T’837 was a very positive aspect. Therefore based on these 
considerations mini-focused follow up libraries were generated relating to these molecules 
and structure-activity relationship analysis was performed. In vitro screening of the 
analogues revealed novel hits with similar or improved activity, thereby further validating 
the initial pharmacophore model and the three initial hit compounds T’138, T’585 and 
T’837.  
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Figure 5.37. Graphical review of the HTS. 
Of the 10,240 compounds screened in the primary screen, five validated hits were 
identified from the HTS process. 
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Several attempts were made to decipher the mechanism of action of the six most promising 
hits; T’138, T’136, T’585, T’402, T’837 and T’956. These compounds did not directly 
interfere with Ad5 binding to FX, instead they primarily caused a post-binding stage block 
of the transduction pathway and all affected optimal intracellular transport to the 
microtubule organising centre, as demonstrated by SPR, flow cytometry and confocal 
microscopy. Investigation of a direct interaction between Ad5 and the compounds could be 
performed by employing SPR techniques; coating Ad5 to a biosensor chip and passing 10 
µM of each compound or DMSO over the chip to monitor compound:Ad5 binding. 
Additionally, efforts to dissect the point of the Ad5 transduction pathway being targeted by 
the compounds could be made, by performing time-addition experiments, i.e. add the 
compounds 0, 15, 30 or 60 min post-infection. Several early points in the FX-mediated 
pathway are well documented (Bradshaw et al., 2010), and this could help assess whether 
the compound was having a critical affect prior to viral internalisation, endosomal escape 
or nuclear import etc.  
Potent compound effects in vitro do not necessarily translate in the in vivo setting. 
However in this instance, in vivo, 10 µM T’138 substantially reduced Ad5 liver 
accumulation 48 h post-injection and, in addition to its closely related analogue T’136, 
dramatically reduced transgene expression at 48 h post-intravenous administration of a 
high viral dose (1 x 1011 vp/mouse). This dose of virus was chosen as it was previously 
demonstrated to cause high levels of liver transduction in mice, thereby providing a clear 
measure of compound effect (Alba et al., 2010). The activity shown by T’138 and T’136 in 
vivo was a very promising result and this biological effect signifies the translational 
potential of the compounds. In this experiment a single dose of 10 µM compound was 
tested, whilst it may be the case that the other four compounds, T’585, T’402, T’837 and 
T’956, all of which have pharmacologically favourable profiles and none of which resulted 
in clear toxicities in vivo, may show activity at higher doses or against lower viral load. 
A major factor for consideration in the potential use of these molecules in the gene therapy 
setting is that all six compounds ablate Ad5 transduction both in the presence and absence 
of FX, as assessed by assays in A549 cells. An inhibitor which specifically blocks FX-
mediated transduction may hold great benefit for systemically administered Ad5 gene 
therapy applications, when combined with vector retargeting strategies. However, as these 
inhibitors appear to block Ad5 gene transfer via CAR and FX:HSPGs, they may not be 
suitable for such applications. This assay was designed to find inhibitors of Ad5 
transduction, therefore this was always a possible outcome. Perhaps to look more 
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specifically at FX-mediated Ad transduction, identifying a small molecule which prevented 
the direct Ad5:FX interaction could be more suitable. There are several ways such a assay 
could be designed, such as employing SPR to screen compounds for those which blocked 
Ad5 binding to FX, or if a cell-based assay was preferable measuring the effect of 
compounds on fluorescently-labelled Ad5 binding in SKOV3 cells. Instead the inhibitors 
identified in this study may be of more value as anti-adenoviral agents.  
As previously mentioned (section 5.1), in the immune compromised host, human Ad 
infections can culminate in disseminated and life threatening disease (Chakrabarti et al., 
2002; Munoz et al., 1998). Although human Ads initially infect defined target tissues such 
as the lung, eye and gastrointestinal system, disseminated infections can occur, manifesting 
in serious clinical syndromes and are often fatal (Chuang et al., 2003; Straussberg et al., 
2001). There are however, no currently approved, selective anti-adenovirus treatments on 
the market. Compounds T’138 and T’136, in particular, identified in this study may be 
suitable lead compounds for such an application, causing a potent effect in vitro and a 
substantial reduction in Ad5 transduction in vivo. Several other potential experiments could 
be performed to investigate this further. Firstly, by assessing whether the inhibitors of Ad5 
transduction can prevent viral replication. In this thesis, all work was performed using a 
replication incompetent Ad5 vector. As 293 cells possess the E1 genes and machinery 
required for replication of this vector in vitro, it would be of interest to investigate if the 
compounds when incubated with 293 cells infected with Ad5, could prevent viral 
replication and viral spread as assessed by the induction of the cytopathic effect after 24 h 
or performing MTT assays (Graham et al., 1977). Assessing the effects of WT Ad5 
replication in A549 cells, would also be of great relevance. Ultimately the anti-viral 
potential of these inhibitors would be investigated in vivo in a suitable animal model. As 
human Ad replication is species specific, the use of appropriate animal models is 
important. Whilst mice are non-permissive to Ad5 replication, Syrian hamsters are 
permissive to replication and therefore a good model in which to examine the effects of the 
small molecules (Dhar et al., 2012). 
Whilst some pan-antiviral agents such as cidofovir and ribavirin have demonstrated 
efficacy against Ad infections, there is currently no antiviral specific to Ad available 
(Nishikawa et al., 2011; Taniguchi et al.; Ulrych et al., 2011). It would be worth 
investigating if the compounds identified in this study are selective to Ad5 or whether they 
prevent transduction of other Ad serotypes. Testing a panel of Ads from each of the seven 
species A to G to investigate the compounds effect on Ad infection in vitro would be of 
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interest, as Ads from species A, B, C and D are most common to infection in transplant 
recipients (Kojaoghlanian et al., 2003; Kroes et al., 2007). It has been reported that in 
pediatric allogeneic stem cell transplantation patients, of the 33 individuals positive for Ad 
infection in one study, more than one serotype was detected in 12 of the patients (Kroes et 
al., 2007). Moreover, testing the effect of the compounds on other types of viruses, to 
ascertain Ad specificity would also be of importance.  
A recent study by Andersson et al. developed a cell-based screen employing a GFP 
expressing replication competent Ad vector to screen 9,800 commercially available small 
organic compounds to identify one that directly or indirectly affected adenoviral protein 
expression in vitro (Andersson et al., 2010). One compound, namely 2-((2-
benzoylamine)benzoyl)amino)-benzoic acid, inhibited viral replication in vitro and showed 
efficacy against Ads from species A to F. However there was no in vivo data reported with 
this compound (Andersson et al., 2010). Whilst several nucleoside analogues inhibit Ad 
replication in vitro, few appear to work against disease and infection in vivo. Therefore, the 
active in vivo inhibitors T’138 and T’136 identified in the current study may be very 
promising as lead compounds to treat Ad5 infection, particularly in the case of 
disseminated Ad disease. 
The compounds screened throughout this project fall into three major categories; those 
which inhibit Ad5 transgene expression in the absence and presence of FX, those which 
enhance FX-mediated Ad5 infectivity and those which cause no effect. The two types of 
compounds showing efficacy may have strong market appeal. In the gene therapy setting, 
compounds capable of enhancing Ad5 infection in the presence of FX may be an attractive 
option for improved treatment of solid tumours via localised injection. Cancer accounts for 
nearly 65% of the gene therapy trials to date, this is followed by cardiovascular disease 
which account for a further 8.5%. This type of strategy could also be adapted for the 
treatment of cardiovascular diseases, via coating stents with the Ad:FX:compound 
complex to improve virus uptake in the vessel wall. Investigation of potential Ad 
transduction enhancers identified from this screen certainly warrants further study. As 
discussed, there is a clear gap in the market for an effective anti-Ad agent. Additionally, 
such an anti-adenoviral agents may also serve as a potential ‘safety valve’ in the gene 
therapy clinical setting e.g. in case of unwanted viral replication following administration 
of an oncolytic Ad, an anti-viral could be given to combat viral spread and be used as an 
additional measure of protection (Bauzon et al., 2009). 
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This study describes the development, optimisation and implementation of a cell-based 
HTS, in a miniaturised 384-well format, to find small molecule inhibitors of Ad5 gene 
transfer in the presence of FX. Six promising hits were identified, T’138, T’136, T’837, 
T’956’ T’585 and T’402 as being potent blockers of Ad5 gene transfer in vitro and two of 
the compounds, T’138 and T’136, successfully reduced Ad5 gene transduction following 
intravenous delivery of the vector in vivo. These pharmacologically favourable small 
molecules represent lead compounds for the development of anti-Ad agents.
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This thesis has focused on investigating and manipulating Ad5 interactions with host 
factors, in particular coagulation FX, a key in vivo tropism determining event following 
intravascular delivery of the vector. A greater understanding of Ad5:FX complex binding 
to hepatocytes was gained through genetic manipulation of key amino acid residues in the 
FX SP domain, which ablated FX-mediated Ad5 binding and transduction in vitro and ex 
vivo. The use of pharmacological agents, kinase inhibitors and small molecules to interfere 
with Ad5 gene transfer in the presence of FX was also investigated. A screen of 80 diverse 
kinase inhibitors and a robust high throughput screening platform to assay 10,240 
compounds from the Pharmacological Diversity Drug-like Set library were developed. 
Through several rounds of screening, compounds effecting cell binding, optimal 
intracellular transport and potent inhibitors of Ad5 transduction in the absence and 
presence of FX were discovered. Therefore, novel agents to manipulate Ad5 gene transfer 
in vitro and in vivo were successfully identified from this work. 
A major hurdle to the development of gene therapy is the lack of efficient vector targeting 
strategies following intravascular administration, the optimal route for many applications 
such as disseminated cancers and minimally invasive for cardiovascular diseases including 
heart failure or ischemic cardiomyopathy (Boecker et al., 2004; Franz et al., 1997). Viral 
vectors are used in almost 70% of clinical trials in gene therapy, approximately 24% of 
which are based on Ads (www.wiley.com//legacy/wileychi/genmed/clinical/). Ads, which 
exhibit high in vivo transduction efficiency, expression of transgenes, a large DNA payload 
capacity, manufacturing feasibility and the ability to propagate replication-defective 
vectors in complementing cell lines, have shown strong promise for gene therapy 
applications. These concepts have also led to Ads being used as molecular vaccine agents 
(reviewed by Matthews and Barouch (Barouch, 2010; Matthews, 2010)). In the gene 
therapy setting, Ad5 the most commonly used Ad vector has shown therapeutic potential, 
principally following local administration. However, this efficacy is largely determined by 
the route of administration, much of which is lost once the vector enters the bloodstream. 
Recent studies described an important pathway that Ads utilise once in the blood, that is, 
the high affinity interaction between the virus hexon protein and circulating coagulation 
FX (Kalyuzhniy et al., 2008; Vigant et al., 2008; Waddington et al., 2008). A broad range 
of human Ad species have the capability to bind to FX (Waddington et al., 2008). FX 
mediates substantial liver gene transfer, decreasing the availability of the vector to target 
tissues. Since this discovery, the interaction with FX has played a significant role in the 
design of gene therapy vectors (Alba et al., 2010; Alba et al., 2009; Kelkar et al., 2004; 
Waddington et al., 2008). It is therefore important to understand and characterise this 
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pathway in detail for the efficient optimisation and development of such vectors for 
clinical applications. 
The haemostatic system provides physiological host defence and the coagulation cascade 
modulates inflammatory activity and limits tissue damage (Petäjä, 2011). However, this 
regulatory system can also be exploited by various pathogens for infection (Lenman et al., 
2011; Sutherland et al., 2012; Waddington et al., 2008). Several species of Ads bind FX 
(Waddington et al., 2008), while coagulation FIX enhances species A Ad18 and Ad31 
infection via a high affinity interaction with the hexon (Jonsson et al., 2009; Lenman et al., 
2011). In the case of wildtype Ad5, respiratory tract infection commonly occurs following 
inhaled droplet transmission. Various stimuli, including inflammatory responses at the 
respiratory mucosa, may trigger exudation of plasma components (e.g. proteins involved in 
coagulation, complement, fibrinolysis) from subepithelial microvessels (Persson et al., 
1991). FX has been shown to be an efficient enhancer of Ad transduction in vitro, even at 
1/100th the physiological level found blood suggesting the Ad:FX pathway may have 
evolved to enhance natural Ad infection in vivo (Jonsson et al., 2009). In addition herpes 
simplex virus type-1 employs thrombin or a combination of coagulation FXa and FVII for 
increased infectivity (Sutherland et al., 2007; Sutherland et al., 2012). In the case of Ad5, 
the FX Gla domain docks within the cup formed by each hexon trimer and the SP domain 
tethers the Ad5:FX complex to hepatocytes through binding HSPGs, resulting in 
subsequent receptor-mediated virus internalisation (Bradshaw et al., 2010; Kalyuzhniy et 
al., 2008; Waddington et al., 2008). Whilst it is evident that several types of viruses can 
utilise components of the coagulation cascade in order to enhance transduction, several 
other viral pathogens have also taken advantage of HSPGs as primary attachment receptors 
in different tissues and cell types. These include human immunodeficiency virus-1 
(Endress et al., 2008), AAV (Summerford et al., 1998), human papilloma virus (Johnson et 
al., 2009) and herpes simplex virus (Shukla et al., 1999). 
In this study, the critical HSPG-interacting residues of FX for Ad5:FX complex attachment 
to hepatocytes were identified. FX plasmid constructs were generated with mutations in the 
seven basic residues of the HBPE, previously defined as R93, K96, R125, R165, K169, 
K236, and R240 (Rezaie, 2000). SPR demonstrated that mutations did not affect binding to 
Ad5. FX-mediated, HSPG-associated cell binding and transduction were abolished. 
Unfortunately due to the complex synthesis of FX, difficulties in rFX production and scale-
up, in vivo studies were not performed. Several methods to improve production could be 
tested, such as increasing the concentration of vitamin K or serum in the media, using 
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suspension cells or co-transfection of the WT FX or FX mutated constructs with an 
intracellular processing enzyme, such as the endoprotease furin, required for efficient 
biosynthesis (Drews et al., 1995; Preininger et al., 1999). Ideally, in vivo analysis would be 
performed, in which 10 µg/ml of the WT or rFX mutants would be injected into warfarin-
treated mice 30 min prior to administration of Ad5 and liver transgene expression 
assessment after 48 h. Nonetheless, both in vitro and ex vivo data generated indicated that 
the cluster of basic amino acids in the SP domain mediated surface interaction of the 
Ad5:FX complex. Therefore this study has broadened the existing knowledge of the FX-
mediated Ad5 transduction pathway. 
Future success in the development of safe, targeted vectors for systemically delivered gene 
therapy will rely on the detailed understanding of complex interactions of Ads with host 
proteins. Aside from the Ad5:FX interaction, a range of other endogenous proteins lead to 
viral sequestration and prevent gene transfer to the desired cells or tissues. These include 
KCs, neutralising antibodies, complement components, erythrocytes and platelets, amongst 
others. Therefore it is evident that in vivo kinetics and Ad5 biodistribution are defined by a 
range of host interactions. While many years of research have been focused on altering the 
tropism of Ad5 vectors, many of these studies have attempted to translate the knowledge 
gained from CAR-mediated in vitro mechanisms to relevant in vivo pathways. The recent 
change in research focus from classical in vitro CAR-mediated infection to FX:HSPG-
dependent mechanisms, requires additional studies to be performed to assess the role of 
different signalling pathways in the early stages of FX-mediated Ad5 infection. 
Post-binding events that occurr following FX-mediated Ad5 binding and the role of 
kinases involved in virus internalisation, intracellular trafficking and successful 
transduction were also investigated in this thesis. Similar to their involvement in the CAR-
mediated pathway, PKA, PI3K and p38MAPK were found to be crucial for the optimal 
intracellular trafficking in the presence of FX in a CARlow cell line in vitro (Li et al., 
1998b; Suomalainen et al., 2001). Here, from screening a panel of other kinase inhibitors, 
a compound thought to have Syk kinase inhibitor activity was found to have a profound 
effect on FX-mediated Ad5 infectivity (Moriya et al., 1997). ER-27319 disrupted efficient 
intracellular transport and decreased Ad5 transduction. Due to the lack of Syk in the cell 
lines tested, it was concluded that this effect was independent of this kinase. Syk has not 
previously been reported to have an involvement in Ad5 gene transfer in vitro. Instead ER-
27319 was postulated to be acting via ITAM expressing cellular proteins. The ITAM 
containing ERM family, which act as cross-linkers between the plasma membrane and the 
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actin cytoskeleton were speculated to mediate the potent effects of the inhibitor on Ad5 
transduction. However, in the time frame imposed by this study this speculation could not 
be verified but warrants further investigation. Additional experimentation could be 
performed to knockout the effects of ezrin, radixin and moesin proteins using an siRNA 
approach, as previously shown to be effective for individual or combined knockdown 
(Kano et al., 2011), in SKOV3 or A549 cells and examine the effects on Ad5 trafficking. 
This would give insight into their importance in the Ad5 infectivity pathway. Whilst the 
effects of ER-27319 are interesting and it may be used in vitro as a tool to manipulate Ad5 
gene transfer, as to our knowledge there are no other compounds available which cause a 
similar affect, its use in animals may be hindered by toxicity issues. In vitro the compound 
results in ~35% cytotoxicity following 48 h incubation, indicating that it may not be 
suitable for in vivo application.  
A wide range of methods of Ad targeting have been developed with varying success. These 
include genetic engineering of the viral capsid (Alba et al., 2009), polymer-conjugated Ad 
complexes (Yao et al., 2011), adaptor molecules (Reynolds et al., 2000), carrier-cell-
mediated delivery (Pereboeva et al., 2003), cell-specific Ad expression cassettes 
(Fukazawa et al., 2010), promoters and microRNA-mediated tissue-specific transgene 
silencing (Cawood et al., 2009). The use of warfarin to decrease circulating levels of 
functional blood factors (Parker et al., 2006) or heparin to block HSPGs (Bradshaw et al., 
2010), have ablated unwanted Ad5 liver transduction. Both innate and adaptive immune 
responses against the Ads are efficient methods of sequestering the virus, greatly reducing 
the circulating half-life of the vector for gene therapy applications. Gadolinium chloride 
(Lieber et al., 1997), clodronate encapsulated liposomes (Wolff et al., 1997) and several 
other methods to deplete KCs led to evasion, at least in part, of an innate immune response. 
These drugs however are sub-optimal for administering to patients about to undergo a 
therapeutic gene therapy procedure due to safety issues related to their anticoagulant 
properties and toxicity profiles (Kumagai et al., 2007; Ropposch et al., 2012). Therefore, 
seeing the potential of a drug intervention approach, the third study in this thesis attempted 
to identify a novel and safe small molecule to manipulate the FX-mediated Ad5 infection 
pathway and prevent gene transfer. Such an inhibitor may also hold promise as an anti-Ad 
agent. 
Ad infections can be asymptomatic or cause localised disease, such as respiratory tract 
infections following inhalation via droplet transmission of species C Ads (Hong et al., 
2001). However, the humoral response also plays an important role in controlling Ad 
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infection and in individuals in which the immune system is disabled, infection can become 
invasive (Echavarría, 2008; Hierholzer, 1992). Clinical manifestations can be aggressive 
leading to hepatitis, hemorrhagic cystitis, pancreatitis, meningoencephalitis and 
disseminated disease (de Mezerville et al., 2006; Khoo et al., 1995). They depend on the 
underlying disease, affected organ, virus serotype and patient age, being particularly severe 
in children (Echavarría, 2008; Lion et al., 2003). Ad infection has also been detected in 
peripheral blood from immunocompromised patients, a significant proportion of whom 
(82% of paediatric patients in one study (Lion et al., 2003)) then go on to develop life-
threatening disseminated adenoviral disease (Lion et al., 2003). In the 
immunocompromised host, disseminated Ad disease is lethal in most instances 
(Chakrabarti et al., 2002). 
While it is uncertain whether FX binding by Ad upon contact with bloodstream is used for 
viral dissemination, it was hypothesised that blocking this pathway may be advantageous 
for limiting disseminated Ad hepatitis and for gene therapy applications where avoidance 
of liver gene transfer is desirable. Therefore a high throughput screening platform to 
identify small molecule inhibitors of the Ad5:FX pathway was developed. Using a 
fluorescence and cell-based in vitro HTS 10,240 small molecules from the 
Pharmacological Diversity Drug-like Set library were evaluated. Primary and secondary 
screening identified 15 compounds that reduced FX-mediated Ad5 gene transfer by > 75% 
without causing cytotoxicity. Upon further analysis, three compounds, T’837, T’585 and 
T’138 were identified as consistently ablating Ad5 transduction both in the absence and 
presence of FX. As virtually all CAR and FX-mediated gene transfer was prevented by 
these compounds, such inhibitors may be more suitable as anti-viral agents rather than for 
gene therapy applications. However, it would also be of interest to investigate if the small 
molecules identified here also block integrin-mediated infection. This could be performed 
by conincubation of 10 µM of each compound with an integrin targeted vector such as 
Ad5RGD4C, which has been genetically engineered to contain a αv integrin binding ligand 
in the HI loop (Dmitriev et al., 1998; Majhen et al., 2009), to assess affects on vector 
transduction. 
Without formally approved antiviral drugs against Ads available, there is a gap in the 
market for such a pharmacological agent (Dropulic et al., 2010). Several drugs including 
ribavirin, cidofovir and ganciclovir, have been tested in clinical settings or in animal 
models and the results are variable (Lindemans et al., 2010; Taniguchi et al., 2012; Ulrych 
et al., 2011; Yabiku et al., 2011). Cidofovir is most commonly used to treat Ad infections, 
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but treatment outcome is often disappointing (Omar et al., 2010; Taniguchi et al., 2012). In 
a retrospective study of Ad infection in patients undergoing haploidentical stem cell 
transplantation, approximately 43% of individuals receiving cidofovir alone to treat 
disseminated Ad infection died (Taniguchi et al., 2012). Additionally, many currently 
licensed drugs target the same viral protein, the viral DNA polymerase, and drug resistance 
is an emerging problem (Dropulic et al., 2010). Furthermore the toxicity associated with 
some antiviral agents limits their use (Dropulic et al., 2010). Safer and more effective 
drugs directed against new viral targets are required. 
Candidate small molecules identified in this thesis were investigated in further detail. They 
did not directly interfere with Ad5 binding to FX, instead they primarily caused a “post-
binding” stage block of the Ad infection pathway and disrupted optimal trafficking to the 
MTOC, as demonstrated by SPR, flow cytometry and confocal microscopy. The three lead 
compounds T’837, T’585 and T’138 shared common structural features and additional in 
vitro screening of compound analogues revealed novel hits with similar or improved 
activity. Whilst several compounds have previously been demonstrated to block Ad 
transduction in vitro, very few have shown efficacy in vivo (Andersson et al., 2010; Öberg 
et al., 2012). Here, intravascular administration of 10 µM T’138 and its analogue T’136 
substantially reduced Ad5 gene transfer in vivo at 48 h post-administration. Therefore, this 
study successfully identifies novel and potent small molecule inhibitors of Ad infection 
pathways which may be attractive for the development of anti-Ad agents. 
Additional studies will be performed to investigate if the small molecule inhibitors 
identified in this study prevent Ad replication. Such an inhibitor may also be useful in the 
gene therapy clinical setting and its administration may act as a safety control for unwanted 
replication of oncolytic Ads (Bauzon et al., 2009; Diaconu et al., 2010). The requirement 
for more potent effects of oncolytic Ads equates to a higher risk of replication-associated 
side effects, such as innate immune reactions and toxicity (Diaconu et al., 2010). The novel 
compounds found in this study may be suitable for the Ad replication-associated symptoms 
in the clinic and improve their safety profiles. In addition to the inhibitors of Ad infection, 
the small molecule enhancers of Ad5 transduction identified in this study warrant future 
study. Such compounds may have potential, in conjunction with FX for increasing Ad5 
transduction efficiency following localised delivery e.g. intra-tumoural injection of the 
vector. 
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In summary, the work presented here increases the understanding and potential 
exploitations of the FX-mediated Ad5 infection pathway. In addition, potent inhibitors of 
this important pathway both in vitro and in vivo were identified, which represent promising 
lead candidates for anti-adenoviral drug development and gene therapy applications.
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Appendix 1 
 
List of the 80 compounds from the Pharmacological Diversity Drug-like Set library chosen 
for initial screening in Chapter 5. 
 
Appendix 2 
 
Duffy MR, Parker AL, Bradshaw AC, Baker AH (2012). Manipulation of adenovirus 
interactions with host factors for gene therapy applications. Nanomedicine 7(2): 271-288  
 
Appendix 3 
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Amino Acids in the Factor X Serine Protease Mediates Surface Attachment of 
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Appendix 1. 80 compound subset from the Pharmacological Diversity Drug-like Set 
library 
 
Compound I.D. Molecular weight 
T6157156 479.60 
T6147393 278.10 
T6157679 209.3 
T5797151 356.43 
T6045662 256.34 
T5938260 368.34 
T5243644 280.37 
T6005553 275.32 
T5888802 413.34 
T5895535 190.16 
T5982390 378.78 
T6090409 315.37 
T5786618 204.25 
T5786988 354.4 
T5786231 273.26 
T6195375 404.25 
T6205233 215.72 
T6205606 293.40 
T6037038 264.24 
T6538287 323.44 
T6260188 125.12 
T6296542 167.63 
T6530803 272.78 
T6531308 334.05 
T6391409 189.21 
T6394162 277.34 
T5666758 317.36 
T6467204 314.23 
T6465064 254.46 
T6464837 206.29 
T6456691 205.64 
T6449216 209.27 
T6421771 193.19 
T6426611 332.74 
T6437770 289.81 
T6466171 270.39 
T6475407 234.25 
T6486717 216.30 
T6494910 205.75 
T6226934 193.17 
T6339082 258.1 
T6330125 220.01 
T6330009 236.33 
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T6159723 313.29 
T6024950 374.44 
T5971725 245.61 
T5603728 442.54 
T5617403 531.99 
T5618922 367.40 
T0506-1018 319.24 
T5330666 517.60 
T0503-2971 358.27 
T0501-4889 325.37 
T0510-1910 354.45 
T0511-5084 476.56 
T0514-6922 469.48 
T5250021 364.46 
T5676844 279.27 
T5749380 354.39 
T5509594 305.78 
T5508544 219.24 
T5359005 342.33 
T0517-7883 294.42 
T0500-2894 328.24 
T5419299 306.16 
T5240685 326.36 
T0519-4248 361.91 
T0519-9051 430.52 
T0515-0234 173.21 
T0516-4802 380.35 
T0514-9644 327.47 
T5343938 286.29 
T5380460 252.17 
T0500-5518 379.41 
T0501-2198 303.40 
T0501-7827 469.53 
T0502-2012 276.38 
T5473838 455.44 
T5474623 230.30 
T5476447 262.28 
 
